


THE INOSITOL TRISPHOSPATE/CALCIUM SIGNALING PATHWAY IN HEALTH AND DISEASE

Michael J. Berridge

Laboratory of Molecular Signalling, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom



Berridge, MJ. The Inositol Trisphosphate/Calcium Signaling Pathway in Health and Disease. *Physiol Rev* 96: 1261–1296, 2016. Published August 10, 2016; doi:10.1152/physrev.00006.2016.—Many cellular functions are regulated by calcium (Ca^{2+}) signals that are generated by different signaling pathways. One of these is the inositol 1,4,5-trisphosphate/calcium ($\text{InsP}_3/\text{Ca}^{2+}$) signaling pathway that operates through either primary or modulatory mechanisms. In its primary role, it generates the Ca^{2+} that acts directly to control processes such as metabolism, secretion, fertilization, proliferation, and smooth muscle contraction. Its modulatory role occurs in excitable cells where it modulates the primary Ca^{2+} signal generated by the entry of Ca^{2+} through voltage-operated channels that releases Ca^{2+} from ryanodine receptors (RYRs) on the internal stores. In carrying out this modulatory role, the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway induces subtle changes in the generation and function of the voltage-dependent primary Ca^{2+} signal. Changes in the nature of both the primary and modulatory roles of $\text{InsP}_3/\text{Ca}^{2+}$ signaling are a contributory factor responsible for the onset of a large number human diseases.

I. INTRODUCTION	1261
II. InsP_3 FORMATION, ACTION, AND...	1261
III. $\text{InsP}_3/\text{Ca}^{2+}$ SIGNALING AND...	1267
IV. CELL PROLIFERATION	1267
V. NEURONAL SIGNALING	1269
VI. MUSCLE CELLS	1277
VII. CHONDROCYTES	1281
VIII. EXOCRINE GLANDS	1282
IX. ENDOCRINE GLANDS	1283
X. LIVER	1284
XI. OSTEOCLAST	1284
XII. NEPHROLITHIASIS	1285
XIII. CONCLUSION	1285

this review, I describe how this $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway plays a role in multiple cellular processes and how subtle changes in the nature of both its primary and modulatory roles contribute to the onset of a large number human diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), asthma, atrial arrhythmias, autism spectrum disorder (ASD), bipolar disorder, cancer, congestive heart failure (CHF), diabetes, Duchenne muscular dystrophy (DMD), epilepsy, Huntington disease (HD), hypertension, liver cholestasis, nephrolithiasis, osteoarthritis, pancreatitis, rheumatoid arthritis, schizophrenia, Sjögren's syndrome (SS), and spinocerebellar ataxias (SCAs).

II. InsP_3 FORMATION, ACTION, AND REGULATION

A. Formation of InsP_3

External stimuli, such as neurotransmitters, hormones, and growth factors, stimulate the formation of InsP_3 by activating either the G protein-coupled receptors (GPCRs) or the protein tyrosine kinase-linked receptors (PTKs) that are coupled to different phospholipase C (PLC) isoforms (FIGURE 2). The GPCRs are coupled to PLC β isoforms, whereas the PTKs are linked to the PLC γ isoforms (79). The activated PLC hydrolyzes the precursor lipid phosphatidylinositol 4,5-bisphosphate ($\text{PtdIns}4,5\text{P}_2$) to form both diacylglycerol (DAG) and InsP_3 . The InsP_3 functions by binding to the InsP_3 receptors (InsP_3Rs) to release Ca^{2+} from the endoplasmic reticulum (ER).




FIGURE 1. In response to agonists, activated receptors stimulate phospholipase C (PLC) that hydrolyzes phosphatidylinositol 4,5-bisphosphate (PtdIns4,5P₂) to form diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (InsP₃). The InsP₃ diffuses into the cell where it interacts with the InsP₃ receptor to release Ca²⁺, which acts as a primary signal to activate processes such as fertilization, proliferation, metabolism, and secretion. In excitable cells, the primary Ca²⁺ signal is generated by receptor-operated channels (ROCs) or voltage-operated channels (VOCs) that promote the entry of external Ca²⁺. This primary signal can be augmented by Ca²⁺ stimulating ryanodine receptors (RYRs) to release Ca²⁺ from internal stores. The InsP₃/Ca²⁺ signaling pathway can modulate this primary signal that functions to control processes such as neuronal excitability, beta-cell insulin secretion, and contraction of skeletal and cardiac cells.

B. InsP₃ Metabolism

The Ca²⁺-mobilizing function of InsP₃ is terminated through its metabolism by either an InsP₃ 3-kinase or an inositol polyphosphate 5-phosphatase (FIGURE 2) (80, 168). This inositol phosphate metabolism generates the inositol that is necessary to synthesize the phosphatidylinositol (PtdIns) that is required to maintain the signaling pathway. It also functions to generate a number of new inositol phosphates that operate in the inositol polyphosphate signaling pathways. The Ins1,4,5P₃ is either phosphorylated to Ins1,3,4,5P₄ by InsP₃ 3-kinase or it is dephosphorylated by type I inositol polyphosphate 5-phosphatase to release Ins1,4P₂. The two products of these pathways are then sequentially dephosphorylated by a number of inositol phosphatases to form free inositol. A key component of this metabolic pathway is the inositol monophosphatase (IMPase) that hydrolyzes InsP₁ to free inositol that is one of the precursors used for the synthesis of PtdIns on the ER. The PtdIns is then transported to the plasma membrane where it functions as the precursor for the formation of

PtdIns4,5P₂. A loss of function mutation in the *IMPA1* gene, which encodes the IMPase, results in severe intellectual disability (112). Lithium (Li⁺) inhibits the IMPase resulting in a decline in the supply of inositol. This reduction of inositol by Li⁺, which is the basis of the inositol depletion hypothesis (46, 48), may explain its action in controlling various neurodegenerative diseases such as bipolar disorder (BPD), Alzheimer's disease (AD), and HD. Li⁺ can also delay the progression of ALS (116). The inositol depletion hypothesis thus provides further evidence that these diseases may be caused by an excessive elevation of the neuronal phosphoinositide signaling pathway as described later. The fact that Li⁺ can improve non-rapid-eye-movement (NREM) sleep (122, 281) also supports the possibility that the InsP₃/Ca²⁺ signaling pathway is an important component of the tonic excitatory drive that regulates brain rhythms as described later (42).

Mutations in the *OCRL1* gene, which encodes inositol polyphosphate-5-phosphatase that converts inositol 1,4,5-trisphosphate to inositol 1,4-bisphosphate and inositol




FIGURE 2. The cell-surface receptors responsible for InsP₃ formation belong to two main classes, the G protein-coupled receptors (GPCRs) and the protein tyrosine kinase-linked receptors (PTKs) that are coupled to different phospholipase C (PLC) isoforms. The GPCRs use the PLC β isoforms, whereas the receptor tyrosine kinases (RTKs) are coupled to the PLC γ isoforms. During the transduction process, the precursor lipid PtdIns_{4,5}P₂ is hydrolyzed by PLC to produce both InsP₃ and diacylglycerol (DAG). The InsP₃ released from the membrane diffuses into the cytosol where it engages the InsP₃ receptors (InsP₃Rs) to release Ca²⁺ from the endoplasmic reticulum. The Ca²⁺-mobilizing function of InsP₃ is terminated through its metabolism by either InsP₃ 3-kinase or InsP₃ 5-phosphatase. The resulting InsP₂ and InsP₄ enter an inositol phosphate metabolic pathway and are recycled back to free inositol. The DAG is recycled back to the precursor CDP-DAG, which then combines with inositol to reform the phosphatidylinositol (PtdIns) that is returned to the plasma membrane to be phosphorylated to the PtdIns_{4,5}P₂ precursor to maintain the InsP₃ signaling pathway. A key component of this metabolic pathway is the inositol monophosphatase (IMPase) that hydrolyzes InsP₁ to free inositol. This IMPase is inhibited by lithium (Li⁺), which thus acts to reduce the supply of inositol resulting in a decline in the activity of the InsP₃/Ca²⁺ signaling pathway.

1,3,4,5-tetrakisphosphate to inositol 1,3,4-trisphosphate, causes Oculocerebrorenal syndrome of Lowe (OCRL) that is an X-linked disorder characterized by congenital cataracts and mental retardation (221).

C. InsP₃R Activation by InsP₃ and Ca²⁺

The primary mode of action of InsP₃ is to bind to InsP₃Rs to release Ca²⁺ from the ER (106, 119, 229, 248, 249, 370, 371, 387). The InsP₃R consists of four subunits that form a tetrameric channel that is embedded in the ER and in the nuclear envelope (NE) (FIGURE 3) (370). The InsP₃Rs consist of three isoforms: InsP₃R1, InsP₃R2, and InsP₃R3 that have similar primary structures, but different physiological properties. Cells exploit these different properties to create Ca²⁺ signals with different spatial and temporal character-

istics to control many different cellular functions. The structure of individual subunits consists of three main domains (370, 371). The receptor is embedded in the ER by six transmembrane domains (TM), and there is a pore (P) loop that connects TM5 to TM6. The loops that extend into the lumen of the ER are glycosylated. An InsP₃R-binding domain is located at the end of the long NH₂-terminal cytoplasmic region and is connected to TM1 by the modulatory domain. The conformational change induced by the binding of InsP₃ and Ca²⁺ is transmitted down to the transmembrane region to open the pore. Many regulators of InsP₃Rs act on the modulatory domain to control the release of Ca²⁺ (FIGURE 4).

The Ca²⁺-mobilizing second messenger InsP₃ and Ca²⁺ are the primary regulators of the InsP₃R (119, 229, 387). Acti-




FIGURE 3. The InsP_3R consists of four subunits, two of which are illustrated here. There are six transmembrane domains, with the pore loop located between TM5 and TM6. There is a long NH_2 -terminal region that extends into the cytoplasm. The InsP_3 and Ca^{2+} bind to sites near the NH_2 -terminal region and induce a conformational change that is transmitted down to the transmembrane region to open the pore to allow Ca^{2+} to enter the cytoplasm. This drawing is based on information contained in Taylor et al. (370).

vation of release begins when InsP_3 binds to the InsP_3 -binding domain. Before the channel opens, InsP_3 has to bind to each of the four subunits (6). Once InsP_3 has occupied all four monomers, it induces a conformational change, which sensitizes the Ca^{2+} -binding site. When Ca^{2+} binds to this site, the channel opens and Ca^{2+} is released into the cytoplasm (FIGURE 3). The action of Ca^{2+} is bimodal in that it stimulates release at low levels, but when Ca^{2+} rises above 300 nM, it becomes inhibitory. This dual control of the InsP_3R by both InsP_3 and Ca^{2+} is central to its multiple functions in cell signaling.

D. InsP_3 -Induced Ca^{2+} Oscillations

A characteristic feature of the InsP_3 signaling pathway is that it usually acts to release Ca^{2+} as brief transients. If signaling has to occur over a longer period, such spikes are repeated to give oscillations (33, 37, 111). Oscillations have been described in multiple cell types such as the insect salivary gland (311), hepatocytes (319, 403), osteoclasts (367), astrocytes (95), renal epithelial cells (2), mesoepithelial cells (293), pancreatic acinar cells (124, 296), oocytes (72, 84), and endothelial cells (258). A characteristic feature of these oscillations is that their

frequency depends on the level of stimulus intensity (36, 47). Many functions such as salivary gland secretion, liver metabolism, smooth muscle contractility, and differential gene transcription, especially in developing systems, are controlled by such frequency coding. Gene expression is initiated more effectively using Ca^{2+} spikes rather than the same average Ca^{2+} concentration maintained at a steady level (209). The transcription factor NF κ B is activated by low frequency spikes, whereas NF-AT activation requires higher frequencies (99). Changes in Ca^{2+} oscillation frequency can also regulate the activity of the protein kinase CaM kinase II (91).

Just how these oscillations are generated is still a matter of considerable debate. In some of the earliest models, it was suggested that the oscillator was based on a periodic sensitization of the InsP_3R brought about by recharging of the intracellular store through the entry of external Ca^{2+} (37). In some cells, such entry is not necessary because much of the Ca^{2+} released during each transient is taken back into the ER. More recent studies have indicated that the oscillatory mechanism is more complicated as there are indications that the level of InsP_3 can oscillate together with the Ca^{2+} (301). The current concept is that oscillations may




FIGURE 4. The InsP₃R functions as a signaling hub in that it can be regulated by a large number of factors such as agonists, antagonists, and modulators. The primary agonists are Ca²⁺ and InsP₃. Adenophostin mimics the action of InsP₃. The receptor is also sensitive to reactive oxygen species (ROS) such as hydrogen peroxide (H₂O₂), and this action can be mimicked by thimerosal. A number of modulators can influence activity either positively (green arrows) or negatively (red arrows). Channel activity is modulated by phosphorylation through various signaling pathways using messengers such as cAMP, cGMP, and PtdIns3,4,5P₃ (PIP₃). Some of these phosphorylations are reversed by protein phosphatase 1 (PP1). High levels of Ca²⁺ inhibit the receptor. There also are a range of pharmacological agents that have been used to inhibit release of Ca²⁺ by the InsP₃R.

be driven by complex feedback interactions operating between InsP₃ and Ca²⁺ (129, 144, 301, 421).

E. InsP₃R Regulation

A large number of stimulators and inhibitors function to regulate InsP₃R activity (119, 170, 249, 292, 305, 387) (FIGURE 4). Such protein-protein interactions indicate that the InsP₃/Ca²⁺ signaling pathway is integrated with many other signaling pathways to control a number of different cellular processes (249). Proteins that have EF-hand Ca²⁺-binding motifs, such as calmodulin, NCS-1, and Ca²⁺-binding protein 1 (CaBP1), can regulate the activity of the InsP₃Rs. In neurons, the CaBP1 acts to stabilize the closed state of the channel in a Ca²⁺-dependent manner (170, 211). Caffeine is an important inhibitor of Ca²⁺ release by the InsP₃Rs (54, 164, 291, 322). Caffeine inhibits both the type 1 (InsP₃R1) (322) and type 3 (InsP₃R3) (180) release channels. Such inhibition of InsP₃-induced Ca²⁺ release may explain the

observation that caffeine reduces the onset of AD (18, 287, 361) and can also reduce the symptoms of acute pancreatitis (164).

Another group of proteins that interact with the InsP₃Rs are some of the protooncogenes and tumor suppressors such as Bcl-2, BRCA1, PTEN, and PML. In general, the protooncogenes reduce InsP₃R activity, whereas tumor suppressors tend to enhance InsP₃R function resulting in apoptotic cell death. For example, the breast cancer 1 (BRCA1) protein binds to the InsP₃R to enhance Ca²⁺ release that then induces apoptosis (149). Conversely, Bcl-2 acts to inhibit the InsP₃R to reduce Ca²⁺ release (73, 318) with important implications for human diseases such as AD, BPD, cancer and HD (98, 140). Another important regulator that has implications for neural diseases is carbonic anhydrase-8 (Car8), which is an allosteric inhibitor of InsP₃R1 (156, 157, 425). Alterations in this regulation of the InsP₃/Ca²⁺ signaling pathway by Car8 has been implicated in chronic inflammatory pain (425).

The activity of the InsP₃Rs is regulated by a cycle of phosphorylation and dephosphorylation operated by a number of protein kinases and phosphatases (383, 418). For example, the cAMP-dependent protein kinase (PKA) phosphorylates InsP₃R resulting in an increase in Ca²⁺ release (96). Phosphorylation events are also responsible for regulating the activity of IRBIT (InsP₃R-binding protein released with InsP₃) that acts to control Ca²⁺ release by the InsP₃Rs (14, 15, 249). Once IRBIT is phosphorylated, it binds to the InsP₃R to prevent the binding of InsP₃, thereby reducing the release of Ca²⁺.

The redox state of the cell is also an important regulator of InsP₃Rs (24, 55, 62, 253). In normal cells the cytoplasm is highly reduced, which is critical for normal cell function and survival. Any shift from a reduced to an oxidized state leads to oxidative stress and dysfunction of multiple cellular processes. Superoxide (O₂^{·-}), hydrogen peroxide (H₂O₂), and peroxynitrite (ONOO[·]) are typical reactive oxygen species (ROS) that can oxidize the InsP₃R to markedly increase its sensitivity. Such dysregulation of the InsP₃/Ca²⁺ signaling pathway plays a role in both aging and in many of the diseases linked to vitamin D deficiency (44, 45).

The InsP₃/Ca²⁺ signaling pathway is also regulated by varying the cellular level of the InsP₃Rs, which depends on the balance between the synthesis of these receptors through transcription and expression and its removal by the endoplasmic reticulum-associated degradation (ERAD) pathway (see below). A number of mechanisms, many of which act through Ca²⁺, regulate InsP₃R transcription (132, 138, 256, 257). These studies reveal that L-type voltage-gated channels, NMDARs, nicotinic acetylcholine receptors (nAChR), and D1 dopamine receptors all act by increasing intracellular levels of Ca²⁺ responsible for triggering expression of InsP₃Rs. Transcription of InsP₃Rs is also regulated in a Ca²⁺-independent manner by factors such as tumor necrosis factor- α (TNF- α) acting through the specificity protein 1 (SP-1) (289, 408). The nuclear factor, erythroid 2-Like 2 (NRF2) transcription factor acts to reduce transcription of the type 3 InsP₃R (InsP₃R3) (397). Finally, various drugs such as psychostimulants, morphine, cocaine, methamphetamine, and nicotine increase the transcription of InsP₃R1, and this might be relevant to their addictive behavior (201, 202, 257).

The subsequent expression of the InsP₃R mRNAs can be regulated by microRNAs (miRs), which function as post-transcriptional regulators. In cardiomyocytes, miR-133a acts to inhibit the expression of InsP₃R2 (100, 387). Down-regulation of miR-133a accounts for an increase in the level of the InsP₃R2s, and this is a major contributory factor for the onset of cardiac hypertrophy. The expression of InsP₃R3 in cholangiocytes, which function in bile secretion, is suppressed by miR-506 (13). As described later, this decline in InsP₃R3 expression is responsible for a number of

cholestatic disorders such as bile duct obstruction, biliary atresia, and biliary cholangitis/cirrhosis.

These transcription and expression mechanisms responsible for the synthesis of InsP₃Rs are balanced by a pathway that removes the functional receptors through the ERAD pathway (222, 405). This ERAD mechanism depends on the ubiquitin-proteasome pathway (UPP) that degrades the InsP₃Rs while they are functioning in the ER. The InsP₃Rs are polyubiquitinated and are then recognized and degraded by the proteasomes. This ubiquitination is carried out by RNF170, which is a RING domain-containing protein ligase that resides on the ER, where it recognizes and associates with activated InsP₃Rs (222, 405). Mutations in RNF170, which has been linked to autosomal dominant cerebellar ataxia (ADCA), interfere with this ubiquitination process and result in a decline in Ca²⁺ signaling via the InsP₃Rs and is likely to be the cause of ADCA (405).

F. InsP₃/Ca²⁺ Signaling and Autophagy

A large number of metabolic signaling pathways contribute to the regulation of autophagy (126). One of the first indication that Ca²⁺ may play a role emerged from studies showing that autophagy could be induced by Ca²⁺ released from the ER (162). Subsequent studies revealed that the InsP₃/Ca²⁺ signaling pathway plays a prominent role in regulating autophagy (69, 90, 147). The action of Ca²⁺ is complicated because it can both stimulate and inhibit autophagy. This contradictory action of Ca²⁺ may depend on either the concentration or the location of Ca²⁺ signals (90). Low local levels of Ca²⁺ may be inhibitory, whereas autophagy may be stimulated by higher global levels of Ca²⁺. A constitutive Ca²⁺ release by the InsP₃R may create a local elevation of Ca²⁺ within the narrow gap between the ER and the mitochondria where it activates mitochondrial energy metabolism to maintain the formation of ATP that then acts to prevent autophagy by reducing the activity of AMP-activated protein kinase (AMPK). This Ca²⁺ signaling operates within the ER/mitochondrial shuttle, which means that this highly localized Ca²⁺ signal is hidden away from the other cytosolic Ca²⁺-sensitive processes.

Elevation in various pathological aggregates such as amyloid, tau, α -synucleins and mutant Huntington fragments, which contribute to neurodegenerative disease such as AD, Parkinson's disease, and HD, may accumulate because of a decline in autophagy. These diseases are also associated with abnormal elevations in the InsP₃/Ca²⁺ signaling pathway that may act to reduce autophagy. Such a mechanism may explain the observation that Li⁺ can induce autophagy in some of these diseases through inhibition of the IMPase (**FIGURE 2**) resulting in inositol depletion and a subsequent reduction in the InsP₃-induced flux of Ca²⁺ that acts to reduce autophagy (115, 262, 325, 326, 327).

III. InsP₃/Ca²⁺ SIGNALING AND DISEASE

The InsP₃/Ca²⁺ signaling pathway is a major component of the highly versatile and dynamic cellular Ca²⁺ signaling system that regulates many different cellular processes (49, 50, 118, 249). One of the striking features of InsP₃/Ca²⁺ signaling is its role in the development of multiple human diseases (TABLE 1) (40, 52, 53, 118, 249). When considering this pathological role, it is important to consider how vitamin D deficiency may act to enhance the alterations in the InsP₃/Ca²⁺ signaling pathway. Vitamin D may act by maintaining the phenotypic stability of both the Ca²⁺ and the redox signaling pathways (44, 45). During Vitamin D deficiency, an increase in the resting state of these pathways would greatly enhance the activity of the InsP₃/Ca²⁺ signaling pathway. In the following sections, the role of InsP₃/Ca²⁺ signaling in different cell types will be described to illustrate how alterations in this signaling pathway contributes to different disease states.

IV. CELL PROLIFERATION

One of the important signals responsible for inducing cell proliferation is an increase in Ca²⁺ (35, 300, 313). For example, histone-induced proliferation of cholangiocytes is driven by the InsP₃/Ca²⁺ signaling pathway (120, 121) through a mechanism that can be suppressed by miR-506, which is known to act by reducing InsP₃R expression (13). One of the actions of InsP₃ is to generate a nucleoplasmic Ca²⁺ signal that is responsible for activating proliferation (314). In liver regeneration, InsP₃/Ca²⁺ signaling triggers hepatocyte proliferation to create the new liver cells to restore liver function (276). The following examples illustrate further how the InsP₃/Ca²⁺ signaling pathway has a prominent role in generating the Ca²⁺ signals that drive cell proliferation and how alterations in this signaling pathway contribute to acute lymphoblastic leukemia, asthma, cancer, infertility, and severe combined immune deficiency (SCID).

A. Fertilization

Before sperm can fertilize the oocyte, they have to become hyperactive to enable them both to pass through the mucous layer within the oviduct and to penetrate the zona pellucida to react with the oocyte plasma membrane. This hyperactivity is driven by an increase in Ca²⁺ released by InsP₃Rs located in the redundant nuclear envelope (RNE) that surrounds the sperm axoneme (158). This hyperactive state is triggered by vitamin D acting in a nongenomic mechanism to activate the formation of the InsP₃ responsible for the release of Ca²⁺ (60, 61).

At fertilization, the sperm fuses with the oocyte and injects phospholipase C ζ (PLC ζ), which is unique to sperm, where

it hydrolyzes PtdIns4,5P₂ to form InsP₃ that acts through the InsP₃Rs to trigger the Ca²⁺ oscillations that activates the egg to begin its development (272, 362, 390). During each spontaneous oscillatory Ca²⁺ transient, which occurs approximately every few minutes, there is a rapid decline in the ER luminal Ca²⁺ concentration. The level of Ca²⁺ is gradually replenished through store-operated Ca²⁺ entry that depends on both STIM1 and Orai1. The buildup of Ca²⁺ within the lumen of the ER may be an important feature of the oscillatory mechanism in that it sensitizes the InsP₃Rs resulting in the activation of the next transient. These sperm-induced Ca²⁺ transients induce chromosome separation and the cell proliferation that occurs during early development.

Mutations in PLC ζ are responsible for some cases of male infertility (11, 272).

B. Lymphocyte Proliferation

Foreign substances are recognized by the sophisticated chemical surveillance system that is operated by the immune system. The thymus-derived cells (T cells) and the bone marrow-derived cells (B cells) are the main lymphocytes responsible for immune responses. T cells deal with intracellular pathogens (cell-mediated immunity). On the other hand, extracellular pathogens are dealt with by the B cells (humoral immunity). This role of the T and B cells is a good example of how cells are induced to proliferate in response to specific stimuli.

Activation of B cells is driven by the B-cell antigen receptor (BCR), which assembles a hetero-oligomeric complex made up of two Ig α and Ig β signaling proteins that are associated with the antigen-binding immunoglobulin IgM receptor that consists of two heavy chains and two light chains. When antigen binds to the IgM, it activates Lyn that is a non-receptor tyrosine kinase that phosphorylates tyrosine residues located on the immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic regions of Ig α and Ig β . The phosphorylated ITAMs recruit and activate various transducing components such as phospholipase C γ 2 (PLC γ 2). Following activation of PLC γ 2, PtdIns4,5P₂ is hydrolyzed to form InsP₃ and DAG that contribute to the activation of proliferation (155, 392). To activate proliferation, InsP₃ must generate a Ca²⁺ signal that lasts for a long period. This prolonged signal is achieved by activating both the release of internal Ca²⁺ and the entry of external Ca²⁺. The first step is for InsP₃ to release Ca²⁺ from the ER by binding to the InsP₃Rs. Once the ER is depleted, the stromal interaction molecule 1 (STIM1) activates Orai1 to induce the entry of external Ca²⁺ (20, 155). This gives rise to a prolonged Ca²⁺ signal, which is encoded in the form of repetitive Ca²⁺ oscillations (255), that activates NFAT resulting in B-cell activation characterized by proliferation and differentiation (19, 329).

Table I. Alterations in the activity of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway contributes to the onset of multiple human diseases

Disease	Modification of the $\text{InsP}_3/\text{Ca}^{2+}$ Signaling Pathway	Reference Nos.
Alzheimer's disease (AD)	Enhanced $\text{InsP}_3/\text{Ca}^{2+}$ signaling in neurons activates memory loss	94, 108, 171, 360
Anhydrosis	Reduced $\text{InsP}_3/\text{Ca}^{2+}$ signaling in sweat glands	191
Amyotrophic lateral sclerosis (ALS)	Enhanced $\text{InsP}_3/\text{Ca}^{2+}$ signaling in motor neurons	189, 366
Asthma	$\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway drives excessive pulmonary smooth muscle cell contraction	56, 145, 294
Atrial arrhythmias	Enhanced $\text{InsP}_3/\text{Ca}^{2+}$ signaling leads to the development of atrial arrhythmias	159, 210, 227, 426
Autism spectrum disorder (ASD)	Decline of $\text{InsP}_3/\text{Ca}^{2+}$ signaling contributes to the onset of ASD	135, 225, 333
Bipolar disorder (BPD)	Excessive $\text{InsP}_3/\text{Ca}^{2+}$ signaling may drive the neuronal excitatory-inhibitory imbalance	103, 332
Cancer	Hyperactivity of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway contributes to the excessive Ca^{2+} signals that drive the onset and progression of cancer	76, 86, 396
Congestive heart failure	Nuclear $\text{InsP}_3/\text{Ca}^{2+}$ signaling drives ventricular cardiac hypertrophy	148, 154, 214, 218, 267, 406, 427
Diabetes	$\text{InsP}_3/\text{Ca}^{2+}$ signaling acts synergistically with glucose to control insulin release from pancreatic β -cells	25
Duchenne muscular dystrophy (DMD)	Enhanced $\text{InsP}_3/\text{Ca}^{2+}$ signaling contributes to skeletal muscle degeneration	23, 81, 212, 259
Epilepsy	An increase in the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway contributes to the excitation-inhibition imbalance	93, 265, 286
Hypertension	Enhanced $\text{InsP}_3/\text{Ca}^{2+}$ signaling contributes to the increased smooth muscle tone	1, 4
Huntington's disease	Enhanced $\text{InsP}_3/\text{Ca}^{2+}$ signaling contributes to the selective loss of striatal neurons	29, 52, 53, 106, 118, 368
Infertility	Mutations in phospholipase C ζ (PLC ζ) result in reduced InsP_3 and a decline in fertilization	11, 272
Kashin-Beck disease	Enhanced $\text{InsP}_3/\text{Ca}^{2+}$ signaling contributes to chondrocyte necrosis	59, 363, 423
Kawasaki disease	$\text{InsP}_3/\text{Ca}^{2+}$ signaling acts in T cells to contribute to the inflammatory response	200, 277, 416
Liver cholestasis	A decline in $\text{InsP}_3/\text{Ca}^{2+}$ signaling reduces bile secretion by cholangiocytes	8, 27, 342
Lymphoblastic leukemia	Alterations in the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway drives enhanced proliferation	282
Nephrolithiasis	Increased $\text{InsP}_3/\text{Ca}^{2+}$ signaling contributes to the formation of kidney stones	177
Osteoarthritis	Enhanced $\text{InsP}_3/\text{Ca}^{2+}$ signaling contributes to cartilage destruction by the chondrocytes	304, 419
Pancreatitis	Enhanced $\text{InsP}_3/\text{Ca}^{2+}$ signaling contributes to pancreatic cell necrosis	134, 164, 279
Rheumatoid arthritis (RA)	Enhanced $\text{InsP}_3/\text{Ca}^{2+}$ signaling contributes to osteoclast proliferation and differentiation	408
Schizophrenia	A decline in $\text{InsP}_3/\text{Ca}^{2+}$ signaling in GABAergic inhibitory neurons	290
Sjogren's syndrome (SS)	A decline in $\text{InsP}_3/\text{Ca}^{2+}$ signaling causes the decrease in salivary gland fluid secretion	372
Spinocerebellar ataxias	Dysregulation of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway leads to degeneration of the Purkinje neurons	53, 66, 106, 335

See text for further details.

In T cells, proliferation and cytokine production depend on a sustained Ca^{2+} signal that results from the activation of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling system in a manner similar to that just described for the B cells (109, 160, 275). The major histocompatibility complex II (MHCII), which detects the antigen, binds to the large T-cell receptor (TCR) complex that activates transducers to generate the signals to induce the transcriptional events that initiate DNA synthesis. A major pathway for lymphocyte activation depends on the stimulation of $\text{PLC}\gamma 1$ that hydrolyzes PtdIns4,5P_2 to form InsP_3 to release Ca^{2+} from the internal store. During T-cell receptor (TCR) Ca^{2+} signaling, the SWAP-70-like adaptor of T cells (SLAT) protein binds to the $\text{InsP}_3\text{R1}$ through its EF-hand and PH domains and has an important role in generating the Ca^{2+} signal that drives T-cell proliferation (117). One of the actions of the anti-apoptotic protein Bcl-2 is to inhibit this release of Ca^{2+} by the InsP_3Rs (140, 318). One of the primary functions of this $\text{InsP}_3/\text{Ca}^{2+}$ signal is to initiate chromatin decondensation that induces the gene transcriptional cascade responsible for T-cell activation (207).

When the ER empties, the STIM1 protein activates the plasma membrane Orai1 channels responsible for the influx of external Ca^{2+} (109). This influx of Ca^{2+} acts to maintain the Ca^{2+} signal for a period of 2 h that is necessary to activate lymphocyte proliferation. This prolonged Ca^{2+} signal activates the transcription factor NFAT that enters the nucleus where it induces the genes responsible for triggering T-cell proliferation.

Alterations in this $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway result in acute lymphoblastic leukemia (282), whereas SCID is caused by mutations of the Orai1 channel (110).

C. Cancer

There is increasing evidence for a link between Ca^{2+} signaling and cancer (260, 303, 313). Alterations in the $\text{InsP}_3/\text{Ca}^{2+}$ signaling system is responsible for some of the aberrant Ca^{2+} signaling changes in cancer cells. For example, chromosome instability results in changes in phosphoinositide signaling pathways, some of which lead to elevated levels of InsP_3 , have been described in glioblastoma multiform that is one of the commonest brain tumors (396). The proliferation and migration of human gastric adenocarcinoma cells is driven by the $\text{InsP}_3/\text{Ca}^{2+}$ and DAG/PKC signaling pathways operating in parallel with each other (86).

Mutations in the *PLCG1* and *PLCG2* genes that encode $\text{PLC}\gamma 1$ and $\text{PLC}\gamma 2$, respectively, have been linked to a number of cancers (196). The $\text{PLC}\gamma 1$ mutations have been found in secondary angiosarcoma (30) and cutaneous T-cell lymphoma (CTCL) (386). Deletions in the *INPP5A* gene, which encodes the InsP_3 5-phosphatase that metabolizes InsP_3 (FIGURE 2), have been found in squamous cell carci-

noma (SCC) (337) and brain tumors (205). Likewise, there is a decline in the expression of the 5-phosphatase in human leukemias (245). Chronic lymphocytic leukemia (CLL), which is driven by alterations in B-cell Ca^{2+} signaling (89), has been linked to mutations in *PLCγ2* (404). Genetic polymorphisms of the *ITPKC* gene, which encodes the InsP_3 3-kinase C protein that inactivates InsP_3 (FIGURE 2), have been linked to an increased risk of developing cervical squamous cell carcinoma (413). Proliferation of cancerous pancreatic duct cells is driven by uridine triphosphate (UTP) that acts through the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway (76). The high expression of $\text{InsP}_3\text{R2}$ has been considered to be a novel biomarker of acute myeloid leukemia (341). In many of these cases, there are indications that the mutations in the InsP_3 pathway result in the elevated Ca^{2+} signals that contribute to the control proliferation.

The InsP_3R , which releases Ca^{2+} from the ER, has been linked to processes that contribute to cancer (3, 150, 321, 364). The proliferation of breast cancer cells depends on $\text{InsP}_3\text{R3}$ channels (263). Dissemination of gastric cancer cells may depend on $\text{InsP}_3\text{R3}$ -induced elevation of Ca^{2+} (321). Caffeine inhibition of $\text{InsP}_3\text{R3s}$ was found to reduce the survival, migration, and invasion of glioblastoma cells (180). In colon cancers, higher expression levels of $\text{InsP}_3\text{R3s}$ are associated with enhanced aggressiveness and poorer prognosis (343). Locomotion of human melanoma cells is enhanced by autocrine motility factor (AMF) that acts through the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway (195). Many of the regulatory proteins that control the activity of these InsP_3Rs are protooncogenes and tumor suppressors such as Bcl-2, Beclin 1, BRCA1, MCL-1, PTEN, and PML (FIGURE 4) (3, 57, 140). In B cells, PKB/Akt2 can inhibit Ca^{2+} release by promoting the activity of Bcl-2, which is known to inhibit the InsP_3Rs (235).

In general, the protooncogenes reduce InsP_3R activity, whereas tumor suppressors tend to enhance InsP_3R function resulting in apoptotic cell death. For example, breast cancer 1 (BRCA1) binds to the InsP_3R to enhance Ca^{2+} release that then induces apoptosis (57, 149). Altering the activity of the InsP_3Rs may enable prostate cancer cells to resist the androgen deprivation treatment that normally acts to kill these cancer cells (64). Conversely, Bcl-2 acts to inhibit the InsP_3R to reduce Ca^{2+} release (73, 318) with important implications for human diseases such as cancer, BPD, AD, and HD (98, 140). For example, Bcl-2 interacts with the InsP_3Rs to reduce the release of Ca^{2+} , which prevents apoptosis and is responsible for the survival of cancer cells (140). In a similar way, oncogenic K-Ras can promote cancer cell survival by suppressing the InsP_3 -mediated release of Ca^{2+} that drives apoptosis (297).

V. NEURONAL SIGNALING

The $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway contributes to both brain development and many of its functions such as axonal

growth (137), memory formation (166, 320), excitability, brain rhythms (42, 151, 358), and gene transcription (209). The neural circuits in the brain consist of excitatory and inhibitory neurons that interact with each other as part of the mechanisms responsible for generating brain rhythms. Changes in the role of $\text{InsP}_3/\text{Ca}^{2+}$ signaling in regulating these neuronal functions are responsible for many neurodegenerative diseases (40, 41, 52, 53, 118).

A. Brain Development

Development of the brain proceeds through a number of distinct phases such as proliferation, migration, and differentiation. First, the embryonic cells, which are set aside to form the brain, begin to proliferate rapidly to form a large population of neuronal precursors. In the next step, these neuronal progenitors begin to differentiate into the specific neuronal cell types that constitute fully functional neuronal circuits. $\text{PLC}\gamma 1$, which generates the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway, plays an important role in brain development (181). This pathway induces the Ca^{2+} oscillations that regulate both proliferation and differentiation (380, 398). As neurons develop, axons grow out to interact with other neurons and the InsP_3 signaling systems contributes to the mechanism that steers the growth cones towards their targets (378). During differentiation, neurons begin to express different neurotransmitters, which mark the emergence of either excitatory or inhibitory neurons. This specification seems to be determined by the generation of spontaneous Ca^{2+} transients. All the cells become active, and those with the highest oscillation frequency act as pacemakers that then recruit neighboring cells giving rise to a Ca^{2+} wave that creates oscillating hubs of cells.

Expression of excitatory transmitters such as acetylcholine (ACh) and glutamate occur in neurons that have low-frequency oscillations, whereas inhibitory transmitters such as glycine and γ -aminobutyric acid (GABA) are expressed in those neurons that display more frequent Ca^{2+} transients. Fully functional neuronal circuits depend on this emergence of the excitatory and inhibitory neurons that interact with each other to generate the rhythms that are essential for brain function (42). The normal function of the brain is critically dependent on the activity of these neurons being balanced. Such excitation-inhibition balance (E-I balance) is critical to maintain normal brain rhythms, and alterations in this balance have been implicated in a number of neural diseases as described below.

B. Brain Rhythms

Having contributed to the development of the brain, the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway continues to control adult brain functions such as the regulation of brain rhythms and synaptic plasticity.

During the sleep/wake cycle, the brain has different neural rhythms (**FIGURE 5**). During the awake state there are a number of brain rhythms such as the fast gamma (20–80 Hz), alpha (8–12 Hz), and theta (6–10 Hz) oscillations. During sleep, the rhythm frequency declines resulting in the delta (1–4 Hz) and slow oscillations (<1 Hz). The ascending arousal system is responsible for regulating the activity of these different oscillatory modes. This arousal system consists of a variety of neurons that project their axons throughout the brain where they release transmitters such as orexin, ACh, norepinephrine (NE), 5-hydroxytryptamine (5-HT), histamine, and dopamine (DA). These transmitters are released globally and are thus able to act simultaneously on both the excitatory and inhibitory neurons that form the functional neural circuits (42, 87, 283). These transmitters act through a number of pathways to induce the depolarization that constitutes the tonic excitatory drive that controls the different brain rhythms. Different signaling mechanisms are responsible for generating this tonic excitatory drive (**FIGURE 5**). PtdIns4,5P_2 hydrolysis causes depolarization by closing the $\text{K}_V7.2/\text{K}_V7.3 \text{ K}^+$ channels that depolarizes the membrane by switching off the M current. The InsP_3 that is released by the hydrolysis of PtdIns4,5P_2 also contributes to depolarization by releasing Ca^{2+} that activates the Ca^{2+} -activated nonselective cation (CAN) channel. The $\text{Cav1.2 L-type Ca}^{2+}$ channel also contributes to the membrane depolarization in that it generates a Ca^{2+} signal that also activates the CAN channel. Neuronal excitability is also regulated by DA and NE that operate through the cAMP signaling pathway. Inactivation of the D2 receptors in the dorsolateral prefrontal cortex (DLPFC) is prevented by neuronal calcium sensor 1 (NCS-1). It is of interest, therefore, to find that the levels of NCS-1, which activates the InsP_3R , are markedly elevated in BPD (332).

Most of the neural circuits in the brain depend on interactions between excitatory and inhibitory neurons that are responsible for the oscillatory activity that characterizes these brain rhythms. In order for the system to operate normally, the response of each neuronal cell type to the tonic excitatory drive must be finely balanced. To achieve this balance, the synaptic inputs operating between the excitatory and inhibitory neurons must be equal. There are indications that alterations in this excitation-inhibition (E-I) balance may occur in various psychiatric diseases such as autism spectrum disorder (ASD), epilepsy, and schizophrenia (102, 234). There may also be a link between alterations in the tonic excitatory drive and BPD in that excessive excitation may be responsible for the manic phase, whereas depression may result from excessive inhibition as described below.

A decline in the activity of these arousal signaling pathways is responsible for sleep. The signaling pathways are not switched off completely as a low level of stimulation is responsible for maintaining the slow wave sleep rhythm




FIGURE 5. The ascending arousal system, which releases transmitters throughout the brain, activates a variety of signaling pathways to generate the tonic excitatory drive responsible for regulating the brain rhythms during the sleep/wake cycle. Orexin, acetylcholine (ACh), and 5-hydroxytryptamine (5-HT) stimulate the hydrolysis of PIP₂ resulting in closure of the K⁺ channels that drives the M-current. The InsP₃ releases Ca²⁺ that activates the Ca²⁺-activated nonselective cation (CAN) channels. The norepinephrine (NE) and dopamine (DA) generate cAMP that opens Na⁺ channels. These three main pathways depolarize the membrane to produce the alterations in the tonic excitatory drive that regulates the brain rhythms.

(31). The InsP₃/Ca²⁺ signaling pathway may contribute to the operation of the pacemaker mechanism that drives the slow waves that characterize NREM sleep. Such a possibility is consistent with the observation that Li⁺, which acts by reducing the activity of the InsP₃/Ca²⁺ signaling pathway (48), is capable of converting rapid eye movement (REM) sleep to NREM sleep (122, 281). Conversely, the accumulation of amyloid- β , which acts to increase the InsP₃/Ca²⁺ signaling pathway, disrupts NREM sleep leading to a decline in memory formation (233).

C. Memory

The first indication that InsP₃ may play a role in memory emerged from studies of long-term depression (LTD) in cerebellar Purkinje cells. These Purkinje cells, which play an important role in motor learning and coordination, depend on the process of LTD at the synapses where parallel fibers innervate the Purkinje cells. The parallel fibers release glutamate that acts on metabotropic glutamate receptors (mGluR) that are coupled to PLC β to generate InsP₃ that then acts on InsP₃Rs on extensions of the ER that project into the spines to control LTD (166). These InsP₃Rs func-

tion as coincident detectors in that they only open when both InsP₃ and Ca²⁺ signals are present. The parallel fibers produce the InsP₃, whereas the climbing fibers induce the membrane depolarization that opens the L-type Ca²⁺ channels to generate the Ca²⁺. For the channel to open, both messengers need to be present, and this InsP₃R-mediated coincident detection then generates the Ca²⁺ signal necessary for the synaptic plasticity that underlies motor learning. In addition to its role in activating LTD in Purkinje neurons, InsP₃ also plays a central role in activating LTD in other neurons (22, 65, 411).

In keeping with the role of the InsP₃/Ca²⁺ signaling pathway in many neural functions, there is increasing evidence that alterations in this pathway are responsible for many neural diseases such as AD, ALS, ASD, BPD, epilepsy, HD, and spinocerebellar ataxias (SCAs).

D. Alzheimer's Disease (AD)

AD is driven by an increase in the amyloidogenic pathway, which results in the release of soluble β -amyloid (A β) by the neurons. These A β monomers form A β oligomers that feed




FIGURE 6. The role of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway in Alzheimer's disease (AD). Hydrolysis of the amyloid precursor protein (APP) releases β -amyloid ($\text{A}\beta$) that forms $\text{A}\beta$ oligomers. The latter bind to the prion protein (PrP_c), which then activates the mGluR5 receptors to induce the formation of InsP_3 , which then releases Ca^{2+} from the internal store. The resulting persistent elevation in Ca^{2+} then activates long-term depression (LTD) resulting in the memory loss in AD. The activation of InsP_3 is inhibited by Li^+ , and its Ca^{2+} -mobilizing actions is reduced by Bcl-2 and caffeine. These three agents have been found to reduce the effects and onset of AD.

back to activate the neurons to bring about an increase in cytosolic Ca^{2+} , which is the basis of the calcium hypothesis of AD. This elevation in neuronal Ca^{2+} signaling induces a decline in memory and later neuronal cell death (41, 42, 139, 360). A significant feature of this alteration in neuronal Ca^{2+} signaling in AD is the reciprocal relationship between the amyloidogenic and Ca^{2+} signaling pathways. The increase in Ca^{2+} induced by the $\text{A}\beta$ oligomers can feed back to stimulate the formation of $\text{A}\beta$ by stimulating the hydrolysis of APP (139, 169, 298, 308) (FIGURE 6). This ability of Ca^{2+} to stimulate the formation of $\text{A}\beta$ may explain why hypoxia can result in AD pathogenesis. Hypoxia results in an increase in the activation of the Ca^{2+} sensing receptor (CaSR), which is known to increase InsP_3 formation that may then lead on to the elevation of Ca^{2+} (21). One of the actions of the $\text{A}\beta$ oligomers that are responsible for AD is to stimulate the formation of InsP_3 that then acts on the InsP_3 Rs to release Ca^{2+} from the ER (94, 108, 171, 360, 381). There are indications that the $\text{A}\beta$ oligomers can induce this release of internal Ca^{2+} either by acting on cell surface receptors such as the metabotropic glutamate receptor 5 (mGluR5) that acts to increase InsP_3 (381) or by influencing the formation of InsP_3 through an intracellular

action (94). In addition, the activation of the InsP_3 Rs may depend on the increase in oxidative stress that occurs in AD (176). The effect of $\text{A}\beta$ disruption of the internal stores of Ca^{2+} can be rather subtle and are context dependent (203). The contribution of excessive activation of the InsP_3 R in the etiology of AD has been emphasized in studies on transgenic mouse models where reducing the number of InsP_3 -sensitive channels greatly improved memory performance (344).

The presenilins, which are part of the γ -secretase intramembrane protease complex that cleaves the amyloid precursor protein (APP) to form the soluble $\text{A}\beta$, have also been found to influence Ca^{2+} homeostasis. Mutations in the presenilins (PS1 and PS2) result in the dysregulation of Ca^{2+} signaling that is responsible for familial AD (FAD) (70). Perhaps the most important action of the PS mutant protein is to increase the gating of the InsP_3 R Ca^{2+} release channel (118, 208, 230, 359). The resulting enhanced release of Ca^{2+} may contribute to the elevated level of resting Ca^{2+} that rises from 100 to 300 nM (199, 219, 240). It is postulated that this elevation in the resting level of Ca^{2+} will activate LTD to erase memories soon after they are formed, thus accounting for the memory loss that characterizes AD (41, 42). As

the disease progresses, the InsP₃-induced dysregulation of Ca²⁺ will begin to drive neuronal cell death resulting in dementia. A very similar sequence of events occurs in the astrocytes, which surround the neurons, in that the A β oligomers activate the InsP₃/Ca²⁺ signaling pathway resulting in apoptosis (280).

The symptoms of AD in transgenic mice can be reduced by Bcl-2 (317), and this can be explained by its ability to inhibit InsP₃ receptors to reduce the release of Ca²⁺ (FIGURE 6) (318). Caffeine is another drug that may act to reduce the risk of dementia (18, 68, 104, 287, 361). This proposed role of caffeine in reducing the risk of AD may be explained by its ability to inhibit Ca²⁺ release from the InsP₃Rs (54, 164, 322). There is increasing evidence that Li⁺ might be another potential drug to control AD (97, 185, 186, 273, 274, 391). As described below, Li⁺ acts to control BPD by reducing the activity of the InsP₃/Ca²⁺ signaling pathway, and such an action could explain how it might act to protect against AD (FIGURE 6) (97, 261, 391). Patients with BPD that have been treated with Li⁺ for a long period have a much lower incidence of AD (185, 186, 273). Treatment with Li⁺ is able to stabilize memory impairment in AD patients (273). There also are indications that Li⁺ may be able to prevent the onset of AD. It has been shown that Li⁺ was able to prevent individuals displaying mild cognitive impairment from progressing to AD (114, 115). Such a possibility is consistent with the observation that Li⁺, which acts by reducing the activity of the InsP₃/Ca²⁺ signaling pathway (48), is capable of reducing REM sleep to increase NREM sleep (122, 281).

There is increasing evidence to show that the NREM sleep responsible for memory consolidation is disrupted by the accumulation of A β (175, 223, 224, 233, 316). This decline in NREM sleep is consistent with the evidence discussed earlier that A β can act to increase the InsP₃/Ca²⁺ signaling pathway that would enhance the tonic excitatory drive thus preventing the onset of the slow waves that characterize NREM sleep (FIGURE 5). This A β -dependent disruption of NREM sleep may also increase the progression of AD, because the rate of A β formation is lowest during this phase of sleep. The levels of A β are highest during wakefulness and decline during sleep (175, 179, 223). Inhibition of orexin, which is one of the transmitters that drives the sleep-wake cycle (FIGURE 5), results in a decline in A β formation (179). Such an action can be explained by the fact that orexin acts to stimulate the InsP₃/Ca²⁺ signaling pathway and its inhibition would reduce the tonic excitatory drive thus restoring NREM sleep during which there is a marked reduction in A β formation. All this information is consistent with the notion that A β accumulation acts to increase the activity of the InsP₃/Ca²⁺ signaling pathway that not only accounts for memory loss but it also disrupts NREM sleep to enhance A β formation thus contributing to the progression of AD.

E. Amyotrophic Lateral Sclerosis

The neurodegenerative disease ALS, which is also known as Lou Gehrig's disease, is caused by degeneration of the motor neurons in the brain stem, spinal cord, and motor cortex. Approximately 10% of ALS cases are caused by familial mutations, whereas the majority are sporadic. Most information is available for the mutations in the oxidant scavenger superoxide dismutase 1 (SOD1). ALS is also caused by mutations in the TAR-DNA binding protein 43 (TDP-43) TARDDBP gene and in the FUS gene, which encodes the fused in sarcoma (FUS) RNA-binding protein, which in some cases can progress to frontotemporal dementia (FTD).

In the case of sporadic ALS, there have been a number of suggestions about what drives the degeneration of motor neurons. These include glutamate excitotoxicity, hyperexcitability, oxidative damage, mitochondrial dysfunction, and Ca²⁺ dysregulation. All of these events are linked together with regard to their role in altering Ca²⁺ homeostasis (167, 204, 366). For example, the increase in oxidation arising from mutations in SOD1 will enhance Ca²⁺ signaling by increasing the sensitivity of both the InsP₃Rs and the RYRs (167, 366). Such dysregulation of Ca²⁺ is enhanced by the fact that motor neurons have low levels of Ca²⁺ buffering proteins (167, 366), which will place considerably more stress on the mitochondria and thus account for mitochondrial dysfunction. Excessive elevation in mitochondrial Ca²⁺ levels activates the mitochondrial permeability transition pore (mPTP) that results in apoptosis and the death of motor neurons.

One reason for this Ca²⁺ dysregulation may be the glutamate excitotoxicity and hyperexcitability of the motor neurons, which is a characteristic feature of ALS (190). This enhanced excitability may arise through an increase in extracellular glutamate that can alter intracellular Ca²⁺ by enhancing both ionotropic (NMDAR and AMPAR) and metabotropic glutamate receptors (mGluR1 and mGluR5) (136). In a mouse model of ALS, reducing the expression of mGluR1 was found to improve both disease progression and survival (250). Since the mGluR1 receptors act by stimulating phosphoinositide hydrolysis, this observation suggests that the InsP₃/Ca²⁺ signaling pathway may contribute to the dysregulation of Ca²⁺ that is responsible for ALS (366). Such a role for the InsP₃/Ca²⁺ signaling pathway can explain why Li⁺ can delay the progression of ALS (116). As described earlier, Li⁺ inhibits the IMPase resulting in a reduction in the activity of this InsP₃/Ca²⁺ signaling system (48).

Such a role for InsP₃/Ca²⁺ signaling in ALS is supported by a number of other observations. Antibodies isolated from patients with ALS were found to stimulate the activity of the InsP₃/Ca²⁺ signaling pathway in motor neurons (285). The life span of transgenic mice containing the mutant SOD1

gene was reduced when the expression of the InsP₃R was increased (353). Expression of PLC δ 1, which is responsible for generating InsP₃, was found to be increased in the neurons of the transgenic ALS mouse. Furthermore, the survival of these ALS mice was prolonged following genetic ablation of PLC δ 1 (354). An increase in activity of the InsP₃/Ca²⁺ signaling pathway may contribute to ALS through its ability to alter the activity of 43 kDa TAR DNA-binding domain protein (TDP-43). Mutations in TDP-43 result in the aggregation of TDP-43 in the cytoplasm, and this contributes to the deterioration of the motor neurons in ALS. This pathological activity of TDP-43 is regulated by Ca²⁺ release from the InsP₃R1 channels (189). Increasing the activity of InsP₃/Ca²⁺ signaling thus promotes the nucleocytoplasmic shuttling of TDP-43 resulting in its accumulation in the cytoplasm where it exerts its deleterious effects on motor neuron survival.

F. Autism Spectrum Disorders

A number of diseases such as autism, Asperger's syndrome, perverse developmental disorder not otherwise specified (PDD-NOS), and Rett syndrome fall under the umbrella of ASD. ASD is a neurodevelopmental disorder that results in a lack of social communication especially with regard to appreciating how other people feel. ASD appears during childhood and continues into adulthood. Trying to understand this syndrome is difficult because there is considerable heterogeneity at both the genetic and phenotypic levels (135, 299).

The neurodevelopmental aspect of ASD is based on the fact that it appears to be linked to alterations in the mechanism responsible for development of the nervous system. As described earlier, spontaneous Ca²⁺ signals begin to appear in certain neuronal generator cells that become pacemaker cells that spread excitation to neighboring cells to form large signaling hubs. This Ca²⁺ signaling contributes to the neuronal differentiation responsible for synapse formation that creates the neuronal circuits in the developing brain.

Recent evidence suggests that ASD results from defects in the Ca²⁺ signaling processes responsible for setting up the structure and function of neural assemblies and particularly the synapses (101, 135, 198). The Ca²⁺ signaling system is one of the important pathways responsible for orchestrating the complex process of brain development. A key element in this regulation is the expression of the Ca²⁺ buffer parvalbumin (PV). When the level of PV declines, there is an alteration in the function of inhibitory neurons that will alter the excitation-inhibition (E-I) balance, and this leads to the onset of ASD (113, 269). Such a mechanism may explain why vitamin D deficiency, which normally functions to maintain the expression of PV and many other components of the Ca²⁺ signaling toolkit (44, 45), has been linked to ASD (107, 172). The InsP₃/Ca²⁺ signaling path-

way plays a key role in regulating both proliferation and differentiation during early development (380, 398). It is not surprising, therefore, to find that alterations in the activity of this InsP₃/Ca²⁺ signaling system may contribute to the onset of autism (135, 333). Studies on the fibroblast taken from autistic patients reveal that there is a marked decline in the InsP₃-induced release of Ca²⁺ (333). Such an observation is consistent with a study of the genetic variants of the oxytocin receptor that have been identified in patients with autism, which also displayed a decline in the InsP₃/Ca²⁺ signaling pathway (225).

G. Bipolar Disorder

A characteristic feature of BPD is the extreme swings between mania and depression. It is still not clear what is responsible for these alternating manic-depressive episodes. These changes in behavior seem to depend on alterations of neuronal signaling, which are a feature of the two hypotheses that attempt to explain BPD. In the neurogenesis hypothesis, it is suggested that there is an alteration in the hippocampal circuitry that arises from a change in neurogenesis induced by stress. The inositol depletion hypothesis is based on the observation that Li⁺ acts by inhibiting the inositol monophosphatase (IMPase) that hydrolyzes inositol monophosphates (Ins4P, Ins1P, and Ins3P) to form free inositol (46, 48). As a result of this inhibitory action, Li⁺ reduces the supply of free inositol necessary to resynthesize the inositol lipids that are required to maintain the InsP₃/Ca²⁺ signaling system, thus resulting in a decline in the activity of this signaling pathway (FIGURE 2). Li⁺ acts through an uncompetitive mechanism that enables this drug to have minimal effects when the InsP₃/Ca²⁺ signaling pathway is functioning normally, but its efficacy increases as the signaling pathway becomes increasingly abnormal. In effect, Li⁺ can be considered to be a homeostatic drug, because it has no effect when the system is operating normally, but its therapeutic action becomes increasingly effective to match the degree of hyperactivity of the InsP₃/Ca²⁺ signaling pathway. In effect, the therapeutic action of Li⁺ is tailored to the severity of the disease state. These actions of Li⁺ to reduce the InsP₃/Ca²⁺ signaling pathway led to the idea that BPD may arise as a result of an overactive phosphoinositide signaling pathway (46, 48). Such a conclusion is supported by the observation that the levels of G $\alpha_{q/11}$ and PLC β 1, which are key components of the phosphoinositide signaling pathway, are elevated in the occipital cortex from patients with BPD (236). In addition, it has been shown that stimulating InsP₃Rs and RYRs creates a depression-like response in mice, whereas inhibition of these channels has an antidepressant-like effect (125).

Ebselen, which is a Li⁺ mimetic that also acts by inhibiting the IMPase, may be a safer drug for controlling BPD (347, 348). Li²⁺ may also act by inhibiting the stimulatory action of the neuronal calcium sensor 1 (NCS-1) on the InsP₃R1

(332). The mood-stabilizing drug valproate may also act by reducing the activity of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway (103). All this evidence suggests that enhanced neural $\text{InsP}_3/\text{Ca}^{2+}$ signaling contributes to both BPD pathology and the nature of the switching process. Enhanced release of ER Ca^{2+} is of major importance in the pathophysiology of BPD (395).

A characteristic feature of BPD is the process of switching from depression to the opposite state of mania, and vice versa (323, 373, 417). Alterations in the activity of various neurotransmitters may play a role in this switching process and is the basis of the catecholaminergic-cholinergic balance hypothesis (385). For example, the switch from depression to mania may be regulated by elevations in the levels of norepinephrine and dopamine (417). Conversely, the switch from mania to depression may depend on elevations in acetylcholine. Understanding the nature of this switching process would greatly enhance our understanding of BPD, but as yet the mechanism is still unclear.

It is possible that the symptoms of BPD, and particularly the switching between depression and mania, may arise from defects in the E-I balance that controls the neuronal activity responsible for driving brain rhythms as described earlier (**FIGURE 5**) (43, 369). Similarly, it has been proposed that major depressive disorder (MDD) may be caused by an alteration in excitatory transmission (374). Such a mechanism is particularly interesting in that Li^+ , which acts to restore the neuronal imbalance, acts to enhance synapse formation by altering the level of phosphoinositides (187). It is also significant that the transmitters that have been implicated in the switching process also regulate the tonic excitatory drive. An alteration in the activity of these transmitters is thus consistent with the idea that an E-I imbalance may be the cause of BPD, because many of these transmitters activate the tonic excitatory drive using a variety of signaling mechanisms (**FIGURE 5**) (42). For example, some of these transmitters (ACh, NE, and orexin) act to induce depolarization by stimulating the hydrolysis of PtdIns4,5P_2 to decrease the M current while the $\text{InsP}_3/\text{Ca}^{2+}$ pathway promotes the Ca^{2+} -activated nonselective cation current (I_{CAN}) (**FIGURE 5**). The possibility that hyperactivity of the $\text{InsP}_3/\text{Ca}^{2+}$ pathway contributes to BPD is supported by studies showing that this disease is associated with *Bcl-2* gene single nucleotide polymorphisms (SNPs), which reduce *Bcl-2* expression that could result in an increase in Ca^{2+} levels that are normally suppressed by *Bcl-2* (98, 226).

Another reason for considering a possible role for changes in the tonic excitatory drive in BPD is the finding that two of the genes that have consistently been linked to BPD play a role in regulating neuronal activity. A number of genes such as *CACNA1C* that encodes the α -1C subunit of the Cav1.2 L-type Ca^{2+} have been identified in a genome-wide association studies (12, 152, 346, 349, 373). This observation

may be particularly significant because the Cav1.2 L-type Ca^{2+} generates a Ca^{2+} signal that contributes to the tonic excitatory drive by activating the CAN channel (**FIGURE 5**). The other gene is *ANK3* that encodes ankyrin-G, which plays a role in positioning the $\text{K}_v7.2/\text{K}_v7.3$ channels to the correct location in the neuronal membrane. $\text{K}_v7.2$ and $\text{K}_v7.3$ are delayed rectifier channels that contribute to the regulation of neuronal excitability by controlling the M current.

In summary, a characteristic feature of BPD is the switching between depression and mania that may result from changes in the E-I balance that will cause mania if the excitatory neurons are hyperactive or depression if the inhibitory neurons are hyperactive (43). Such hyperactivity, which is reduced by Li^+ , has been confirmed in neurons taken from bipolar patients (246). One of the causes of this imbalance is likely to be an increase in the activity of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway. In the case of a mouse model of depression, inhibition of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway was found to exert an antidepressant effect (125). Correcting this signaling abnormality may explain the therapeutic action of Li^+ , which acts by reducing the activity of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway.

H. Epilepsy

Spontaneous recurrent epileptiform discharges (SREDs) are a characteristic feature of epilepsy. Such seizure activity, which is usually induced by brain injuries such as trauma, stroke, or infections, seem to arise through an alteration in the E-I balance described earlier (355). The activity of the inhibitory neurons appears to decline to account for the increased activity of the excitatory neurons. A number of intracellular signaling pathways such as an increases in Ca^{2+} (92, 93, 242, 286) and nitric oxide (NO) (197) or a decrease in the PtdIns3,4,5P_3 levels (71) have been implicated in this alteration in the E-I balance. The Ca^{2+} hypothesis (92) that proposes there is an alteration in Ca^{2+} homeostasis appears to be particularly important because it can account for a number of features of epilepsy such as the decline in cognition (161, 402) and its relationship to AD (63, 75).

The alteration in Ca^{2+} homeostasis that occurs in epilepsy is caused by various brain injuries that result in a large release of glutamate that then stimulates the NMDARs to bring about a large Ca^{2+} influx that alters the Ca^{2+} signaling system. In particular, there is a decline in the expression of the SERCA pump on the ER and an increase in the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway (93, 286). A role for $\text{InsP}_3/\text{Ca}^{2+}$ signaling has also been implicated in the onset of seizures induced by the organophosphorus (OP) compound soman, which is a chemical warfare agent. Soman was found to induce an increase in InsP_3 formation (58) that appears to be driven by an increase in the activity of the metabotropic glutamate receptors (264).

The mechanism driving the increase in the $\text{InsP}_3/\text{Ca}^{2+}$ signaling system is unclear, but it may be caused by an increase in the brain-derived neurotrophic factor (BDNF) that operates through the TrkB receptor to induce epilepsy (217). TrkB activates PLC γ to increase InsP_3 that acts to maintain the elevation of Ca^{2+} . Epilepsy can be prevented by using a specific peptide to uncouple the interaction between TrkB and the PLC γ (141). A genome-wide transcriptomic analysis has revealed that the InsP_3 signaling pathway is genetically associated with epilepsy (252). The significance of enhanced InsP_3 action in epilepsy is highlighted by the observation that the anti-epileptic drug levetiracetum acts to inhibit the release of Ca^{2+} by the InsP_3 Rs (265). Depletion of Ca^{2+} within the ER resulting from the decline in SERCA and the increased levels of InsP_3 results in an increase of store-operated Ca^{2+} due to the activation of the STIM1/Orai1 entry pathway (356). The decline in SERCA resembles that found in the heart during congestive heart failure (CHF). The net result of the enhanced release of Ca^{2+} from the ER and entry across the plasmalemma is to bring about a persistent increase in the resting level of Ca^{2+} and the enhanced network activity that gives rise to epilepsy (356).

The elevation in Ca^{2+} that is triggered during a seizure persists after the seizure and can account for many of the features of epilepsy. This Ca^{2+} elevation will increase the tonic excitatory drive, which is responsible for controlling brain rhythms (FIGURE 5), and will thus enhance neuronal excitability and could set the stage for subsequent seizures. The decline in cognition could also be explained by the elevated Ca^{2+} that would stimulate LTD to erase memories. It has been proposed that a similar persistent elevation in Ca^{2+} may also explain memory erasure in AD as described above (41, 42), and it could also account for the fact that seizures are a common feature of AD (63, 75). It seems that in both AD and epilepsy, the persistent elevation in the resting levels of Ca^{2+} can account for both memory loss and epileptogenesis.

I. Huntington's Disease

In HD, there is a progressive decline in intellect that culminates in death after 10–15 yr. This neurological disease has been linked to a polyglutamine expansion in the NH₂ terminus of the Huntington protein (Htt^{exp}) that results in an alteration in Ca^{2+} signaling that is responsible for the death of the GABAergic medium spiny neurons located in the striatum (85). The modified Htt^{exp} binds strongly to the COOH-terminal region of the InsP_3 R1 resulting in an increase in its sensitivity to InsP_3 , thus giving rise to larger Ca^{2+} signals that disrupt neuronal function and induce neuronal cell death (51, 53, 106, 118, 368). In a mouse model of HD, activation of the InsP_3 R1 causes depletion of ER Ca^{2+} that results in store-operated Ca^{2+} entry that contributes to the striatal synaptic loss (407). Mutant Htt accumulation and aggregation was reduced when the levels of the

InsP_3 R1 was reduced using shRNA (29), thus confirming that the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway plays a role in HD. The significance of this pathway is also consistent with recent observations suggesting that Li⁺, which acts to reduce the activity of $\text{InsP}_3/\text{Ca}^{2+}$ signaling, may be a significant drug for treating HD (327, 331).

J. Schizophrenia

Schizophrenia occurs in ~1% of the human population and is a severe psychiatric condition that is characterized by hallucinations, paranoia, poor attention, decline in social interactions, and lack of motivation. There also is a decline in cognition. An alteration in brain rhythms may be responsible for the changes in these higher-order brain functions that are a feature of schizophrenia (43). Many of the genetic susceptibility elements code for components of Ca^{2+} signaling, thus supporting the experimental evidence indicating that changes in Ca^{2+} signaling is a feature of schizophrenia. There is increasing support for the NMDA receptor (NMDAR) hypofunction hypothesis (350, 375). A decline in the Ca^{2+} signaling pathway resulting from a decrease in the activity of NMDARs alters the phenotype stability of the GABAergic inhibitory neurons. A decline in the release of the neurotransmitter GABA distorts the brain rhythms leading to an alteration in the information processing that occurs during sensory stimulation, attention selection, and working memory.

The GABAergic inhibitory neurons also express GPCRs such as the mGluR1, mGluR5, and M1 receptors that activate the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway that acts to augment the Ca^{2+} signal that maintains phenotypic stability. There also is evidence of a decline in the activity of serotonergic neurons located in the prefrontal cortex of patients with schizophrenia (178, 239). Many of these neurons express the 5-HT_{2A} that act to increase $\text{InsP}_3/\text{Ca}^{2+}$ signaling (88). Alteration in this phosphoinositide signaling pathway plays a role in schizophrenia pathogenesis. Considerable interest is now focused on the metabotropic glutamate receptor 5 (mGluR5), which is closely associated with the NMDAR through scaffolding proteins such as Homer, SHANK, guanylate-kinase-associated protein, and PSD95. Alterations in mGluR5 may contribute to schizophrenia (237), and mutations in SHANK have been linked to various neuropsychiatric diseases including schizophrenia (131, 142). Furthermore, a deficit in ACh signaling mediated through muscarinic receptors has also been implicated in schizophrenia (328). A decrease in the expression of the regulators of G protein signaling 4 (RGS4), which modulates the activity of the PLC β 1 that mediates the activity of these GPCRs, is a consistent feature of schizophrenia (251). In schizophrenia patients, there are deletions of PLC β 1 in the orbital-frontal cortex (220). Abnormal expression patterns of PLC β 1 have been observed in patients with schizophrenia (194). Schizophrenic symptoms have also been observed in PLC β 1 knockout mice (243).

In addition to these alterations in the transducing mechanisms responsible for generating the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway, there also is evidence for changes in the function of the $\text{InsP}_3\text{R1s}$. For example, one of the actions of the susceptibility gene *Disrupted-in-schizophrenia-1* (DISC1) is to alter the activity of the $\text{InsP}_3\text{R1s}$ (290). DISC1 interferes with the transport of the mRNA of the *ITPR1* gene that encodes the $\text{InsP}_3\text{R1s}$. It attaches the *ITPR1* mRNA to the kinesin-1 molecular motor that then propels it down the microtubules to distribute it throughout the dendritic tree. Once in position, the *ITPR1* mRNA begins to express the $\text{InsP}_3\text{R1}$ channels (379), which are key components of neuronal Ca^{2+} signaling mechanisms.

K. Spinocerebellar Ataxias

SCA is characterized by poor coordination of movement that can affect the legs, hands, and speech. There are many different types of SCA, and some of the causes have been linked to a dysregulation of the cerebellar $\text{InsP}_3/\text{Ca}^{2+}$ signaling network that alters its role in the coordination of movement (53, 66, 106, 118, 335). Many of the ataxias have been linked to mutations in the *ITPR1* gene, which encodes the $\text{InsP}_3\text{R1}$ that releases Ca^{2+} from the ER located within the spines of the Purkinje cells (365). For example, *ITPR1* is one of the genes known to be associated with SCA15 (384). Missense mutations in the *ITPR1* have also been identified in spinocerebellar ataxia type 29 (SCA29) (163). Mutations in the *ITPR1* have also been identified in children with sporadic ataxic cerebral palsy (334). Degeneration of Purkinje cells and the onset of ataxia have been described in mice following deletion of *Inpp5a*, which encodes the InsP_3 5-phosphatase that is one of the major pathways for inactivating InsP_3 (FIGURE 2) (414). The spinocerebellar ataxia type 6 (SCA6) form of this disease is caused by a mutation in the α_{1A} subunit of the $\text{CaV}2.1$ P/Q channel that provides the Ca^{2+} signal that acts together with InsP_3 to open the InsP_3Rs (67). The SCA2 form is caused by mutations in ataxin-2 (Atx2), which associates with the COOH-terminal region of the Purkinje cell $\text{InsP}_3\text{R1}$ resulting in an increase in its sensitivity (215). In Russian and Japanese families with SCA, the *ITPR1* gene that encodes the $\text{InsP}_3\text{R1}$ was found to have a central role in SCA pathogenesis (146, 338).

Autosomal dominant cerebellar ataxia (ADCA), which is a type of SCA, has been linked to mutations in RNF170 that is an ER membrane ubiquitin ligase. RNF170 functions to ubiquitinate activated InsP_3Rs . The mutation of RNF170 interferes with this ubiquitination process and results in a decline in Ca^{2+} signaling via the InsP_3Rs and is likely to be the cause of ADCA (405). The dysregulation of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway results in abnormal elevation of Ca^{2+} that alters motor coordination and progresses to a gradual degeneration of the Purkinje neurons, which is a characteristic feature of SCA. This central role of the InsP_3R

in SCA is supported by the fact that the symptoms of SCA in mice can be alleviated by suppression of this signaling pathway in Purkinje cells (183).

VI. MUSCLE CELLS

The $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway plays a role in regulating skeletal, cardiac, and smooth muscle cell functions. In skeletal and cardiac cells, InsP_3 has a modulatory role. Alterations in this modulatory role in skeletal muscle leads to Duchenne muscular dystrophy (DMD), whereas in cardiac cells it causes congestive heart failure and atrial arrhythmias (FIGURE 1). In the case of certain smooth muscle cells, it provides the primary Ca^{2+} signal and alterations in this signal contribute to asthma and hypertension.

A. Skeletal Muscle

The $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway contributes to the regulation of skeletal muscle throughout its life history. During myoblast development, it generates the Ca^{2+} oscillations that are essential to induce the expression of the muscle-specific transcription factors such as myogenin and myocyte enhancer factor 2 (MEF2) (16). As the myoblast develops into skeletal muscle cells, they express the RYR1 that drives muscle contraction. Although the $\text{InsP}_3/\text{Ca}^{2+}$ pathway does not play a direct role in excitation-contraction (E-C), it has an important modulatory role in various muscle functions.

During the process of E-C coupling, the sarcolemma action potential is converted into an increase in Ca^{2+} that stimulates contraction. The muscle action potential, which invades the entire sarcolemma including the t-tubules where it functions to activate the $\text{CaV}1.1$ voltage-operated Ca^{2+} channel that interacts directly with the RYR1 to release Ca^{2+} from the SR. Once it is released, the Ca^{2+} diffuses to the sarcomeres where it binds to the troponin C (TnC) that induces contraction by facilitating an interaction between actin and myosin.

In addition to this primary Ca^{2+} signaling pathway, skeletal muscle retains the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway that drove development to regulate processes both in the nucleus and in the cytoplasm (83). There appear to be two mechanisms responsible for activating the PLC that generates InsP_3 : it is activated by insulin (82) and by membrane depolarization (213, 382). The insulin-dependent activation of the $\text{InsP}_3/\text{Ca}^{2+}$ pathway regulates metabolism by activating the insertion of the glucose transporter 4 (GLUT4) into the sarcolemma. The glucose that enters the cell through GLUT4 is phosphorylated by hexokinase to form glucose 6-phosphate (G6P) that is synthesized into glycogen by the glycogen synthase (82). The depolarization-induced activation of $\text{InsP}_3/\text{Ca}^{2+}$ also operates to control gene transcription (382).

B. Duchenne Muscular Dystrophy (DMD)

The $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway has been implicated in DMD, which is a progressive muscle-wasting disease. This disease results from mutations in the gene that encodes dystrophin, which has been shown to result in an increase in Ca^{2+} signaling that drives Ca^{2+} -sensitive proteases responsible for muscle degeneration. One of the consequences of the mutations in dystrophin, which is located on the inner surface of the sarcolemma, is to enhance the activity of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway (23, 212). In fetal muscle, the delayed myogenesis during dystrophy is caused by the InsP_3 -dependent release of Ca^{2+} (105). The dystrophic phenotype could be reversed by various treatments that reduced the activity of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway such as the expression of normal dystrophin (23, 81), knockdown of the type 1 InsP_3R , or its inhibition by 2-aminoethoxydiphenyl borate (259). Inhibition of the InsP_3R by over expressing Bcl-2 was also able to prevent apoptosis in dystrophic myotubes (28). An increase in the activity of $\text{InsP}_3/\text{Ca}^{2+}$ signaling also contributes to the muscular dystrophy that occurs in dilated cardiomyopathy (247).

C. Cardiac Cells

The heart, which pumps blood around the body, is driven by the sinoatrial (SA) node pacemaker system. The pacemaker cells in the SA node generate the repetitive action potentials that travel through gap junctions to excite both the ventricular and atrial cells. The functions of these three cardiac cells that drive each heartbeat are modulated by the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway (387).

D. SA Node Pacemaker Cells

The cardiac pacemaker cells in the SA node are responsible for driving the rhythmical contraction of the heart. The specialized pacemaker cells in the SA have a sophisticated oscillatory mechanism based on both a membrane and a cytosolic Ca^{2+} oscillator that generates the repetitive action potentials. The main component of the membrane oscillator is the HCN4 Na^+ channel that is activated by hyperpolarization and then slowly decays to drive the slow pacemaker depolarization. The cytosolic Ca^{2+} oscillator consists of both RYRs and InsP_3Rs that interact with each other to release the pulse of Ca^{2+} that then contributes to this pacemaker depolarization by enhancing the activity of $\text{Na}^+/\text{Ca}^{2+}$ exchanger (NCX) resulting in a $I_{\text{Na}/\text{Ca}}$ current. This periodic release of Ca^{2+} from the SR depends on the activity of the SERCA pumps that refill the store, and this slow accumulation of Ca^{2+} within the SR lumen acts to sensitize the RYRs to initiate periodic Ca^{2+} sparks (389). These sparks begin to develop toward the end of the pacemaker depolarization when they trigger a sudden release of Ca^{2+} immediately preceding and contributing to the onset

of the action potential. These bursts of Ca^{2+} occur close to the cell surface where there is close apposition between the sarcoplasmic reticulum (SR) and the sarcolemma. The appearance of these sparks is facilitated by the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway that contributes to the activation of the RYRs responsible for the pacemaker depolarization. Activation of InsP_3 by either endothelin or $\alpha 1$ -adrenergic receptors enhances both the frequency and amplitude of the Ca^{2+} sparks that are driving the cardiac pacemaker potential (174). The primary function of InsP_3 is to stimulate the $\text{InsP}_3\text{R}2$ to release Ca^{2+} that then acts to sensitize the RYRs to increase the frequency and amplitude of the Ca^{2+} sparks (173, 182).

E. Atrial Cardiac Cells

Contraction of the atrial chambers of the heart is driven by the striated atrial cells. Unlike the ventricular cells, the atria do not have t-tubules and the SR is closely applied to the sarcolemma through junctional zones that contain the RYR2 channels. The atrial cell Ca^{2+} signal initiates at these junctional zones. The remainder of the SR sheet, which also contains RYRs, extends into the cell perpendicularly. The initial signal generated at the junctional zone is amplified and spreads into the cell by these nonjunctional RYRs. The atrial $\text{InsP}_3\text{R}2$ receptors have two locations: the junctional zones and the nucleus (192, 214). Those $\text{InsP}_3\text{R}2$ s that are located together with the RYRs in the junctional zone have a significant modulatory role in that they respond to endothelin-1 to induce a positive inotropic response.

In response to the atrial action potential, the L-type Ca^{2+} channels in the sarcolemma facing the junctional zone generate a small pulse of Ca^{2+} that activates the RYRs to create a Ca^{2+} spark immediately below the sarcolemma. However, this small spark usually fails to ignite the RYRs on the rest of the SR and thus accounts for why atrial contractions are often rather weak. Much stronger contractions occur when atrial cells are stimulated by either a β -adrenergic agonist or by endothelin. There are two ways whereby these agonists induce a large positive inotropic response. First, they enhance the amplitude of the initial spark at the junctional zone so that it can breach the mitochondrial firewall to gain access to the nonjunctional RYR2s thereby generating a larger global Ca^{2+} signal that drives stronger contractions. Second, these hormones can increase the sensitivity of the RYR2s that also enables the initial spark to create a Ca^{2+} wave that penetrates the cell. The location of the InsP_3 receptors at the atrial cell junctional zone in immediate juxtaposition to the RYR2 thus enables them to play an important modulatory role in atrial cell excitation-contraction (E-C) coupling. The endothelin-1 acts on InsP_3 receptors in the junctional zone to augment the Ca^{2+} spark sufficiently so that it spreads throughout the cell by recruiting the RYR2s on the nonjunctional SR to increase the force of contraction (192, 228).

F. Atrial Arrhythmias

The most common cardiac arrhythmias are the atrial arrhythmias, which are caused by an increase in the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway. Endothelin acts to increase the formation of InsP_3 that results in the excessive Ca^{2+} signaling responsible for the development of these atrial arrhythmias (159, 210, 227, 426) that can result in sudden heart death. In patients with chronic atrial fibrillation, there is an upregulation in the expression of the InsP_3Rs (412). These arrhythmias also arise following deletion of the GTPase-activating protein RGS4 that inhibits the $\text{G}_{q/11}$ responsible for activating the $\text{PLC}\beta$ that generates InsP_3 (278, 377). A role for InsP_3 is supported by the observation that application of 2-aminoethoxydiphenyl, which had no effect on Ca^{2+} signaling under control conditions, specifically suppressed atrial arrhythmias (227, 409). Arrhythmias are also abolished in mice lacking $\text{InsP}_3\text{R2}$ receptors (210). Endothelin can also induce arrhythmias in ventricular cardiac myocytes that also are driven by InsP_3 (306).

G. Ventricular Cardiac Cells

In ventricular cells, E-C coupling depends on the entry of Ca^{2+} across the sarcolemma where it then activates the release of Ca^{2+} by RYRs located on the sarcoplasmic reticulum (SR). This Ca^{2+} -induced Ca^{2+} release process is facilitated by a unique structural relationship between the sarcolemma and SR. The sarcolemma has regular tubular invaginations (t-tubules) that extend deep into the cell. At regular intervals along the length of the t-tubule there are junctional zones, which are specialized regions where the SR contacts the t-tubule. Each ventricular cell has $\sim 10,000$ junctional zones each of which has about 10 $\text{CaV}1.2$ L-type channels that face ~ 100 RYRs in the associated SR region. The L-type channels in the t-tubule region generate the trigger Ca^{2+} that then stimulates the juxtaposed RYRs in the SR that face the t-tubule. Each of these events is induced by the action potential that sweeps along the sarcolemma to initiate ventricular cell E-C coupling.

This ventricular Ca^{2+} signaling system can readily adapt to changes in cardiac function. Both positive and negative inotropy can be induced by various hormones acting in a reversible manner over short periods of time. In response to persistent modulatory signals, the ventricular cells can undergo phenotypic remodeling that induces an enlargement (hypertrophy) of the heart. This onset of hypertrophy can have pathological consequences if it progresses to CHF. Hypertrophy can thus be either physiological or pathological. In the former case, the hypertrophy is a normal compensatory response to an increase in work load and is reversible in that the heart reverts back to its previous shape once the work load is reduced. The irreversible CHF that results in sudden heart death develops when the pressure overload persists and there is a phenotypic change in the

remodelling process that switches it from being a compensatory mechanism to a more pathological process.

H. Congestive Heart Failure

The dysfunctional cardiac remodeling that results in CHF is a major cause of human morbidity and mortality. A persistent increase in cardiac work load is one of the main causes that initiates the onset of CHF. One of the major causes of CHF is hypertension, which is associated with an increase in hormones such as endothelin-1, angiotensin II, and catecholamines. These hormones have a profound effect on the Ca^{2+} dynamics of ventricular cells through their activation of phosphoinositide hydrolysis to increase the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway (192, 388). In ventricular cells, the $\text{InsP}_3\text{R2s}$ are located on the nuclear membrane. The opening of these release channels depends on the presence of both InsP_3 and Ca^{2+} (FIGURE 7). Even though endothelin-1 can enhance the level of InsP_3 in cardiac cells, it is not able to release Ca^{2+} when acting by itself. However, during each cardiac Ca^{2+} transient that drives contraction, there is a cytosolic pulse of Ca^{2+} that can provide the costimulatory Ca^{2+} signal necessary to activate the $\text{InsP}_3\text{R2s}$ that then creates a local Ca^{2+} signal in the nucleus during the course of each contraction. This InsP_3 -dependent nuclear Ca^{2+} signal is modulated by NCS-1, which is one of the regulators of the InsP_3Rs (FIGURE 4) (266). The $\text{InsP}_3\text{R2s}$ function as coincident detectors in that they integrate the InsP_3 signal generated by the endothelin-1 receptors and the contractile Ca^{2+} signal to generate the nuclear Ca^{2+} signal that activates the transcriptional events responsible for the onset of hypertrophy (148, 154, 214, 218, 267, 406, 427). One of the genes that is activated is *ITPR2* that codes for the $\text{InsP}_3\text{R2}$ that is responsible for the nuclear Ca^{2+} signal that drives hypertrophy (324).

The persistent nuclear Ca^{2+} pulses driven by the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway induces a process of dedifferentiation characterized by the activation of a program of fetal cardiac gene transcription. Cardiac function is markedly altered as a result of this remodeling, because there is a reduction in the amplitude of the Ca^{2+} signal and the weaker cardiac contractions result in the failing heart. A particularly important change is the downregulation of the SERCA2a pump resulting from a decrease in its expression. In addition, this inhibition of SERCA2a is exacerbated by the inactivation of the adrenergic modulatory mechanism resulting in an increase in the activity of the $\text{Na}^+/\text{Ca}^{2+}$ exchanger that reduces the uptake of external Ca^{2+} that further reduces the ability of the SERCA pump to load the SR with Ca^{2+} . This decline in the ability of the SERCA pump to load the store with Ca^{2+} results in larger diastolic Ca^{2+} concentrations and a significant decline in the systolic Ca^{2+} transient. This severe downregulation of Ca^{2+} signaling brought about by the InsP_3 nuclear Ca^{2+} signals is a characteristic feature of CHF.




FIGURE 7. The role of $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway in cardiac hypertrophy. Angiotensin II and endothelin stimulate the formation of InsP_3 that acts together with the Ca^{2+} released from the ryanodine receptor 2 (RYR2) to activate the $\text{InsP}_3\text{R2s}$ (I) to trigger a nuclear Ca^{2+} signal that activates the HDAC and NFAT shuttles to stimulate the transcription factors responsible for switching on the fetal genes that induce hypertrophy.

I. Kawasaki Disease

Kawasaki disease is caused by vasculitis, and this inflammation of the blood vessels has an effect on many organs such as the heart, lymph nodes, skin, and mucous membranes inside the mouth, nose, and throat. It is characterized by high temperature that can last for 5 days. A significant aspect of the disease is acquired heart disease in children where it damages the coronary arteries resulting in inflammation of the heart, dysrhythmias, and aneurysms. The cause of this disease is still not clear, but there are indications that $\text{InsP}_3/\text{Ca}^{2+}$ signaling may function to activate the T cells that contribute to the inflammatory response. Kawasaki disease has been linked to a mutation in the *ITPKC* gene that encodes the InsP_3 3-kinase that phosphorylates and inactivates the Ca^{2+} -mobilizing activity of InsP_3 (FIGURE 2) (200, 277, 416).

J. Smooth Muscle

1. Smooth muscle contraction and hypertension

Contraction of the smooth muscle cells (SMCs), which surround the vascular blood vessels, is driven by oscillatory Ca^{2+} signals that are driven by the $\text{InsP}_3/\text{Ca}^{2+}$ signaling

pathway that is activated by transmitters such as ACh, 5-hydroxytryptamine (5-HT), and norepinephrine (NE) and hormones such as endothelin-1 (ET-1) (38). The release of stored Ca^{2+} , which drives these oscillations to maintain the vascular tone, is driven by both InsP_3R and RYR channels. Variations in transmitter concentration are translated into changes in the frequency of the Ca^{2+} oscillations and is another example of the frequency-modulated mechanism for regulating cellular function as described earlier (36, 47).

An increase in the activity of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway may contribute to the increased myogenic tone that results in the hypertension that induces cardiac disease (4). For example, in human pulmonary arterial SMCs, the enhanced expression of the Ca^{2+} -sensing receptor (CaSR) acts to increase the activity of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway (410). In hypertensive rats, expression of the InsP_3Rs is markedly elevated (1). Increased entry of Ca^{2+} through L-type channels acts through the calcineurin/NFAT transcriptional pathway to increase the expression of the InsP_3Rs that contributes to hypertension through increased vascular smooth muscle (VSM) contractility. Such an action is consistent with the observation that there is increase in the expression of InsP_3Rs in spontaneously hypertensive rats (SHRs) (32).

Blood vessels are lined with endothelial cells that play an important role in regulating smooth muscle tone. Various stimuli act on these endothelial cells to stimulate $\text{InsP}_3/\text{Ca}^{2+}$ signaling that then generates various vasoactive agents such as nitric oxide (NO), prostacyclin, and endothelium-derived hyperpolarizing factor, which act to control smooth muscle contractility. The increased blood pressure that occurs during hypertension results in a marked decline in the activity of $\text{InsP}_3/\text{Ca}^{2+}$ signaling, and this interferes with the ability of the endothelial cells to reduce smooth muscle contraction (400).

2. Smooth muscle cell proliferation and asthma

Proliferation of smooth muscle cells is an example of how a differentiated cell can switch back into the cell cycle to return to cell division. This return to proliferation by SMCs is particularly significant for wound healing. However, such switching back into a proliferative state has a number of pathophysiological consequences in that it causes asthma, hypertension, and pulmonary vasoconstriction. In the case of pulmonary artery smooth muscle cells, proliferation is activated by a mechanism remarkably similar to that found in T cells (see above). An increase in InsP_3 releases Ca^{2+} from the ER, and this then induces prolonged Ca^{2+} signaling through the activation of the STIM1/Orai1 entry pathway (351, 428).

Asthma and chronic obstructive pulmonary disease (COPD) are the two main respiratory diseases. The increase in SMC proliferation described above contributes to asthma because it results in a thickening of the bronchial wall. In addition, asthma is also caused by other alterations in the airways such as inflammation, bronchial hyperresponsiveness, and obstruction of the airways by excessive contraction of the SMCs. The excessive contraction of the airway SMCs, which is driven by the $\text{InsP}_3/\text{Ca}^{2+}$ pathway, is one of the main causes of asthma (145). In COPD, there is an overexpression of muscarinic M3 receptors that is responsible for the enhanced $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway that drives the excessive contraction (294). One of the most successful bronchodilators used to control COPD is tiotropium that acts by inhibiting the M3 receptors to reduce the elevated $\text{InsP}_3/\text{Ca}^{2+}$ signaling to reduce SMC contraction and sputum production in airway mucous glands (294). The extensive lung tissue damage that occurs during COPD is caused by the infiltration of neutrophils. This damage can be prevented by the secretory leukoprotease inhibitor (SLPI) that acts by reducing the activity of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway that is responsible for neutrophil functions such as chemotaxis and the release of proteolytic enzymes (312).

VII. CHONDROCYTES

The maintenance of articular cartilage is carried out by the chondrocytes that regulate both the formation and the deg-

radation of the matrix, which is composed of aggrecan and collagen type II. The latter provides the tensile support, whereas the negatively charged proteoglycan aggrecan is responsible for the compressive resistance of cartilage in that it attracts water molecules to create its shock absorbing property (231). The chondrocytes, which are embedded within cartilage, are responsible for synthesizing and assembling these extracellular matrix (ECM) components. Alterations in this synthetic role of the chondrocytes lead to changes in the properties of cartilage that are responsible for osteoarthritis.

A. Osteoarthritis

Osteoarthritis (OA) is a debilitating disease that is caused by degenerative changes in the cartilage that results in intense pain in the load-bearing joints such as the knees and hips. Chronic inflammation, which is a major contributory factor for OA, generates the cytokines and proteases that induce the chondrocytes to alter the synthesis of the type II collagen and proteoglycans. In addition, there is an increased release of matrix proteinases (MMPs) (e.g., MMP-1 and MMP-13) resulting in a dramatic alteration in cartilage composition (231). The normal collagen II is replaced with collagen I, and there is a marked decline in the expression of aggrecan.

These pathological changes that give rise to OA depend on an alteration in the secretory activity of the chondrocytes that is driven by proinflammatory cytokines (TNF- α and IL-1 β). One of the causes for this alteration on chondrocyte activity is an increase in Ca^{2+} signaling that occurs during OA (271, 304, 419). For example, IL-1 β acts on chondrocytes to increase the activity of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway (304). During OA, calcium phosphate crystals appear in the cartilage and contribute to cartilage destruction by activating Ca^{2+} signals in the chondrocytes (271).

The TNF- α may also act to enhance Ca^{2+} signaling because it is known to increase the expression of the $\text{InsP}_3\text{R}1$ (289). The importance of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway in OA is highlighted by the observation that there is an increase in the expression of $\text{PLC}\gamma 2$ and in some of the genes that regulate this enzyme (56). There also is an increase in the expression of $\text{PLC}\gamma 1$ in chondrocytes from patients with OA (410). Reducing the activity of $\text{PLC}\gamma 1$ by U73122 or by siRNA was able to restore the expression of collagen II and reduce the release of MMP-13 (419), thus emphasizing how an abnormal $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway contributes to the pathological progression of osteoarthritis.

B. Kashin-Beck Disease

Kashin-Beck disease (KBD) is an osteochondral disease, which is particularly prevalent in Siberia, China, and North

Korea. The KBD symptoms, which arise from cartilage damage, are joint pain, enlarged interphalangeal joints, and reduced movement in many joints of the body (330). The causes of the disease are still not clear, but there does seem to be a link to various dietary components such as mycotoxins, fulvic acid, and deficiencies in selenium and iodine. Recently, a genome-wide association study has revealed that the *ITPR2* gene that encodes the InsP₃R2 channel is a susceptibility gene for KBD (423). Chondrocyte necrosis and cell death is driven by mitochondrial-induced apoptosis (216, 393). It is likely that this increase in apoptosis may be driven by an increase in the activity of the InsP₃R2, which is known to release Ca²⁺ from the ER to trigger apoptosis through the mitochondria (59, 363).

VIII. EXOCRINE GLANDS

A. Pancreatic Acinar Cells

Both fluid and proteins are secreted by pancreatic acinar cells. The proteins are the digestive enzymes that are stored in the zymogen granules located in the apical part of the cell. Secretagogues such as cholecystokinin (CCK) and ACh induce the Ca²⁺ signals that have spatial and temporal characteristics designed to maximize protein and fluid secretion (296). ACh acts on muscarinic receptors to induce the InsP₃/Ca²⁺ signaling pathway. In addition to being located on the ER, the InsP₃Rs are also found on the zymogen granules (295). Neighboring RYRs act to amplify the Ca²⁺ signal that generates a Ca²⁺ wave that can extend into the basal region. The CCK uses a different signaling pathway in that it generates cyclic ADP ribose (cADPR) and nicotinic acid-adenine dinucleotide phosphate (NAADP) that release Ca²⁺ from the acidic organelles and the ER.

As occurs in many other exocrine cells, the Ca²⁺ signal is normally localized in the apical region where it appears as an oscillation that controls both fluid secretion and the release of zymogen granules. With regard to fluid secretion, the Ca²⁺ stimulates apical Ca²⁺-sensitive Cl⁻ channels (CaCCs), and the resulting entry of Cl⁻ into the lumen provides the driving forces for the entry of both Na⁺ and water (288).

The Ca²⁺ signals located in the apical region are usually prevented from spreading into the rest of the cell by a mitochondrial firewall (376). However, when stimuli are increased, there is a much larger apical Ca²⁺ signal that breaches the mitochondrial firewall and spreads out towards the basal region in the form of a propagating Ca²⁺ wave.

B. Pancreatitis

Pancreatitis has two forms. Acute pancreatitis appears suddenly and lasts for a few days. On the other hand, the

chronic form can continue for many years. Chronic alcohol abuse is a major cause of pancreatitis. An increase in alcohol reduces the role of alcohol dehydrogenase (ADH) that functions normally to bring about the oxidative metabolism of ethanol. As a consequence, the nonoxidative metabolism of ethanol to fatty acid ethyl esters (FAEEs) is increased, which appears to be responsible for various alcoholic diseases such as pancreatitis (133). In pancreatitis, one of the actions of FAEEs is to stimulate the type 2 and type 3 InsP₃Rs that are found on the ER and zymogen granules. This leads to the pathogenic activation of the trypsin located in the apical zymogen granules (134). Such activation of the digestive enzymes within the cell triggers a process of autodigestion leading to necrosis that is a feature of pancreatitis. In a mouse model, pancreatitis was prevented by deleting the InsP₃R2 channels (279). Caffeine can reduce the symptoms of acute pancreatitis by inhibiting the InsP₃/Ca²⁺ signaling pathway (164). All this evidence supports the notion that an alteration in InsP₃/Ca²⁺ signaling plays a key role in the development of pancreatitis.

C. Salivary Gland

The function of salivary glands is to secrete saliva that facilitates the ingestion of food, and it also acts to moisten the oral cavity between meals. It is the small labial, buccal, and palatal glands that continuously secrete saliva to moisten the mouth. During feeding, much more saliva is required, and this is produced by the large submandibular, parotid, and sublingual salivary glands. Secretion by these glands is triggered by mechanical, thermal, or chemical stimuli. The main stimulus released from the parasympathetic neurons is ACh that binds to muscarinic (M3) receptors to activate the InsP₃/Ca²⁺ signaling system (9, 10, 244). In the InsP₃R2 and InsP₃R3 double knockout mice, there is marked decline in salivary gland secretion (124). The resulting Ca²⁺ signal depends both on Ca²⁺ release from internal stores that is maintained by Ca²⁺ entry through store-operated channels (SOCs). The increase in Ca²⁺ stimulates the CaCCs that enables Cl⁻ to enter the lumen where it provides the driving force for the entry of both Na⁺ and water. The elevated Ca²⁺ also acts to open the BK channel that hyperpolarizes the basolateral membrane to create the electrochemical gradient that drives the movement of Cl⁻ into the lumen.

D. Sjögren's Syndrome

Sjögren's syndrome (SS) is an autoimmune exocrinopathy that is characterized by a decline in fluid secretion by the salivary glands. A recent study has revealed that this secretory defect in the salivary glands of SS patients results from a decline in the expression of the InsP₃Rs that function to release the Ca²⁺ that activates fluid secretion (372). This observation is consistent with the observation that patients with SS express anti-InsP₃R antibodies (254).

E. Sweat Glands

The tubular epithelial sweat glands located on the surface of the body consist of a distal secretory coil followed by a reabsorptive region. The secretory coil cells secrete an isotonic NaCl solution that then passes through the straighter reabsorptive region where most of the Na^+ and Cl^- is reabsorbed, and this results in the hypotonic sweat that is then transferred through pores onto the skin surface. Both parasympathetic and sympathetic neurons function to regulate the secretion of sweat. The norepinephrine (NE) released from the sympathetic neurons stimulates the cAMP signaling pathway to activate the cystic fibrosis transmembrane conductance regulator (CFTR) channel that transfers Cl^- into the lumen of the sweat gland. In addition, the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway, which is activated by ACh released from the parasympathetic neurons, functions by activating CaCCs to create a flux of Cl^- into the lumen. This Cl^- transfer drives a parallel flux of Na^+ which thus creates the accumulation of NaCl to provide the osmotic gradient for the flow of water.

F. Anhidrosis

In anhidrosis, which is also known as hypohidrosis, there is a marked decline in the formation of sweat that results in hyperthermia or heat stroke and can lead to death. The importance of the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway in sweat secretion, as described above, has emerged from the study of a missense *ITPR2* gene mutation that encodes $\text{InsP}_3\text{R}2$, which has been linked to anhidrosis in five members of a consanguineous family (191).

G. Lung Submucosal Glands

The serous fluid-secreting cells in the submucosal glands of the lung function to secrete the fluid that contributes to the formation of the mucus that protects the lung airway epithelium against viruses, pathogens, and foreign particles. Various stimuli such as ACh, ATP, histamine, and substance P, which act through the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway, regulate the rate of fluid secretion (206). The InsP_3 formed by these stimuli activates the type 1 $\text{InsP}_3\text{R}1$ embedded in the ER positioned close to the apical membrane, to release Ca^{2+} that then acts to open the CaCC.

IX. ENDOCRINE GLANDS

A. Pancreatic β -Cell Insulin Secretion

Elevation of glucose in the plasma stimulates insulin release from pancreatic β -cells by regulating both the biosynthesis and release of insulin. The way insulin is secreted is of interest clinically, because the development of diabetes re-

sults from the onset of insulin resistance caused by a decline in the secretion of insulin.

In addition to glucose, the activity of β -cells is also sensitive to other factors such as ACh, which is released by the α -cells, that acts in a paracrine manner to sensitize the β -cells to respond to glucose (315). When considering the control of insulin secretion, therefore, it is necessary to understand both the primary action of glucose and how ACh acts through the $\text{InsP}_3/\text{Ca}^{2+}$ pathway to modulate the activity of glucose (FIGURE 1). Elevated levels of plasma glucose induce a slow Ca^{2+} oscillation (4–6 min periodicity) that drives the secretion of insulin. Faster Ca^{2+} spikes (10- to 20-s periodicity) occur during the crest of the slow Ca^{2+} spikes.

The glucose transporter 2 (GLUT2) enables glucose to enter the β -cell where it is immediately phosphorylated by hexokinase IV to form glucose-6-phosphate (G-6-P). The G-6-P is then metabolized to fructose 6-phosphate (F-6-P), which is transformed into fructose-2,6-P₂ (F-2,6-P₂) by phosphofructose kinase-2 (PFK2). The next step is for the F-2,6-P₂ to activate PFK1 that transforms F-6-P to fructose-1,6-P₂ (F-1,6-P₂). The latter enters the glycolytic and tricarboxylic acid (TCA) cycles resulting in an elevation in ATP. The latter acts by inhibiting the ATP-sensitive K^+ (K_{ATP}) channel resulting in the membrane depolarization that then activates the L-type voltage-operated channels (VOCs) to generate localized Ca^{2+} pulses to induce the release insulin.

This primary role of glucose in stimulating insulin secretions can be modulated by the activity of other stimuli as illustrated by the action of ACh and free fatty acids (FFAs). The ACh acts through the M3 muscarinic receptor that operates through the $\text{InsP}_3/\text{Ca}^{2+}$ pathway (25) and is another example of the modulatory role of this signaling system (FIGURE 1). Similarly, the FFAs activate the GPR40 receptor that increases the $\text{InsP}_3/\text{Ca}^{2+}$ pathway, which acts to potentiate glucose-induced insulin secretion (232). There is a complex relationship between the glucose-induced Ca^{2+} signal and the contribution from the $\text{InsP}_3/\text{Ca}^{2+}$ pathway, which appear to act synergistically to control the release of insulin (130, 352).

B. Diabetes and Gallstone Formation

Alterations in the activity of the modulatory role of the $\text{InsP}_3/\text{Ca}^{2+}$ pathway in regulating insulin secretion may contribute to the onset of diabetes (25). For example, genetic variations in the M3 receptor, which normally activates the $\text{InsP}_3/\text{Ca}^{2+}$ pathway, have been linked to early-onset type 2 diabetes in Pima Indians (143). Second-generation antipsychotics, such as olanzapine and clozapine, can result in insulin resistance through their ability to inhibit M3 receptors (399). In a transgenic mouse line, a mutation in the *Itpr1* gene that encodes the $\text{InsP}_3\text{R}1$ channel has been

linked to glucose intolerance and susceptibility to diet-induced diabetes (415). It is also significant that there are alterations in the $\text{InsP}_3/\text{Ca}^{2+}$ pathway during aging, and these changes may contribute to the onset of diabetes (26). Vascular smooth muscle cell growth and dysfunction is induced by transforming growth factor- β (TGF- β) (424). One of the actions of TGF- β is to reduce the activity of $\text{InsP}_3\text{R}1$, which may contribute to the diabetic pathophysiology of aortic and preglomerular smooth muscle cells (284, 340).

In diabetic patients, there was a decreased expression of InsP_3R and the cholecystokinin receptor (CCK-R), which generates InsP_3 (422). The resulting decline in the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway accounts for the decline in gallbladder emptying and gallstone formation, which is a comorbidity often associated with diabetes.

X. LIVER

The liver has important functions, many of which are regulated through the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway (7, 27, 127, 128). It regulates glucose and energy metabolism, synthesizes urea and a large number of plasma proteins, and is also responsible for bile secretion. $\text{InsP}_3/\text{Ca}^{2+}$ signaling plays a central role in controlling the process of gluconeogenesis (238, 394). Oxidative substrates are constantly being transferred between the plasma and liver cells. For example, when the supply of glucose is plentiful, insulin controls the uptake of glucose that is converted by glycogen synthase to glycogen that is stored in the liver. When glucose levels decline, the hormone glucagon stimulates glycogenolysis that results in the hydrolysis of glycogen to release glucose that can reenter the plasma. This glycogen hydrolysis is mediated by the enzyme phosphorylase, which is activated by phosphorylase kinase, which is a Ca^{2+} -sensitive enzyme. Hormones such as vasopressin and norepinephrine act through the $\text{InsP}_3/\text{Ca}^{2+}$ signaling system to stimulate the phosphorylase kinase to increase glycogenolysis.

The $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway also acts to regulate bile secretion (8, 307). The bile that is formed by the liver is transferred and stored in the gallbladder where it has two main functions. It contributes to fat digestion and absorption by the intestine, and it also functions to remove waste products from the blood. Bile secretion begins in the distal hepatocytes that transfer bile salts and other organic solutes into the canalicular lumen. This initial fluid is then passed down the canaliculus where it is modified by the cholangiocytes that are particularly active in secreting bicarbonate (HCO_3^-).

This secretion of HCO_3^- is regulated by two main signaling pathways. Agonists such as acetylcholine generate InsP_3 that acts on the type 3 InsP_3 receptor ($\text{InsP}_3\text{R}3$) located in the apical region of the cell to release Ca^{2+} that then stim-

ulates a CaCC (TMEM16A) to enable Cl^- to flow into the canalicular lumen. The accumulation of luminal Cl^- then provides the driving force for the transfer of bicarbonate (HCO_3^-), which creates the osmotic gradient for the transfer of water. In addition to regulating Cl^- transport into the lumen, Ca^{2+} also controls the SK Ca^{2+} -activated K^+ channels on the basolateral membrane that act to maintain a hyperpolarized membrane potential that is necessary to drive the flux of Cl^- into the lumen. The apical membrane is also sensitive to ATP that is either released upstream by the hepatocytes and thus acts in a paracrine manner or is released by the cholangiocytes to act in an autocrine manner. The ATP stimulates P2Y receptors that generate InsP_3 that increases the release of Ca^{2+} that drives secretion as described above.

A. Liver Cholestasis

Since the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway contributes to the control of many liver cell functions, it is not surprising to find that alteration in InsP_3 function plays a pivotal role in a number of liver diseases (8, 27, 342). One of the serious liver diseases is cholestasis, which is caused by an alteration in the function of bile secretion. A decline in the expression of the type 3 InsP_3R ($\text{InsP}_3\text{R}3$) contributes to a number of cholestatic disorders such as obstruction of the bile duct, biliary atresia, biliary cholangitis/cirrhosis, and sclerosing cholangitis (7, 8). The decline in the InsP_3R may depend on various factors such as the nuclear factor, erythroid 2-like 2 (NRF2) transcription factor that acts to inhibit the expression of the *ITP3R* gene (397) and an increase in microRNA 506 (miR-506) that acts by reducing the expression of the $\text{InsP}_3\text{R}3$ in the cholangiocytes (13). Alterations in the activity of the $\text{InsP}_3\text{R}3$ have also been implicated in various metabolic diseases. In particular, an increase in the $\text{InsP}_3/\text{Ca}^{2+}$ signaling pathway contributes to the dysregulation of metabolism that occurs during insulin resistance and obesity (27).

XI. OSTEOCLAST

The balance between the activity of the osteoclasts (bone resorption) and osteoblasts (bone formation) is central to the process of bone remodeling. Osteoclasts, which are derived from hematopoietic stem cells, are large multinucleated motile bone resorptive cells (153). Their primary function is to degrade bone, and they are responsible for normal skeletal function and for calcium homeostasis. The ratio of osteoblasts to osteoclasts determines the process of bone remodeling. The rate of bone resorption depends on the formation and activity of the osteoclasts. As the osteoclasts are formed, they attach and spread out over the bone surface to initiate the process of bone resorption. The formation of osteoclasts, which is known as osteoclastogenesis, is controlled by factors such as colony-stimulating factor-1

(CSF-1), tumor necrosis-related factor called receptor activator of nuclear factor κ B (NF- κ B) ligand (RANKL), and inflammatory cytokines such as interleukins and TNF. Of the various signaling pathways that are activated by these factors, the Ca^{2+} signaling pathway is beginning to attract considerable attention (123, 165, 268, 367, 420).

Activation of the RANK pathway, which is particularly important for generating Ca^{2+} signals, stimulates costimulatory transducing system such as FcR γ and DAP12 that then activate PLC γ to induce the formation of InsP₃ (193, 345). The RANK pathway can also increase InsP₃ by acting on Rac1 to generate ROS that then activate PLC γ (188). The InsP₃ formed by these two pathways then acts on the InsP₃R2s to release Ca^{2+} that sets up a prolonged Ca^{2+} oscillation that then stimulates entry of NFATc1 into the nucleus where it induces transcription of those genes that drive osteoclast development (268, 367). The ability of osteoprotegerin to inhibit osteoclast differentiation depends on its ability to reduce this Ca^{2+} signaling pathway (123). As described below, the onset of rheumatoid arthritis is driven by excessive activation of this Ca^{2+} signaling pathway.

A. Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease that results in synovial inflammation and joint destruction that can lead to severe morbidity and premature mortality (5, 357). The pathogenesis of RA is driven by autoreactive B cells (302). One of the major cytokines driving osteoclast inflammation in RA is TNF- α (241, 270). Periodontitis is a related disease that is also caused by inflammation driven by TNF- α (153). One of the actions of TNF- α is to enhance InsP₃R1 expression, which induces osteoclastogenesis by increasing the Ca^{2+} oscillations that are driven by the RANK signaling pathway (408).

XII. NEPHROLITHIASIS

Nephrolithiasis arises due to an increase in kidney calcification that results in the formation of kidney stones (17). These stones, which consist mainly of calcium phosphate and calcium oxalate, can develop both in the lumen of the kidney tubules and in the surrounding tissue. In addition to obstructing the tubule lumen, these Ca^{2+} crystals may also damage the kidney through inflammatory reactions driven by cytokines such as TNF- α (184). There are multiple causes of nephrolithiasis, which is a complex disease. Stone formation has been linked to mutations of a number of genes that function in Ca^{2+} signaling. A number of these genes such as CaSR (77, 339), ITPKC (177), and Orai1 (78) function in the InsP₃/Ca²⁺ signaling pathway. The Ca²⁺-sensing receptor (CaSR) is strongly expressed on the basolateral membrane of the thick ascending loop of Henle

(TALH) cells where it reacts to increases in extracellular Ca²⁺ by initiating the formation of InsP₃ that then releases Ca²⁺ from the ER to activate Ca²⁺ entry through the Orai1 channel. The ITPKC gene encodes the InsP₃ 3-kinase that phosphorylates and inactivates the Ca²⁺-mobilizing activity of InsP₃ (FIGURE 2). Mutations in the ITPKC gene will result in an increase in the InsP₃/Ca²⁺ signaling pathway that will enhance the transepithelial flux of Ca²⁺ that contributes to the formation of kidney stones.

XIII. CONCLUSION

The InsP₃/Ca²⁺ signaling pathway functions to regulate many different cellular processes. The versatility and universality of this signaling pathway is based on two main operational modes. In many cells, it provides the primary Ca²⁺ signal that plays a direct role in regulating processes as diverse as fertilization, cell proliferation, secretion, metabolism, and smooth muscle contraction. Its other mode of action is to modulate the activity of various excitable cells such as neurons, insulin-secreting beta cells, as well as cardiac and skeletal muscle. In these cells the primary Ca²⁺ signal is generated by the entry of Ca²⁺ through voltage-operated channels and the release of Ca²⁺ from internal stores by RYRs. The generation and function of this voltage-dependent primary Ca²⁺ signaling system is altered in subtle ways by the modulatory activity of the InsP₃/Ca²⁺ signaling pathway.

What is remarkable about the primary and modulatory actions of the InsP₃/Ca²⁺ pathway is how it has been implicated in a large number diseases including some of the major human diseases such as cardiac and Alzheimer's diseases. The formation of InsP₃ is inhibited by Li⁺ and the release of Ca²⁺ by the InsP₃Rs is inhibited by caffeine. These two drugs have now been shown to alleviate or reduce the symptoms of a number of diseases such as Alzheimer's disease, bipolar disorder, Huntington's disease, and acute pancreatitis.

ACKNOWLEDGMENTS

Address for reprint requests and other correspondence: M. J. Berridge, Laboratory of Molecular Signalling, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK (e-mail: michael.berridge@babraham.ac.uk).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author.

REFERENCES

1. Abou-Saleh H, Pathan AR, Daalis A, Hubrack S, Abou-Jassoum H, Al-Naeimi H, Rusch NJ, Machaca K. Inositol 1,4,5-trisphosphate (IP₃) receptor up-regulation in hyperten-

- sion is associated with sensitization of Ca^{2+} release and vascular smooth muscle contractility. *J Biol Chem* 288: 32941–32951, 2013.
2. Aizman O, Uhlén P, Lal M, Bismar H, Aperia A. Ouabain, a steroid hormone that signals with slow calcium oscillations. *Proc Natl Acad Sci USA* 98: 13420–13424, 2001.
 3. Akl H, Bultynck G. Altered Ca^{2+} signaling in cancer cells: proto-oncogenes and tumor suppressors targeting IP_3 receptors. *Biochim Biophys Acta* 1835: 180–193, 2013.
 4. Althoff TF, Offermanns S. G-protein-mediated signaling in vascular smooth muscle cells—implications for vascular disease. *J Mol Med* 93: 973–981, 2015.
 5. Alves CH, Farrell E, Vis M, Colin EM, Lubberts E. Animal models of bone loss in inflammatory arthritis: from cytokines in the bench to novel treatments for bone loss in the bedside—a comprehensive review. *Clin Rev Allergy Immunol*. In press, doi:10.1007/s12016-015-8522-7.
 6. Alzayady KJ, Wang L, Chandrasekhar R, Wagner LE 2nd, Van Petegem F, Yule DI. Defining the stoichiometry of inositol 1,4,5-trisphosphate binding required to initiate Ca^{2+} release. *Sci Signal* 9: ra35, 2016.
 7. Amaya MJ, Nathanson MH. Calcium signaling in the liver. *Comp Physiol* 3: 515–539, 2013.
 8. Amaya MJ, Nathanson MH. Calcium signaling and the secretory activity of bile duct epithelia. *Cell Calcium* 55: 317–324, 2014.
 9. Ambudkar IS. Ca^{2+} signaling and regulation of fluid secretion in salivary gland acinar cells. *Cell Calcium* 55: 297–305, 2014.
 10. Ambudkar IS. Calcium signalling in salivary gland physiology and dysfunction. *J Physiol* 594: 2813–2824, 2016.
 11. Amdani SN, Jones C, Coward K. Phospholipase C zeta (PLC ζ): oocyte activation and clinical links to male factor infertility. *Adv Biol Regul* 53: 292–308, 2013.
 12. Ament SA, Szelinger S, Glusman G, Ashworth J, Hou L, Akula N, Shekhtman T. Rare variants in neuronal excitability genes influence risk for bipolar disorder. *Proc Natl Acad Sci USA* 112: 3576–3581, 2015.
 13. Ananthanarayanan M, Banales JM, Guerra MT, Spirli C, Munoz-Garrido P, Mitchell-Richards K, Tafur D, Saez E, Nathanson MH. Post-translational regulation of the type III inositol 1,4,5-trisphosphate receptor by miRNA-506. *J Biol Chem* 290: 184–196, 2015.
 14. Ando H, Mizutani A, Matsu-ura T, Mikoshiba K. IRBIT, a novel inositol 1,4,5-trisphosphate (IP_3) receptor-binding protein, is released from the IP_3 receptor upon IP_3 binding to the receptor. *J Biol Chem* 278: 10602–10612, 2003.
 15. Ando H, Mizutani A, Kiefer H, Tsuzurugi D, Michikawa T, Mikoshiba K. IRBIT suppresses IP_3 receptor activity by competing with IP_3 for the common binding site on the IP_3 receptor. *Mol Cell* 22: 795e806, 2006.
 16. Antigny F, Konig S, Bernheim L, Frieden M. Inositol 1,4,5 trisphosphate receptor I is a key player of human myoblast differentiation. *Cell Calcium* 56: 513–521, 2014.
 17. Arcidiacono T, Mingione A, Macrina L, Pivari F, Soldati L, Vezzoli G. Idiopathic calcium nephrolithiasis: a review of pathogenic mechanisms in the light of genetic studies. *Am J Nephrol* 40: 499–506, 2014.
 18. Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy D, Tan J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. *Neuroscience* 142: 941–952, 2006.
 19. Baba Y, Kurosaki T. Impact of Ca^{2+} signaling on B cell function. *Trends Immunol* 32: 589–594, 2011.
 20. Baba Y, Kurosaki T. Role of calcium signaling in B cell activation and biology. *Curr Top Microbiol Immunol* 393: 143–174, 2016.
 21. Bai S, Mao M, Tian L, Yu Y, Zeng J, Ouyang K, Yu L, Li L, Wang D, Deng X, Wei C, Luo Y. Calcium sensing receptor mediated the excessive generation of β -amyloid peptide induced by hypoxia in vivo and in vitro. *Biochim Biophys Res Commun* 459: 568–573, 2015.
 22. Baker KD, Edwards TM, Rickard NS. The role of intracellular calcium stores in synaptic plasticity and memory consolidation. *Neurosci Biobehav Rev* 37: 1211–1239, 2013.
 23. Balghi H, Sebille S, Mondin L, Cantereau A, Constantin B, Raymond G, Cognard C. Mini-dystrophin expression down-regulates IP_3 -mediated calcium release events in resting dystrophin-deficient muscle cells. *J Gen Physiol* 128: 219–230, 2006.
 24. Bánsági S, Golenár T, Madesh M, Csordás G, RamachandraRao S, Sharma K, Yule DI, Joseph SK, Hajnóczky G. Isoform- and species-specific control of inositol 1,4,5-trisphosphate (IP_3) receptors by reactive oxygen species. *J Biol Chem* 289: 8170–8181, 2014.
 25. Barker CJ, Berggren PO. New horizons in cellular regulation by inositol polyphosphates: insights from the pancreatic β -cell. *Pharmacol Rev* 65: 641–669 2013.
 26. Barker CJ, Li L, Köhler M, Berggren PO. β -Cell Ca^{2+} dynamics and function are compromised in aging. *Adv Biol Regul* 57: 112–119, 2015.
 27. Bartlett PJ, Gaspers LD, Pierobon N, Thomas AP. Calcium-dependent regulation of glucose homeostasis in the liver. *Cell Calcium* 55: 306–316, 2014.
 28. Basset O, Boittin FX, Cognard C, Constantin B, Ruegg UT. Bcl-2 overexpression prevents calcium overload and subsequent apoptosis in dystrophic myotubes. *Biochem J* 395: 267–276, 2006.
 29. Bauer PO, Hudec R, Ozaki S, Okuno M, Ebisui E, Mikoshiba K, Nukina N. Genetic ablation and chemical inhibition of IP_3RI reduce mutant huntingtin aggregation. *Biochem Biophys Res Commun* 416: 13–17, 2011.
 30. Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, Wedge DC, Ramakrishna M, Cooke SL, Pillay N. Recurrent *PTPRB* and *PLCG1* mutations in angiosarcoma. *Nat Genet* 46: 376–379, 2014.
 31. Bellesi M, Riedner BA, Garcia-Molina GN, Cirelli C, Tononi G. Enhancement of sleep slow waves: underlying mechanisms and practical consequences. *Front Syst Neurosci* 8: 208, 2014.
 32. Bernier S, Guillemette G. Increased inositol 1,4,5-trisphosphate binding capacity in vascular smooth muscle of spontaneously hypertensive rats. *Am J Hypertens* 6: 217–225, 1993.
 33. Berridge MJ. Calcium oscillations. *J Biol Chem* 265: 9583–9586, 1990.
 34. Berridge MJ. Inositol trisphosphate and calcium signalling. *Nature* 361: 315–325, 1993.
 35. Berridge MJ. Calcium signalling and cell proliferation. *Bioessays* 17: 491–500, 1995.
 36. Berridge MJ. The AM and FM of calcium signalling. *Nature* 386: 759–760, 1997.
 37. Berridge MJ. Inositol trisphosphate and calcium oscillations. *Biochem Soc Symp* 74: 1–7, 2007.
 38. Berridge MJ. Smooth muscle cell calcium activation mechanisms. *J Physiol* 586: 5047–5061, 2008.
 39. Berridge MJ. Inositol trisphosphate and calcium signalling mechanisms. *Biochim Biophys Acta* 1793: 933–940, 2009.
 40. Berridge MJ. Calcium signalling remodelling and disease. *Biochem Soc Trans* 40: 297–309, 2012.
 41. Berridge MJ. Dysregulation of neural calcium signalling in Alzheimer disease, bipolar disorder and schizophrenia. *Prion* 6: 1–12, 2012.
 42. Berridge MJ. Calcium regulation of neural rhythms, memory and Alzheimer's disease. *J Physiol* 592: 281–293, 2014.
 43. Berridge MJ. Calcium signalling and psychiatric disease: bipolar disorder and schizophrenia. *Cell Tissue Res* 357: 477–492, 2014.
 44. Berridge MJ. Vitamin D: a custodian of cell signalling stability in health and disease. *Biochem Soc Trans* 43: 349–358, 2015.
 45. Berridge MJ. Vitamin D cell signalling in health and disease. *Biochim Biophys Res Commun* 460: 53–71, 2015.
 46. Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. *Biochem J* 206: 587–595, 1982.
 47. Berridge MJ, Galione A. Cytosolic calcium oscillators. *FASEB J* 2: 3074–3082, 1988.
 48. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: unifying hypothesis. *Cell* 59: 411–419, 1989.

49. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. *Nature Rev Mol Cell Biol* 1: 11–21, 2000.
50. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. *Nature Rev Mol Cell Biol* 4: 517–529, 2003.
51. Bezprozvanny I. Inositol 1,4,5-triphosphate receptor, calcium signalling and Huntington's disease. *Subcell Biochem* 45: 323–335, 2007.
52. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. *Trends Mol Med* 15: 89–100, 2009.
53. Bezprozvanny I. Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias. *Neurochem Res* 36: 1186–1197, 2011.
54. Bezprozvanny I, Bezprozvannaya S, Ehrlich BE. Caffeine-induced inhibition of inositol (1,4,5)-trisphosphate-gated calcium channels from cerebellum. *Mol Biol Cell* 5: 97–103, 1994.
55. Bird GS, Burgess GM, Putney JW Jr. Sulphydryl reagents and cAMP-dependent kinase increase the sensitivity of the inositol 1,4,5-trisphosphate receptor in hepatocytes. *J Biol Chem* 268: 17917–17923, 1993.
56. Biswas S, Manikandan J, Pushparaj PN. Decoding the differential biomarkers of rheumatoid arthritis and osteoarthritis: a functional genomics paradigm to design disease specific therapeutics. *Bioinformation* 6: 153–157, 2011.
57. Bittremieux M, Parys JB, Pinton P, Bultynck G. ER functions of oncogenes and tumor suppressors: modulators of intracellular Ca^{2+} signaling. *Biochim Biophys Acta* 1863: 1364–1378, 2016.
58. Bodjarian N, Carpentier P, Baubichon D, Blanchet G, Lallement G. Involvement of non-muscarinic receptors in phosphoinositide signalling during soman-induced seizures. *Eur J Pharmacol* 289: 291–297, 1995.
59. Boehning D, Patterson RL, Snyder SH. Apoptosis and calcium: new roles for cytochrome c and inositol 1,4,5-trisphosphate. *Cell Cycle* 3: 252–254, 2004.
60. Blomberg Jensen M. Vitamin D and male reproduction. *Nat Rev Endocrinol* 10: 175–186, 2014.
61. Blomberg Jensen M, Bjerrum PJ, Jessen TE, Nielsen JE, Joensen UN, Olesen IA, Petersen JH, Juul A, Dissing S, Jørgensen N. Vitamin D is positively associated with sperm motility and increases intracellular calcium in human spermatozoa. *Hum Reprod* 26: 1307–1317, 2011.
62. Bootman MD, Taylor CW, Berridge MJ. The thiol reagent, thimerosal, evokes Ca^{2+} spikes in HeLa cells by sensitizing the inositol 1,4,5-trisphosphate receptor. *J Biol Chem* 267: 25113–25119, 1992.
63. Born HA. Seizures in Alzheimer's disease. *Neuroscience* 286: 251–263, 2015.
64. Boutin B, Tajeddine N, Monaco G, Molgo J, Vertommen D, Rider M, Parys JB, Bultynck G, Gailly P. Endoplasmic reticulum Ca^{2+} content decrease by PKA-dependent hyperphosphorylation of type I IP_3 receptor contributes to prostate cancer cell resistance to androgen deprivation. *Cell Calcium* 57: 312–320, 2015.
65. Brennan AR, Dolinsky B, Vu MA, Stanley M, Yeckel MF, Arnsten AF. Blockade of IP_3 -mediated SK channel signaling in the rat medial prefrontal cortex improves spatial working memory. *Learn Mem* 15: 93–96, 2008.
66. Brown S-A, Loew LM. Integration of modeling and clinical findings synthesizes and refines the central role of inositol 1,4,5-trisphosphate receptor in spinocerebellar ataxia. *Front Neurosci* 8: 453–461, 2015.
67. Bürk K, Kaiser FJ, Tennstedt S, Schöls L, Kreuz FR, Wieland T. A novel missense mutation in CACNA1A evaluated by *in silico* protein modeling is associated with non-epidodic spinocerebellar ataxia with slow progression. *Eur J Med Genet* 57: 207–211, 2014.
68. Cao C, Loewenstein DA, Lin X, Zhang C, Wang L, Duara R, Wu Y, Giannini A, Bai G, Cai J, Greig M, Schofield E, Ashok R, Small B, Potter H, Arendash GW. High blood caffeine levels in MCI linked to lack of progression to dementia. *J Alzheimers Dis* 30: 559–572, 2012.
69. Cárdenas C, Miller RA, Smith I, Bui T, Molgó J, Müller M, Vais H, Cheung KH, Yang J, Parker I, Thompson CB, Birnbaum MJ, Hallows KR, Foskett JK. Essential regulation of cell bioenergetics by constitutive InsP_3 receptor Ca^{2+} transfer to mitochondria. *Cell* 142: 270–283, 2010.
70. Chakraborty S, Stutzmann GE. Calcium channelopathies and Alzheimer's disease: insight into therapeutic success and failures. *Eur J Pharmacol* 739: 83–95, 2014.
71. Chang P, Walker MC, Williams RS. Seizure-induced reduction in PIP_3 levels contributes to seizure-activity and is rescued by valproic acid. *Neurobiol Dis* 62: 296–306, 2014.
72. Cheek TR, McGuinness OM, Vincent C, Moreton RB, Berridge MJ, Johnson MH. Fertilisation and thimerosal stimulate calcium spiking patterns in mouse oocytes by separate mechanisms. *Development* 119: 179–189, 1993.
73. Chen R, Valencia I, Zhong F, McColl KS, Roderick HL, Bootman MD, Berridge MJ, Conway SJ, Holmes AB, Mignery GA, Velez P, Distelhorst CW. Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate. *J Cell Biol* 166: 193–203, 2004.
74. Cheung KH, Me, i L, Mak DO, Hayashi I, Iwatsubo T, Kang DE, Foskett JK. Gain-of-function enhancement of IP_3 receptor modal gating by familial Alzheimer's disease-linked presenilin mutants in human cells and mouse neurons. *Sci Signal* 3: ra22, 2010.
75. Chin J, Scharfman HE. Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms. *Epilepsy Behav* 26: 343–351, 2013.
76. Choi JH, Ji YG, Lee DH. Uridine triphosphate increases proliferation of human cancerous pancreatic duct epithelial cells by activating P2Y2 receptor. *Pancreas* 42: 680–686, 2013.
77. Chou YH, Woon PY, Chen WC, Hsu YW, Chang JM, Hwang DY, Chiu YC, Kuo HC, Chang WP, Hou MF, Liu ME, Chang JG, Chang WC. A genetic polymorphism (rs17251221) in the calcium-sensing receptor gene (CASR) is associated with stone multiplicity in calcium nephrolithiasis. *PLoS One* 6: e25227, 2011.
78. Chou YH, Juo SH, Chiu YC, Liu ME, Chen WC, Chang CC, Chang WP, Chang JG, Chang WC. A polymorphism of the ORAI1 gene is associated with the risk and recurrence of calcium nephrolithiasis. *J Urol* 185: 1742–1746, 2011.
79. Cocco L, Follo MY, Manzoli L, Suh PG. Phosphoinositide-specific phospholipase C in health and disease. *J Lipid Res* 56: 1853–1860, 2015.
80. Connolly TM, Bansal VS, Bross TE, Irvine RF, Majerus PW. The metabolism of tris- and tetraphosphates of inositol by 5-phosphomonoesterase and 3-kinase enzymes. *J Biol Chem* 262: 2146–2149, 1987.
81. Constantin B, Sebille S, Cognard C. New insights in the regulation of calcium transfers by muscle dystrophin-based cytoskeleton: implications in DMD. *J Muscle Res Cell Motil* 27: 375–386, 2006.
82. Contreras-Ferrat A, Llanos P, Vásquez C, Espinosa A, Osorio-Fuentealba C, Arias-Calderon M, Lavandero S, Klip A, Hidalgo C, Jaimovich E. Insulin elicits a ROS-activated and an IP_3 -dependent Ca^{2+} release, which both impinge on GLUT4 translocation. *J Cell Sci* 127: 1911–1923, 2014.
83. Csernoch L, Jacquemond V. Phosphoinositides in Ca^{2+} signaling and excitation-contraction coupling in skeletal muscle: an old player and newcomers. *J Muscle Res Cell Motil* 36: 491–499, 2015.
84. Cuthbertson KS, Cobbold PH. Phorbol ester and sperm activate mouse oocytes by inducing sustained oscillations in cell Ca^{2+} . *Nature* 316: 541–542, 1985.
85. Czeredys M, Gruszczynska-Biegala J, Schacht T, Methner A, Kuznicki J. Expression of genes encoding the calcium signalosome in cellular and transgenic models of Huntington's disease. *Front Mol Neurosci* 6: 42, 2013.
86. Dai L, Zhuang L, Zhang B, Wang F, Chen X, Xia C, Zhang B. DAG/PKCδ and $\text{IP}_3/\text{Ca}^{2+}/\text{CaMK II}\beta$ operate in parallel to each other in PLCγ1-driven cell proliferation and migration of human gastric adenocarcinoma cells, through Akt/mTOR/S6 pathway. *Int J Mol Sci* 16: 28510–28522, 2015.
87. Datta S. Cellular and chemical neuroscience of mammalian sleep. *Sleep Medicine* 11: 431–440, 2010.
88. Day M, Olson PA, Platzer J, Striessnig J, Surmeier DJ. Stimulation of 5-HT₂ receptors in prefrontal pyramidal neurons inhibits Ca(v)1.2 L type Ca^{2+} currents via a PLCbeta/ IP_3 /calcineurin signaling cascade. *J Neurophysiol* 87: 2490–2504, 2002.
89. Debant M, Hemon P, Brigaudeau C, Renaudineau Y, Mignen O. Calcium signaling and cell fate: how can Ca^{2+} signals contribute to wrong decisions for chronic lymphocytic leukemic B lymphocyte outcome? *Int J Dev Biol* 59: 379–389, 2015.

90. Decuypere JP, Bultynck G, Parys JB. A dual role for Ca^{2+} in autophagy regulation. *Cell Calcium* 50: 242–250, 2011.
91. De Koninck P, Schulman H. Sensitivity of CaM kinase II to the frequency of Ca^{2+} oscillations. *Science* 279: 227–230, 1998.
92. Delorenzo RJ, Sun DA, Deshpande LS. Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintenance of epilepsy. *Pharmacol Ther* 105: 229–266 2005.
93. DeLorenzo RJ, Sun DA, Blair RE, Sombati S. An in vitro model of stroke-induced epilepsy: elucidation of the roles of glutamate and calcium in the induction and maintenance of stroke-induced epileptogenesis. *Int Rev Neurobiol* 81: 59–84, 2007.
94. Demuro A, Parker I. Cytotoxicity of intracellular $\text{A}\beta$ 42 amyloid oligomers involves Ca^{2+} release from the endoplasmic reticulum by stimulated production of inositol trisphosphate. *J Neurosci* 33: 3824–3833, 2013.
95. De Pittà M, Goldberg M, Volman V, Berry H, Ben-Jacob E. Glutamate regulation of calcium and IP_3 oscillating and pulsating dynamics in astrocytes. *J Biol Phys* 35: 383–411, 2009.
96. DeSouza N, Reiken S, Ondrias K, Yang YM, Matkovich S, Marks AR. Protein kinase A and two phosphatases are components of the inositol 1,4,5-trisphosphate receptor macromolecular signaling complex. *J Biol Chem* 277: 39397–39400, 2002.
97. Diniz BS, Machado-Vieira R, Forlenza OV. Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. *Neuropsychiatr Dis Treat* 9: 493–500, 2013.
98. Distelhorst CW, Bootman MD. Bcl-2 interaction with the inositol 1,4,5-trisphosphate receptor: role in Ca^{2+} signaling and disease. *Cell Calcium* 50: 234–241, 2011.
99. Dolmetsch RE, Xu KL, Lewis RS. Calcium oscillations increase the efficiency and specificity of gene expression. *Nature* 392, 933–936, 1998.
100. Drawnel FM, Wachten D, Molkentin JD, Maillet M, Aronsen JM, Swift F, Sjaastad I, Liu N, Catalucci D, Mikoshiba K, Hisatsune C, Okkenhaug H, Andrews SR, Bootman MD, Roderick HL. Mutual antagonism between IP₃RII and miRNA-133a regulates calcium signals and cardiac hypertrophy. *J Cell Biol* 199: 783–798, 2012.
101. Ebrahimi-Fakhri D, Sahin M. Autism and the synapse: emerging mechanisms and mechanism-based therapies. *Curr Opin Neurol* 28: 91–102, 2015.
102. Eichler SA, Meier JC. E-I balance and human diseases- from molecules to networking. *Front Mol Neurosci* 1: 2–5, 2008.
103. Eickholt BJ, Towers GJ, Ryves WJ, Eikel D, Adley K, Ylinen LM, Chadborn NH, Harwood AJ, Nau H, Williams RS. Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure. *Mol Pharmacol* 67: 1426–1433, 2005.
104. Eskelinen MH, Kivipelto M. Caffeine as a protective factor in dementia and Alzheimer's disease. *J Alzheimers Dis* 20 Suppl 1: S167–S174, 2010.
105. Farini A, Sitzia C, Cassinelli L, Colleoni F, Parolini D, Giovanella U, Maciotta S, Colombo A, Meregalli M, Torrente Y. Inositol 1,4,5-trisphosphate (IP_3)-dependent Ca^{2+} signaling mediates delayed myogenesis in Duchenne muscular dystrophy fetal muscle. *Development* 143: 658–669, 2016.
106. Fedorenko OA, Popugaeva E, Enomoto M, Stathopoulos PB, Ikura M, Bezprozvanny I. Intracellular calcium channels: inositol-1,4,5-trisphosphate receptors. *Eur J Pharmacol* 739: 39–48, 2014.
107. Feng J, Shan L, Du L, Wang B, Li H, Wang W, Wang T, Dong H, Yue X, Xu Z, Staal WG, Jia F. Clinical improvement following vitamin D₃ supplementation in Autism Spectrum Disorder. *Nutr Neurosci*. In press. doi:10.1080/1028415X.2015.1123847.
108. Ferreiro E, Oliveira CR, Pereira C. Involvement of endoplasmic reticulum Ca^{2+} release through ryanodine and inositol 1,4,5-triphosphate receptors in the neurotoxic effects induced by the amyloid-beta peptide. *J Neurosci Res* 76: 872–880, 2004.
109. Feske S. Calcium signalling in lymphocyte activation and disease. *Nat Rev Immunol* 7: 690–702, 2007.
110. Feske S, Gwack Y, Prakriya M, Srikanth S, Poppel SH, Tanasa B, Hogan PG, Lewis RS, Daly M, Rao A. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. *Nature* 441: 179–185, 2006.
111. Fewtrell C. Ca^{2+} oscillations in non-excitable cells. *Annu Rev Physiol* 55: 427–454, 1993.
112. Figueiredo T, Melo US, Pessoa AL, Nobrega PR, Kitajima JP, Rusch H, Vaz F, Lucato LT, Zatz M, Kok F, Santos S. A homozygous loss-of-function mutation in inositol monophosphatase 1 (IMPA1) causes severe intellectual disability. *Mol Psychiatry*. In press. doi:10.1038/mp.2015.150.
113. Filice F, Vörckel KJ, Sungur AÖ, Wöhr M, Schwaller B. Reduction in parvalbumin expression not loss of the parvalbumin-expressing GABA interneuron subpopulation in genetic parvalbumin and shank mouse models of autism. *Mol Brain* 9: 10, 2016.
114. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. *Br J Psychiatry* 198: 351–356, 2011.
115. Forlenza OV, De-Paula VJ, Diniz BS. Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. *ACS Chem Neurosci* 5: 443–450, 2014.
116. Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, Lazzeri G, Spalloni A, Bellio N, Lenzi P, Modugno N, Siciliano G, Isidoro C, Murri L, Ruggieri S, Paparelli A. Lithium delays progression of amyotrophic lateral sclerosis. *Proc Natl Acad Sci USA* 105: 2052–2057, 2008.
117. Fos C, Becart S, Canonigo Balencio AJ, Boehning D, Altman A. Association of the EF-hand and PH domains of the guanine nucleotide exchange factor SLAT with IP₃ receptor I promotes Ca^{2+} signaling in T cells. *Sci Signal* 7: ra93, 2014.
118. Foskett JK. Inositol trisphosphate receptor Ca^{2+} release channels in neurological diseases. *Pflügers Arch* 460: 481–494, 2010.
119. Foskett JK, White C, Cheung KH, Mak DO. Inositol trisphosphate receptor Ca^{2+} release channels. *Physiol Rev* 87: 593–658, 2007.
120. Francis H, Glaser S, Demorow S, Gaudio E, Ueno Y, Venter J, Dostal D, Onori P, Franchitto A, Marziani M, Vaculin S, Vaculin B, Katki K, Stutes M, Savage J, Alpini G. Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP₃/CaMKI/CREB pathway. *Am J Physiol Cell Physiol* 295: C499–C513, 2008.
121. Francis HL, Demorow S, Franchitto A, Venter JK, Mancinelli RA, White MA, Meng F, Ueno Y, Carpino G, Renzi A, Baker KK, Shine HE, Francis TC, Gaudio E, Alpini GD, Onori P. Histamine stimulates the proliferation of small and large cholangiocytes by activation of both IP₃/ Ca^{2+} and cAMP-dependent signaling mechanisms. *Lab Invest* 92: 282–294, 2012.
122. Friston KJ, Sharpley AL, Solomon RA, Cowen PJ. Lithium increases slow wave sleep: possible mediation by brain 5-HT₂ receptors? *Psychopharmacology* 98: 139–140, 1989.
123. Fu Y, Gu J, Wang Y, Yuan Y, Liu X, Bian J, Liu ZP. Involvement of the Ca^{2+} signaling pathway in osteoprotegerin inhibition of osteoclast differentiation and maturation. *J Vet Sci* 16: 151–156, 2015.
124. Futatsugi A, Nakamura T, Yamada MK, Ebisu E, Nakamura K, Uchida K, Kitaguchi T, Takahashi-Iwanaga H, Noda T, Aruga J, Mikoshiba K. IP₃ receptor types 2 and 3 mediate exocrine secretion underlying energy metabolism. *Science* 309: 2232–2234, 2005.
125. Galeotti N, Bartolini A, Ghelardini C. Blockade of intracellular calcium release induces an antidepressant-like effect in the mouse forced swimming test. *Neuropharmacology* 50: 309–316, 2006.
126. Galluzzi L, Pietrocola F, Levine B, Kroemer G. Metabolic control of autophagy. *Cell* 159: 1263–1276, 2014.
127. Gaspers LD, Thomas AP. Calcium signaling in liver. *Cell Calcium* 38: 329–342, 2005.
128. Gaspers LD, Mémin E, Thomas AP. Calcium-dependent physiologic and pathologic stimulus-metabolic response coupling in hepatocytes. *Cell Calcium* 52: 93–102, 2012.
129. Gaspers LD, Bartlett PJ, Politi A, Burnett P, Metzger W, Johnston J, Joseph SK, Höfer T, Thomas AP. Hormone-induced calcium oscillations depend on cross-coupling with inositol 1,4,5-trisphosphate oscillations. *Cell Rep* 9: 1209–1218, 2014.
130. Gautam D, Han SJ, Hamdan FF, Jeon J, Li B, Li JH, Cui Y, Mears D, Lu H, Deng C, Heard T, Wess J. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. *Cell Metab* 3: 449–461, 2006.

131. Gauthier J, Champagne N, Lafrenière RG, Xiong L, Spiegelman D, Brustein E, Lapointe M, Peng H, Côté M, Noreau A, Hamdan FF, Addington AM, Rapoport JL, Delisi LE, Krebs MO, Joober R, Fathall F, Mouaffak F, Haghghi AP, Néri C, Dubé MP, Samuels ME, Marinneau C, Stone EA, Awadalla P, Barker PA, Carbonetto S, Drapeau P, Rouleau GA, S2D Team. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. *Proc Natl Acad Sci USA* 107: 7863–7868, 2010.
132. Genazzani AA, Carafoli E, Guerini D. Calcineurin controls inositol 1,4,5-trisphosphate type I receptor expression in neurons. *Proc Natl Acad Sci USA* 96: 5797–5801, 1999.
133. Gerasimenko JV, Lur G, Sherwood MW, Ebisui E, Tepikin AV, Mikoshiba K, Gerasimenko OV, Petersen OH. Pancreatic protease activation by alcohol metabolite depends on Ca^{2+} release via acid store IP₃ receptors. *Proc Natl Acad Sci USA* 106: 10758–10763, 2009.
134. Gerasimenko JV, Gerasimenko OV, Petersen OH. The role of Ca^{2+} in the pathophysiology of pancreatitis. *J Physiol* 592: 269–280, 2014.
135. Gilman SR, Iossifov I, Levy D, Ronemus M, Wigler M, Vitkup D. Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. *Neuron* 70: 898–907, 2011.
136. Giribaldi F, Milanese M, Bonifacino T, Anna Rossi PI, Di Prisco S, Pittaluga A, Tacchetti C, Puliti A, Usai C, Bonanno G. Group I metabotropic glutamate autoreceptors induce abnormal glutamate exocytosis in a mouse model of amyotrophic lateral sclerosis. *Neuropharmacology* 66: 253–263, 2013.
137. Gomez TM, Spitzer NC. In vivo regulation of axon extension and path finding by growth-cone calcium transients. *Nature* 397: 350–355, 1999.
138. Graef IA, Mermelstein PG, Stankunas K, Neilson JR, Deisseroth K, Tsien RW, Crabtree GR. L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. *Nature* 401: 703–708, 1999.
139. Green KN, LaFerla FM. Linking calcium to Abeta and Alzheimer's disease. *Neuron* 59: 190–194, 2008.
140. Greenberg EF, Lavik AR, Distelhorst CW. Bcl-2 regulation of the inositol 1,4,5-trisphosphate receptor and calcium signaling in normal and malignant lymphocytes: potential new target for cancer treatment. *Biochim Biophys Acta* 1843: 2205–2210, 2014.
141. Gu B, Huang YZ, He XP, Joshi RB, Jang W, McNamara JO. A peptide uncoupling BDNF receptor TrkB from phospholipase Cγ1 prevents epilepsy induced by status epilepticus. *Neuron* 88: 484–491, 2015.
142. Guilmatre A, Huguet G, Delorme R, Bourgeron T. The emerging role of SHANK genes in neuropsychiatric disorders. *Dev Neurobiol* 74: 113–122, 2014.
143. Guo Y, Traurig M, Ma L, Kobes S, Harper I, Infante AM, Bogardus C, Baier LJ, Prochazka M. CHRM3 gene variation is associated with decreased acute insulin secretion and increased risk for early-onset type 2 diabetes in Pima Indians. *Diabetes* 55: 3625–3629, 2006.
144. Hajnóczky G, Thomas AP. Minimal requirements for calcium oscillations driven by the IP₃ receptor. *EMBO J* 16: 3533–3543, 1997.
145. Hall IP. Second messengers, ion channels and pharmacology of airway smooth muscle. *Eur Respir J* 15: 1120–1127, 2000.
146. Hara K, Shiga A, Nozaki H, Mitsui J, Takahashi Y, Ishiguro H, Yomono H, Kurisaki H, Goto J, Ikeuchi T, Tsuji S, Nishizawa M, Onodera O. Total deletion and a missense mutation of ITPR1 in Japanese SCA15 families. *Neurology* 71: 547–551, 2008.
147. Harr MW, Distelhorst CW. Apoptosis and autophagy: decoding calcium signals that mediate life or death. *Cold Spring Harb Perspect Biol* 2: a005579, 2010.
148. Harzheim Movassagh D, Foo M, RS, Ritter O, Tashfeen A, Conway SJ, Bootman MD, Roderick HL. Increased InsP₃Rs in the junctional sarcoplasmic reticulum augment Ca^{2+} transients and arrhythmias associated with cardiac hypertrophy. *Proc Natl Acad Sci USA* 106: 11406–11411, 2009.
149. Hedgepeth SC, Garcia MI, Wagner 2nd LE, Rodriguez AM, Chintapalli SV, Snyder RR, Hankins GD, Henderson BR, Brodie KM, Yule DI, van Rossum DB, Boehning D. The BRCA1 tumor suppressor binds to inositol 1,4,5-trisphosphate receptors to stimulate apoptotic calcium release. *J Biol Chem* 290: 7304–7313, 2015.
150. Heighway J, Betticher DC, Hoban PR, Altermatt HJ, Cowen R. Coamplification in tumors of KRAS2, type 2 inositol 1, 4, 5 triphosphate receptor gene, and a novel human gene, KRAG. *Genomics* 35: 207–214, 1996.
151. Hernandez-Lopez S, Tkatch T, Perez-Garcia E, Galarraga E, Hamm H, Surmeier DJ. D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca^{2+} currents and excitability via a novel PLCbeta1-IP₃-calcineurin-signaling cascade. *J Neurosci* 20: 8987–8995, 2000.
152. Heyes S, Pratt WS, Rees E, Dahmene S, Ferron L, Owen MJ, Dolphin AC. Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders. *Prog Neurobiol* 134: 36–54, 2015.
153. Hienz SA, Paliwal S, Ivanovski S. Mechanisms of bone resorption in periodontitis. *J Immunol Res* 2015: 615486, 2015.
154. Higazi Fearnley DR, Drawnel CJ, FM, Talasila A, Corps EM, Ritter O, McDonald F, Mikoshiba K, Bootman MD, Roderick HL. Endothelin-1-stimulated InsP₃-induced Ca^{2+} release is a nexus for hypertrophic signalling in cardiac myocytes. *Mol Cell* 33: 472–482, 2009.
155. Hikida M, Kurosaki T. Regulation of phospholipase C-gamma2 networks in B lymphocytes. *Adv Immunol* 88: 73–96, 2005.
156. Hirasawa M, Xu X, Trask RB, Maddatu TP, Johnson BA, Naggett JK, Nishina PM, Ikeda A. Carbonic anhydrase related protein 8 mutation results in aberrant synaptic morphology and excitatory synaptic function in the cerebellum. *Mol Cell Neurosci* 35: 161–170, 2007.
157. Hirota J, Ando H, Hamada K, Mikoshiba K. Carbonic anhydrase-related protein is a novel binding protein for inositol 1,4,5-trisphosphate receptor type I. *Biochem J* 372: 435–441, 2003.
158. Ho HC, Suarez SS. An inositol 1,4,5-trisphosphate receptor-gated intracellular Ca^{2+} store is involved in regulating sperm hyperactivated motility. *Biol Reprod* 65: 1606–1615, 2001.
159. Hohendanner F, Walther S, Maxwell JT, Kettlewell S, Awad S, Smith GL, Lonchyna VA, Blatter LA. Inositol-1,4,5-trisphosphate induced Ca^{2+} release and excitation-contraction coupling in atrial myocytes from normal and failing hearts. *J Physiol* 593: 1459–1477, 2015.
160. Hogan PG, Lewis RS, Rao A. Molecular basis of calcium signaling in lymphocytes: STIM and ORAI. *Annu Rev Immunol* 28: 491–533, 2010.
161. Holmes GL. Cognitive impairment in epilepsy: the role of network abnormalities. *Epileptic Disord* 17: 101–116, 2015.
162. Höyer-Hansen M, Bastholm L, Szyniarowski P, Campanella M, Szabadkai G, Farkas T, Bianchi K, Fehrenbacher N, Elling F, Rizzuto R, Mathiasen IS, Jaättelä M. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. *Mol Cell* 25: 193–205, 2007.
163. Huang L, Chardon JW, Carter MT, Friend KL, Dudding TE, Schwartzentruber J, Zou R, Schofield PW, Douglas S, Bulman DE, Boycott KM. Missense mutations in ITPR1 cause autosomal dominant congenital nonprogressive spinocerebellar ataxia. *Orphanet J Rare Dis* 7: 67–73, 2012.
164. Huang W, Cane MC, Mukherjee R, Szatmary P, Zhang X, Elliott V, Ouyang Y, Chavanov M, Latavie D, Wen L, Booth DM, Haynes AC, Petersen OH, Tepikin AV, Criddle DN, Sutton R. Caffeine protects against experimental acute pancreatitis by inhibition of inositol 1,4,5-trisphosphate receptor-mediated Ca^{2+} release. *Gut*. In press. doi:10.1136/gutjnl-2015-309363.
165. Hwang SY, Putney JW Jr. Calcium signaling in osteoclasts. *Biochim Biophys Acta* 1813: 979–983, 2011.
166. Inoue T, Kato K, Kohda K, Mikoshiba K. Type I inositol 1,4,5-trisphosphate receptor is required for induction of long-term depression in cerebellar Purkinje neurons. *J Neurosci* 18: 5366–5373, 1998.
167. Irvin CW, Kim RB, Mitchell CS. Seeking homeostasis: temporal trends in respiration, oxidation, and calcium in SOD1 G93A Amyotrophic Lateral Sclerosis mice. *Front Cell Neurosci* 9: 248, 2015.
168. Irvine RF, Lloyd-Burton SM, Yu JC, Letcher AJ, Schell MJ. The regulation and function of inositol 1,4,5-trisphosphate 3-kinases. *Adv Enzyme Regul* 46: 314e323, 2006.
169. Itkin A, Dupres V, Dufrêne YF, Bechinger B, Ruyschaert JM, Raussens V. Calcium ions promote formation of amyloid β -peptide (1–40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. *PLoS One* 6: e18250, 2011.

170. Ivanova H, Vervliet T, Missiaen L, Parys JB, De Smedt H, Bultynck G. Inositol 1,4,5-trisphosphate receptor-isoform diversity in cell death and survival. *Biochim Biophys Acta* 1843: 2164–2183, 2014.
171. Jensen LE, Bultynck G, Luyten T, Amijee H, Bootman MD, Roderick HL. Alzheimer's disease-associated peptide A β 42 mobilizes ER Ca $^{2+}$ via InsP₃R-dependent and -independent mechanisms. *Front Mol Neurosci* 6: 36, 2013.
172. Jia F, Wang B, Shan L, Xu Z, Staal WG, Du L. Core symptoms of autism improved after vitamin D supplementation. *Pediatrics* 135: e196–e198, 2015.
173. Ju YK, Woodcock EA, Allen DG, Cannell MB. Inositol 1,4,5-trisphosphate receptors and pacemaker rhythms. *J Mol Cell Cardiol* 53: 375–381, 2012.
174. Ju YK, Liu J, Lee BH, Lai D, Woodcock EA, Lei M, Cannell MB, Allen DG. Distribution and functional role of inositol 1,4,5-trisphosphate receptors in mouse sinoatrial node. *Circ Res* 109: 848–857, 2011.
175. Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology—a bidirectional relationship. *Nat Rev Neurol* 10: 115–119, 2014.
176. Kaja S, Duncan RS, Longoria S, Hilgenberg JD, Payne AJ, Desai NM, Parikh RA, Burroughs SL, Gregg EV, Goad DL, Koulen P. Novel mechanism of increased Ca $^{2+}$ release following oxidative stress in neuronal cells involves type 2 inositol-1,4,5-trisphosphate receptors. *Neuroscience* 175: 281–291, 2011.
177. Kan WC, Chou YH, Chiu SJ, Hsu YW, Lu HF, Hsu W, Chang WC. Study of the association between ITPKC genetic polymorphisms and calcium nephrolithiasis. *Biomed Res Int* 2014: 397826, 2014.
178. Kang K, Huang XF, Wang Q, Deng C. Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia—a postmortem study. *Prog Neuropsychopharmacol Biol Psychiatry* 33: 867–871, 2009.
179. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. *Science* 326: 1005–1007, 2009.
180. Kang SS, Han KS, Ku BM, Lee YK, Hong J, Shin HY, Almonte AG, Woo DH, Brat DJ, Hwang EM, Yoo SH, Chung CK, Park SH, Paek SH, Roh EJ, Lee SJ, Park JY, Traynelis SF, Lee CJ. Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. *Cancer Res* 70: 1173–1183, 2010.
181. Kang DS, Yang YR, Lee C, Kim S, Ryu SH, Suh PG. Roles of phosphoinositide-specific phospholipase C γ 1 in brain development. *Adv Biol Regul* 60: 167–173, 2016.
182. Kapoor N, Tran A, Kang J, Zhang R, Philipson KD, Goldhaber JL. Regulation of calcium clock-mediated pacemaking by inositol-1,4,5-trisphosphate receptors in mouse sinoatrial nodal cells. *J Physiol* 593: 2649–2663, 2015.
183. Kasumu AW, Liang X, Egorova P, Vorontsova D, Bezprozvanny I. Chronic suppression of inositol 1,4,5-trisphosphate receptor-mediated calcium signaling in cerebellar purkinje cells alleviates pathological phenotype in spinocerebellar ataxia 2 mice. *J Neurosci* 32: 12786–12796, 2012.
184. Keddis MT, Rule AD. Nephrolithiasis and loss of kidney function. *Curr Opin Nephrol Hypertens* 22: 390–396, 2013.
185. Kessing LV, Sondergaard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. *Arch Gen Psychiatry* 65: 1331–1335, 2008.
186. Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? *Bipolar Disord* 12: 87–94, 2010.
187. Kim HJ, Thayer SA. Lithium increases synapse formation between hippocampal neurons by depleting phosphoinositides. *Mol Pharmacol* 75: 1021–1030, 2009.
188. Kim MS, Yang YM, Son A, Tian YS, Lee SI, Kang SW, Muallem S, Shin DM. RANKL-mediated reactive oxygen species pathway that induces long lasting Ca $^{2+}$ oscillations essential for osteoclastogenesis. *J Biol Chem* 285: 6913–6921, 2010.
189. Kim SH, Zhan L, Hanson KA, Tibbetts RS. High-content RNAi screening identifies the Type 1 inositol triphosphate receptor as a modifier of TDP-43 localization and neurotoxicity. *Hum Mol Genet* 21: 4845–4856, 2012.
190. King AE, Woodhouse A, Kirkcaldie MTK, Vicker JC. Excitotoxicity in ALS: overstimulation or overreaction? *Exp Neurol* 275: 162–171, 2016.
191. Klar J, Hisatsune C, Baig SM, Tariq M, Johansson AC, Rasool M, Malik NA, Ameur A, Sugura K, Feuk L, Mikoshiba K, Dahl N. Abolished InsP₃R2 function inhibits sweat secretion in both humans and mice. *J Clin Invest* 124: 4773–4780, 2014.
192. Kockskämper J, Zima AV, Roderick HL, Pieske B, Blatter LA, Bootman MD. Emerging roles of inositol 1,4,5-trisphosphate signaling in cardiac myocytes. *J Mol Cell Cardiol* 45: 128–147, 2008.
193. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. *Nature* 428: 758–763, 2004.
194. Koh HY. Phospholipase C-beta1 and schizophrenia-related behaviors. *Adv Biol Regul* 53: 242–248, 2013.
195. Kohn EC, Liotta LA, Schiffmann E. Autocrine motility factor stimulates a three-fold increase in inositol trisphosphate in human melanoma cells. *Biochem Biophys Res Commun* 166: 757–764, 1990.
196. Koss H, Bunney TD, Behjati S, Katan M. Dysfunction of phospholipase C γ in immune disorders and cancer. *Trends Biochem Sci* 39: 603–611, 2014.
197. Kovács R, Rabanus A, Otáhal J, Patzak A, Kardos J, Albus K, Heinemann U, Kann O. Endogenous nitric oxide is a key promoting factor for initiation of seizure-like events in hippocampal and entorhinal cortex slices. *J Neurosci* 29: 8565–8577, 2009.
198. Krey JF, Dolmetsch RE. Molecular mechanisms of autism: a possible role for Ca $^{2+}$ signaling. *Curr Opin Neurobiol* 17: 112–119, 2007.
199. Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacska BJ. A β plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. *Neuron* 59: 214–225, 2008.
200. Kuo HC, Hsu YW, Lo MH, Huang YH, Chien SC, Chang WC. Single-nucleotide polymorphism rs7251246 in ITPKC is associated with susceptibility and coronary artery lesions in Kawasaki disease. *PLoS One* 9: e91118, 2014.
201. Kurokawa K, Mizuno K, Ohkuma S. Possible involvement of type 1 inositol 1,4,5-trisphosphate receptors upregulated by dopamine D1 and D2 receptors in mouse nucleus accumbens neurons in the development of methamphetamine-induced place preference. *Neuroscience* 227: 22–29, 2012.
202. Kurokawa K, Mizuno K, Shibasaki M, Ohkuma S. Regulation of type 1 inositol 1,4,5-trisphosphate receptor by dopamine receptors in cocaine-induced place conditioning. *Synapse* 66: 180–186, 2012.
203. Lazzari C, Kipanyula Agostini M MJ, Pozzan T, Fasolato C. A β 42 oligomers selectively disrupt neuronal calcium release. *Neurobiol Aging* 36: 877–885, 2015.
204. Leal SS, Gomes CM. Calcium dysregulation links ALS defective proteins and motor neuron selective vulnerability. *Front Cell Neurosci* 9: 225–230, 2015.
205. Lee SH, Davison JA, Vidal SM, Belouchi A. Cloning, expression and chromosomal location of NKX6B TO 10Q26, a region frequently deleted in brain tumors. *Mamm Genome* 12: 157–162, 2001.
206. Lee RJ, Foskett JK. Ca $^{2+}$ signalling and fluid secretion by secretory cells of the airway epithelium. *Cell Calcium* 55: 325–336, 2014.
207. Lee MD, Bingham KN, Mitchell TY, Meredith JL, Rawlings JS. Calcium mobilization is both required and sufficient for initiating chromatin decondensation during activation of peripheral T-cells. *Mol Immunol* 63: 540–549, 2015.
208. Leissring MA, Paul BA, Parker I, Cotman CW, LaFerla FM. Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in *Xenopus* oocytes. *J Neurochem* 72: 1061–1068, 1999.
209. Li W, Llopis J, Whitney M, Zlokarnik G, Tsien R. Cell-permeant caged InsP₃ ester shows that Ca $^{2+}$ spike frequency can optimize gene expression. *Nature* 392: 936–941, 1998.
210. Li X, Zima AV, Sheikh F, Blatter LA, Chen J. Endothelin-1-induced arrhythmogenic Ca $^{2+}$ signaling is abolished in atrial myocytes of inositol-1,4,5-trisphosphate(IP₃)-receptor type 2-deficient mice. *Circ Res* 96: 1274–1281, 2005.
211. Li C, Enomoto M, Rossi AM, Seo MD, Rahman T, Stathopoulos PB, Taylor CW, Ikura M, Ames JB. CaBP1, a neuronal Ca $^{2+}$ sensor protein, inhibits inositol trisphosphate receptors by clamping intersubunit interactions. *Proc Natl Acad Sci USA* 110: 8507–8512, 2013.

212. Liberona JL, Powell JA, Shenoi S, Petherbridge L, Caviedes R, Jaimovich E. Differences in both inositol 1,4,5-trisphosphate mass and inositol 1,4,5-trisphosphate receptors between normal and dystrophic skeletal muscle cell lines. *Muscle Nerve* 21: 902–909, 1998.
213. Liberona JL, Ca'rdenas JC, Reyes R, Hidalgo J, Molgo J, Jaimovich E. Sodium-dependent action potentials induced by brevetoxin-3 trigger both IP₃ increase and intracellular Ca²⁺ release in rat skeletal myotubes. *Cell Calcium* 44: 289–297, 2008.
214. Lipp P, Laine M, Tovey SC, Burrell KM, Berridge MJ, Li W, Bootman MD. Functional InsP₃ receptors that may modulate excitation-contraction coupling in the heart. *Curr Biol* 10: 939–942, 2000.
215. Liu J, Tang TS, Tu H, Nelson O, Herndon E, Huynh DP, Pulst SM, Bezprozvanny I. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type2. *J Neurosci* 29: 9148–9162, 2009.
216. Liu JT, Guo X, Ma WJ, Zhang YG, Xu P, Yao JF, Bai YD. Mitochondrial function is altered in articular chondrocytes of an endemic osteoarthritis, Kashin-Beck disease. *Osteoarthritis Cartilage* 18: 1218–1226, 2010.
217. Liu G, Gu B, He XP, Joshi RB, Wackerle HD, Rodriguez RM, Wetsel WC, McNamara JO. Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy. *Neuron* 79: 31–38, 2013.
218. Ljubojevic S, Radulovic S, Leitinger G, Sedej S, Sacherer M, Holzer M, Winkler C, Pritz E, Mittler T, Schmidt A, Sereinigg M, Wakula P, Zissimopoulos S, Bisping E, Post H, Marsche G, Bossuyt J, Bers DM, Kockskämper J, Pieske B. Early remodeling of peri-nuclear Ca²⁺ stores and nucleoplasmic Ca²⁺ signaling during the development of hypertrophy and heart failure. *Circulation* 130: 244–255, 2014.
219. Lopez JR, Lyckman A, Oddo S, Laferla FM, Querfurth HW, Shtifman A. Increased intraneuronal resting [Ca²⁺] in adult Alzheimer's disease mice. *J Neurochem* 105: 262–271, 2008.
220. Lo Vasco VR, Cardinale G, Polonia P. Deletion of PLC β 1 gene in schizophrenia-affected patients. *J Cell Mol Med* 16: 844–851, 2012.
221. Lowe M. Structure and function of the Lowe syndrome protein OCRL1. *Traffic* 6: 711–719, 2005.
222. Lu JP, Wang Y, Sliter DA, Pearce MM, Wojcikiewicz RJ. RNFI70 protein, an endoplasmic reticulum membrane ubiquitin ligase, mediates inositol 1,4,5-trisphosphate receptor ubiquitination and degradation. *J Biol Chem* 286: 24426–24433, 2011.
223. Lucey BP, Bateman RJ. Amyloid- β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis. *Neurobiol Aging* 35: S29–S34, 2014.
224. Lucey BP, Holtzman DM. How amyloid, sleep and memory connect. *Nat Neurosci* 18: S29–933–934. 2015.
225. Ma WJ, Hashii M, Munesue T, Hayashi K, Yagi K, Yamagishi M, Higashida H, Yokoyama S. Non-synonymous single-nucleotide variations of the human oxytocin receptor gene and autism spectrum disorders: a case-control study in a Japanese population and functional analysis. *Mol Autism* 4: 22–35, 2013.
226. Machado-Vieira R, Pivovarova NB, Stanika RI, Yuan P, Wang Y, Zhou R, Zarate CA Jr, Drevets WC, Brantner CA, Baum A, Laje G, McMahon FJ, Chen G, Du J, Manji HK, Andrews SB. The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. *Biol Psychiatry* 69: 344–352, 2011.
227. Mackenzie L, Bootman MD, Laine M, Berridge MJ, Thuring J, Holmes A, Li WH, Lipp P. The role of inositol 1,4,5-trisphosphate receptors in Ca²⁺ signalling and the generation of arrhythmias in rat atrial myocytes. *J Physiol* 541: 395–409, 2002.
228. Mackenzie L, Roderick HL, Berridge MJ, Conway SJ, Bootman MD. The spatial pattern of atrial cardiomyocyte calcium signalling modulates contraction. *J Cell Sci* 117: 6327–6337, 2004.
229. Mak DO, Foskett JK. Inositol 1,4,5-trisphosphate receptors in the endoplasmic reticulum: a single-channel point of view. *Cell Calcium* 58: 67–78, 2015.
230. Mak DO, Cheung KH, Toglia P, Foskett JK, Ullah G. Analyzing and quantifying the gain-of-function enhancement of IP₃ receptor gating by Familial Alzheimer's Disease-causing mutants in presenilins. *PLoS Comput Biol* 11: e1004529, 2015.
231. Maldonado M, Nam J. The role of changes in extracellular matrix of cartilage in the presence of inflammation on the pathology of osteoarthritis. *Biomed Res Int* 2013: 284873, 2013.
232. Mancini AD, Poitout V. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? *Trends Endocrinol Metab* 24: 398–407, 2013.
233. Mander BA, Marks SM, Vogel JW, Rao V, Lu B, Saletin JM, Ancoli-Israel S, Jagust WJ, Walker MP. β -Amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. *Nat Neurosci* 18: 1051–1057, 2015.
234. Marin O. Interneuron dysfunction in psychiatric disorders. *Nat Rev Neurosci* 13: 107–120, 2012.
235. Martin VA, Wang WH, Lipchik AM, Parker LL, He Y, Zhang S, Zhang ZY, Geahlen RL. Akt2 inhibits the activation of NFAT in lymphocytes by modulating calcium release from intracellular stores. *Cell Signal* 24: 1064–1073, 2012.
236. Mathews R, Li PP, Young LT, Kish SJ, Marsh JJ. Increased G alpha q/I immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder. *Biol Psychiatry* 41: 649–656, 1997.
237. Matosin N, Newell KA. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. *Neurosci Biobehav Rev* 37: 256–268, 2013.
238. Matsumoto M. InsP₃R-Ca²⁺ signaling takes center stage in the hormonal regulation of hepatic gluconeogenesis. *Cell Res* 22: 1530–1532, 2012.
239. Matsumoto I, Inoue Y, Iwazaki T, Pavay G, Dean B. 5-HT_{2A} and muscarinic receptors in schizophrenia: a postmortem study. *Neurosci Lett* 379: 164–168, 2005.
240. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. β -Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. *J Neurosci* 12: 376–389, 1992.
241. McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis—shaping the immunological landscape. *Nat Rev Rheumatol* 12: 63–68, 2016.
242. McNamara JO, Huang YZ, Leonard AS. Molecular signaling mechanisms underlying epileptogenesis. *Sci STKE* 356: re12, 2006.
243. McOmisch Burrows E CE, Howard M, Scarr E, Kim D, Shin HS, Dean B, van den Buuse M, Hannan AJ. Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. *Mol Psychiatry* 13: 661–672, 2008.
244. Melvin JE, Yule D, Shuttleworth T, Begenisich T. Regulation of fluid and electrolyte secretion in salivary gland acinar cells. *Annu Rev Physiol* 67: 445–469, 2005.
245. Mengubas K, Jabbar SA, Nye KE, Wilkes S, Hoffbrand AV, Wickremasinghe RG. Inactivation of calcium ion-regulating inositol polyphosphate second messengers is impaired in subpopulations of human leukemia cells. *Leukemia* 8: 1718–1725, 1994.
246. Mertens J, Wang QW, Kim Y, Yu DX, Pham S, Yang B, Zheng Y, Diffenderfer KE, Zhang J, Soltani S, Eames T, Schafer ST, Boyer L, Marchetto MC, Nurnberger JL, Calabrese JR, Ødegaard KJ, McCarthy MJ, Zandi PP, Alda M, Nievergelt CM; Pharmacogenomics of Bipolar Disorder Study, Mi S, Brennan KJ, Kelsoe JR, Gage FH, Yao J. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. *Nature* 527: 95–99, 2015.
247. Mijares A, Altamirano F, Kolster J, Adams JA, López JR. Age-dependent changes in diastolic Ca²⁺ and N⁺ concentrations in dystrophic cardiomyopathy: role of Ca²⁺ entry and IP₃. *Biochem Biophys Res Commun* 452: 1054–1059, 2014.
248. Mikoshiba K. IP₃ receptor/Ca²⁺ channel: from discovery to new signaling concepts. *J Neurochem* 102: 1426–1446, 2007.
249. Mikoshiba K. Role of IP₃ receptor signaling in cell functions and diseases. *Adv Biol Regul* 57: 217–227, 2015.
250. Milanese M, Giribaldi F, Melone M, Bonifacino T, Musante I, Carminati E, Rossi PI, Vergani L, Voci A, Conti F, Puliti A, Bonanno G. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. *Neurobiol Dis* 64: 48–59, 2014.
251. Mimics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. *Mol Psychiatry* 6: 293–301, 2001.
252. Mirza N, Appleton R, Burn S, Carr D, Crooks D, du Plessis D, Duncan R, Farah JO, Josan V, Miyajima F, Mohanraj R, Shukrala A, Sills GJ, Marson AG, Pirmohamed M. Identifying the biological pathways underlying human focal epilepsy: from complexity to coherence to centrality. *Hum Mol Genet* 24: 4306–4316, 2015.

253. Missiaen L, Taylor CW, Berridge MJ. Spontaneous calcium release from inositol trisphosphate-sensitive calcium stores. *Nature* 352: 241–244, 1991.
254. Miyachi K, Iwai M, Asada K, Saito I, Hankins R, Mikoshiba K. Inositol 1,4,5-trisphosphate receptors are autoantibody target antigens in patients with Sjögren's syndrome and other systemic rheumatic diseases. *Mod Rheumatol* 17: 137–143, 2007.
255. Miyakawa T, Maeda A, Yamazawa T, Hirose K, Kuroasaki T, Iino M. Encoding of Ca^{2+} signals by differential expression of IP_3 receptor subtypes. *EMBO J.* 18: 1303–1308, 1999.
256. Mizuno K, Kurokawa K, Ohkuma S. Dopamine D1 receptors regulate type I inositol 1,4,5-trisphosphate receptor expression via both AP-1- and NFATc4-mediated transcriptional processes. *J Neurochem* 122: 702–713, 2012.
257. Mizuno K, Kurokawa K, Ohkuma S. Nicotinic acetylcholine receptors regulate type I inositol 1,4,5-trisphosphate receptor expression via calmodulin kinase IV activation. *J Neurosci Res* 93: 660–665, 2015.
258. Moccia F, Berra-Romani R, Tritto S, Signorelli S, Taglietti V, Tanzi F. Epidermal growth factor induces intracellular Ca^{2+} oscillations in microvascular endothelial cells. *J Cell Physiol* 194: 139–150, 2003.
259. Mondin L, Balghi H, Constantini B, Cognard C, Sebille S. Negative modulation of inositol 1,4,5-trisphosphate type I receptor expression prevents dystrophin-deficient muscle cells death. *Am J Physiol Cell Physiol* 297: C1133–C1145, 2009.
260. Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ. Calcium and cancer: targeting Ca^{2+} transport. *Nat Rev Cancer* 7: 519–530, 2007.
261. Morris G, Berk M. The putative use of lithium in Alzheimer's disease. *Curr Alzheimer Res* 13: 853–861, 2016.
262. Motoi Y, Shimada K, Ishiguro K, Hattori N. Lithium and autophagy. *ACS Chem Neurosci* 5: 434–442, 2014.
263. Mound A, Rodat-Despoix L, Bougarn S, Ouadid-Ahidouch H, Matifat F. Molecular interaction and functional coupling between type 3 inositol 1,4,5-trisphosphate receptor and BKCa channel stimulate breast cancer cell proliferation. *Eur J Cancer* 49: 3738–3751, 2013.
264. Myhrer T, Mariussen E, Enger S, Aas P. Capacities of metabotropic glutamate modulators in counteracting soman-induced seizures in rats. *Eur J Pharmacol* 718: 253–260, 2013.
265. Nagarkatti N, Deshpande LS, DeLorenzo RJ. Levetiracetam inhibits both ryanodine and IP_3 receptor activated calcium induced calcium release in hippocampal neurons in culture. *Neurosci Lett* 436: 289–293, 2008.
266. Nakao S, Wakabayashi S, Nakamura TY. Stimulus-dependent regulation of nuclear Ca^{2+} signaling in cardiomyocytes: a role of neuronal calcium sensor-I. *PLoS One* 10: e0125050, 2015.
267. Nakayama H, Bodí I, Maillet M, DeSantiago J, Domeier TL, Mikoshiba K, Lorenz JN, Blatter LA, Bers DM, Molkentin JD. The IP_3 receptor regulates cardiac hypertrophy in response to select stimuli. *Circ Res* 107: 659–666, 2010.
268. Negishi-Koga T, Takayanagi H. Ca^{2+} -NFATc1 signaling is an essential axis of osteoclast differentiation. *Immunol Rev* 231: 241–256, 2009.
269. Nelson SB, Valakh V. Excitatory/inhibitory balance and circuit homeostasis in autism spectrum disorders. *Neuron* 87: 684–698, 2015.
270. Nevius E, Gomes AC, Pereira JP. Inflammatory cell migration in rheumatoid arthritis: a comprehensive review. *Clin Rev Allergy Immunol.* In press.
271. Nguyen C, Lieberherr M, Bordat C, Velard F, Côme D, Lioté F, Ea HK. Intracellular calcium oscillations in articular chondrocytes induced by basic calcium phosphate crystals lead to cartilage degradation. *Osteoarthr Cartil* 20: 1399–1408, 2007.
272. Nomikos M. Novel signalling mechanism and clinical applications of sperm-specific PLC ζ . *Biochem Soc Trans* 43: 371–376, 2015.
273. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. *Br J Psychiatry* 190: 359–360, 2007.
274. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. *Curr Alzheimer Res* 10: 104–107, 2013.
275. Oh-hora M, Rao A. Calcium signaling in lymphocytes. *Curr Opin Immunol* 20: 250–258, 2008.
276. Oliveira AG, Andrade VA, Guimarães ES, Florentino RM, Sousa PA, Marques PE, Melo FM, Ortega MJ, Menezes GB, Leite MF. Calcium signalling from the type I inositol 1,4,5-trisphosphate receptor is required at early phase of liver regeneration. *Liver Int* 35: 1162–1171, 2015.
277. Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, Nakamura Y, Yanagawa H, Wakui K, Fukushima Y, Kishi F, Hamamoto K, Terai M, Sato Y, Ouchi K, Saji T, Narita A, Kaburagi Y, Yoshikawa T, Suzuki K, Tanaka T, Nagai T, Cho H, Fujino A, Sekine A, Nakamichi R, Tsunoda T, Kawasaki T, Nakamura Y, Hata A. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. *Nat Genet* 40: 35–42, 2008.
278. Opel A, Nobles M, Montaigne D, Finlay M, Anderson N, Breckenridge R, Tinker A. Absence of the regulator of G-protein signaling, RGS4, predisposes to atrial fibrillation and is associated with abnormal calcium handling. *J Biol Chem* 290: 19233–19244, 2015.
279. Orabi AI, Luo Y, Ahmad MU, Shah AU, Mannan Z, Wang D, Sarwar S, Muili KA, Shugrue C, Kolodecik TR, Singh VP, Lowe ME, Thrower E, Chen J, Husain SZ. IP_3 Receptor type 2 deficiency is associated with a secretory defect in the pancreatic acinar cell and an accumulation of zymogen granules. *PLoS One* 7: e48465, 2012.
280. Oseki KT, Monteforte PT, Pereira GJ, Hirata H, Ureshino RP, Bincoletto C, Hsu YT, Smaili SS. Apoptosis induced by $\text{A}\beta_{25–35}$ peptide is Ca^{2+} - IP_3 signaling-dependent in murine astrocytes. *Eur J Neurosci* 40: 2471–2478, 2014.
281. Ota SM, Moreira KD, Suchecki D, Oliveira MG, Tiba PA. Lithium prevents REM sleep deprivation-induced impairments on memory consolidation. *Sleep* 36: 1677–1684, 2013.
282. Ouyang K, Leandro Gomez-Amaro R, Stachura DL, Tang H, Peng X, Fang X, Traver D, Evans S M Chen J. Loss of IP_3R -dependent Ca^{2+} signalling in thymocytes leads to aberrant development and acute lymphoblastic leukemia. *Nat Commun* 5: 4814, 2014.
283. Pace-Schott EF, Hobson JA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. *Nat Rev Neurosci* 3: 591–605, 2002.
284. Pacher P, Sharma K, Csordás G, Zhu Y, Hajnóczky G. Uncoupling of ER-mitochondrial calcium communication by transforming growth factor-beta. *Am J Physiol Renal Physiol* 295: F1303–F1312, 2008.
285. Pagani MR, Reisin RC, Uchitel OD. Calcium signaling pathways mediating synaptic potentiation triggered by amyotrophic lateral sclerosis IgG in motor nerve terminals. *J Neurosci* 26: 2661–2672, 2006.
286. Pal S, Sun D, Limbrick D, Rafiq A, DeLorenzo RJ. Epileptogenesis induces long-term alterations in intracellular calcium release and sequestration mechanisms in the hippocampal neuronal culture model of epilepsy. *Cell Calcium* 30: 285–296, 2001.
287. Panza F, Solfrizzi V, Barulli MR, Bonfiglio C, Guerra V, Osella A, Seripa D, Sabbà C, Pilotto A, Logroscino G. Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review. *J Nutr Health Aging* 19: 313–328, 2015.
288. Park MK, Lomax RB, Tepikin AV, Petersen OH. Local uncaging of caged Ca^{2+} reveals distribution of Ca^{2+} -activated Cl^- channels in pancreatic acinar cells. *Proc Natl Acad Sci USA* 98: 10948–10953, 2001.
289. Park KM, Yule DI, Bowers WJ. Tumor necrosis factor- α -mediated regulation of the inositol 1,4,5-trisphosphate receptor promotor. *J Biol Chem* 284: 27557–27566, 2009.
290. Park SJ, Jeong J, Park YU, Park KS, Lee H, Lee N, Kim SM, Kuroda K, Nguyen MD, Kaihachi K, Park SK. Disrupted-in schizophrenia-I (DISCI) regulates endoplasmic reticulum calcium dynamics. *Sci Rep* 5: 8694, 2015.
291. Parker I, Ivorra I. Caffeine inhibits inositol trisphosphate-mediated liberation of intracellular calcium in *Xenopus* oocytes. *J Physiol* 433: 229–240, 1991.
292. Patterson RL, Boehning D, Snyder SH. Inositol 1,4,5-trisphosphate receptors as signal integrators. *Annu Rev Biochem* 73: 437–465, 2004.
293. Pecze L, Schwaller B. Characterization and modeling of Ca^{2+} oscillations in mouse primary mesothelial cells. *Biochim Biophys Acta* 1853: 632–645, 2015.

294. Pelaia G, Varella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, Lombardo N, Maselli R. Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD. *Ther Clin Risk Manag* 11: 1563–1572, 2015.
295. Petersen OH. Ca^{2+} signalling in the endoplasmic reticulum/secretory granule microdomain. *Cell Calcium* 58: 397–404, 2015.
296. Petersen OH, Tepikin AV. Polarized calcium signaling in exocrine gland cells. *Annu Rev Physiol* 70: 273–299, 2008.
297. Pierro C, Cook SJ, Foets TC, Bootman MD, Roderick HL. Oncogenic K-Ras suppresses IP₃-dependent Ca^{2+} release through remodelling of the isoform composition of IP₃Rs and ER luminal Ca^{2+} levels in colorectal cancer cell lines. *J Cell Sci* 127: 1607–1619, 2014.
298. Pierrot N, Santos SF, Feyt C, Morel Brion JP, Octave JN. Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-beta accumulation. *J Biol Chem* 281: 39907–39914, 2006.
299. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, Conroy J, Magalhaes TR, Correia C, Abrahams BS, Almeida J, Bacchelli E, Bader GD, Bailey AJ, Baird G, Battaglia A, Berney T, Bolshakova N, Bölte S, Bolton PF, Bourgeron T, Brennan S, Brian J, Bryson SE, Carson AR, Casallo G, Casey J, Chung BH, Cochrane L, Corsello C, Crawford EL, Crossett A, Cytrynbaum C, Dawson G, de Jonge M, Delorme R, Drmic I, Duketis E, Duque F, Estes A, Farrar P, Fernandez BA, Folstein SE, Fombonne E, Freitag CM, Gilbert J, Gillberg C, Glessner JT, Goldberg J, Green A, Green J, Guter SJ, Hakonarson H, Heron EA, Hill M, Holt R, Howe JL, Hughes G, Hus V, Iglozzi R, Kim C, Klauck SM, Kolevzon A, Korvatska O, Kustanovich V, Lajonchere CM, Lamb JA, Laskawiec M, Leboyer M, Le Coultre A, Leventhal BL, Lionel AC, Liu XQ, Lord C, Lotspeich L, Lund SC, Maestrini E, Mahoney W, Mantoulas C, Marshall CR, McConechie H, McDougle CJ, McGrath J, McMahon WM, Merikangas A, Migita O, Minshew NJ, Mirza GK, Munson J, Nelson SF, Noakes C, Noor A, Nygren G, Oliveira G, Papanikolaou K, Parr JR, Parrini B, Paton T, Pickles A, Pilorge M, Piven J, Ponting CP, Posey DJ, Poustka A, Poustka F, Prasad A, Ragoussis J, Renshaw K, Rickaby J, Roberts W, Roeder K, Roge B, Rutter ML, Bierut LJ, Rice JP, Salt J, Sansom K, Sato D, Segurado R, Sequeira AF, Senman L, Shah N, Sheffield VC, Soorya L, Sousa I, Stein O, Sykes N, Stoppioni V, Strawbridge C, Tancredi R, Tansey K, Thiruvahindrapuram B, Thompson AP, Thomson S, Tryfon A, Tsiantis J, Van Engeland H, Vincent JB, Volkmar F, Wallace S, Wang K, Wang Z, Wassink TH, Webber C, Weksberg R, Wing K, Wittemeyer K, Wood S, Wu J, Yaspan BL, Zurawiecki D, Zwaigenbaum L, Buxbaum JD, Cantor RM, Cook EH, Coon H, Cuccaro ML, Devlin B, Ennis S, Gallagher L, Geschwind DH, Gill M, Haines JL, Hallmayer J, Miller J, Monaco AP, Nurnberger JJ Jr, Paterson AD, Pericak-Vance MA, Schellenberg GD, Szatmari P, Vicente AM, Vieland VJ, Wijsman EM, Scherer SW, Sutcliffe JS, Betancur C. Functional impact of global rare copy number variation in autism spectrum disorders. *Nature* 466: 368–372, 2010.
300. Pinto MC, Kihara AH, Goulart VA, Tonelli FM, Gomes KN, Ulrich H, Resende RR. Calcium signaling and cell proliferation. *Cell Signal* 27: 2139–2149, 2015.
301. Politi A, Gaspers LD, Thomas AP, Höfer T. Models of IP₃ and Ca^{2+} oscillations: frequency encoding and identification of underlying feedbacks. *Biophys J* 90: 3120–3133, 2006.
302. Pozsgay J, Babos F, Uray K, Magyar A, Gyulai G, Kiss É, Nagy G, Rojkovich B, Hudecz F, Sármay G. In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles. *Arthritis Res Ther* 18: 15, 2016.
303. Prevarskaya Na R, Shuba Y. Remodelling of Ca^{2+} transport in cancer: how it contributes to cancer hallmarks? *Philos Trans R Soc Lond B Biol Sci* 369: 20130097, 2014.
304. Pritchard S, Guilak F. Effects of interleukin-1 on calcium signaling and the increase of filamentous actin in isolated and in situ articular chondrocytes. *Arthritis Rheum* 54: 2164–2174, 2006.
305. Prole DL, Taylor CW. Inositol 1,4,5-trisphosphate receptors and their protein partners as signalling hubs. *J Physiol* 594: 2849–2866, 2016.
306. Proven A, Roderick HL, Conway SJ, Berridge MJ, Horton JK, Capper SJ, Bootman MD. Inositol 1,4,5-trisphosphate supports the arrhythmogenic action of endothelin-1 on ventricular cardiac myocytes. *J Cell Sci* 119: 3363–3375, 2006.
307. Pusl T, Nathanson MH. The role of inositol 1,4,5-trisphosphate receptors in the regulation of bile secretion in health and disease. *Biochem Biophys Res Commun* 322: 1318–1325, 2004.
308. Querfurth HK, Selkoe DJ. Calcium ionophore increases amyloid beta peptide production by cultured cells. *Biochemistry* 33: 4550–4561, 1994.
309. Rahman T. Dynamic clustering of IP₃ receptors by IP₃. *Biochem Soc Trans* 40: 325–330, 2012.
310. Rahman T, Skupin A, Falcke M, Taylor CW. Clustering of InsP₃ receptors by InsP₃ retunes their regulation by InsP₃ and Ca^{2+} . *Nature* 458: 655–659, 2009.
311. Rapp PE, Berridge MJ. The control of transepithelial potential oscillations in the salivary gland of *Calliphora erythrocephala*. *J Exp Biol* 93: 119–132, 1981.
312. Reeves EP, Banville N, Ryan DM, O'Reilly N, Bergin DA, Pohl K, Molloy K, McElvaney OJ, Alsaleh K, Aljorfi A, Kandalaf O, O'Flynn E, Geraghty P, O'Neill SJ, McElvaney NG. Intracellular secretory leukoprotease inhibitor modulates inositol 1,4,5-trisphosphate generation and exerts an anti-inflammatory effect on neutrophils of individuals with cystic fibrosis and chronic obstructive pulmonary disease. *Biomed Res Int* 2013: 560141, 2013.
313. Roderick HL, Cook SJ. Ca^{2+} signalling checkpoints in cancer: remodelling Ca^{2+} for cancer cell proliferation and survival. *Nature Rev Cancer* 8: 361–375, 2008.
314. Rodrigues MA, Gomes DA, Leite MF, Grant W, Zhang L, Lam W, Cheng YC, Bennett AM, Nathanson MH. Nucleoplasmic calcium is required for cell proliferation. *J Biol Chem* 282: 17061–17068, 2007.
315. Rodriguez-Diaz R, Dando R, Jacques-Silva MC, Fachado A, Molina J, Abdulreda MH, Ricordi C, Roper SD, Berggren PO, Caicedo A. Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming beta cell function in humans. *Nat Med* 17: 888–892, 2011.
316. Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM. Disruption of the sleep-wake cycle and diurnal fluctuation of β -amyloid in mice with Alzheimer's disease pathology. *Sci Transl Med* 4: 150ra122, 2012.
317. Rohn TT, Vyas V, Hernandez-Estrada T, Nichol KE, Christie LA, Head E. Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. *J Neurosci* 28: 3051–3059, 2008.
318. Rong YP, Distelhorst CW. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. *Annu Rev Physiol* 70: 73–91, 2008.
319. Rooney T, Sass E, Thomas AP. Characterization of cytosolic calcium oscillations induced by phenylephrine and vasopressin in single fura-2-loaded hepatocytes. *J Biol Chem* 264: 17131–17141, 1989.
320. Rose CR, Konnerth A. Stores not just for storage: intracellular calcium release and synaptic plasticity. *Neuron* 31: 519–522, 2001.
321. Sakakura C, Hagiwara A, Fukuda K, Shimomura K, Takagi T, Kin S, Nakase Y, Fujiyama J, Mikoshiba K, Okazaki Y, Yamagishi H. Possible involvement of inositol 1,4,5-trisphosphate receptor type 3 (IP₃R3) in the peritoneal dissemination of gastric cancers. *Anticancer Res* 23: 3691–3697, 2003.
322. Saleem H, Tovey SC, Molinski TF, Taylor CW. Interactions of antagonists with subtypes of inositol 1,4,5-trisphosphate (IP₃) receptor. *Br J Pharmacol* 171: 3298–3312, 2014.
323. Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA Jr. The neurobiology of the switch process in bipolar disorder: a review. *J Clin Psychiatry* 71: 1488–1501, 2010.
324. Sankar N, deTombe PP, Mignery GA. Calcineurin-NFATc regulates type 2 inositol 1,4,5-trisphosphate receptor (InsP₃R2) expression during cardiac remodeling. *J Biol Chem* 289: 188–198, 2014.
325. Sarker S, Floto RA, Berger Z, Imanisio S, Cordenier A, Pasco M, Cook LJ, Rubinsztein DC. Lithium induces autophagy by inhibiting inositol monophosphatase. *J Cell Biol* 170: 1101–1111, 2005.
326. Sarker S, Rubinsztein DC. Inositol and IP₃ levels regulate autophagy: biology and therapeutic speculations. *Autophagy* 2: 132–134, 2006.
327. Sarker S, Krishna G, Imanisio S, Saiki S, O'Kane CJ, Rubinsztein DC. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. *Hum Mol Genet* 17: 170–178, 2008.
328. Scarr E, Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia. *J Neurochem* 107: 1188–1195, 2008.
329. Scharenberg AM, Humphries LA, Rawlings DJ. Calcium signalling and cell-fate choice in B cells. *Nat Rev Immunol* 7: 778–789, 2007.

330. Schepman K, Engelbert RH, Visser MM, Yu C, de Vos R. Kashin Beck Disease: more than just osteoarthritis: a cross-sectional study regarding the influence of body function-structures and activities on level of participation. *Int Orthop* 35: 767–776, 2011.
331. Scheuing L, Chiu CT, Liao HM, Linares GR, Chuang DM. Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned? *Int J Biol Sci* 10: 1024–1038, 2014.
332. Schlecker C, Boehmerle W, Jeromin A, DeGray B, Varshney A, Sharma Y, Szigeti-Buck K, Ehrlich BE. Neuronal calcium sensor-1 enhancement of InsP_3 receptor activity is inhibited by therapeutic levels of lithium. *J Clin Invest* 116: 1668–1674, 2006.
333. Schmunk G, Boubion BJ, Smith IF, Parker I, Gargus JJ. Shared functional defect in IP_3 -mediated calcium signaling in diverse monogenic autism syndromes. *Transl Psychiatry* 22: e643, 2015.
334. Schnekenberg PR, Perkins EM, Miller JW, Davies WI, D'Adamo MC, Pessia M, Fawcett KA, Sims D, Gillard E, Hudspith K, Skehel P, Williams J, O'Regan M, Jayawant S, Jefferson R, Hughes S, Lustenberger A, Ragoussis J, Jackson M, Tucker SJ, Németh AH. De novo point mutations in patients diagnosed with ataxic cerebral palsy. *Brain* 138: 1817–1832, 2015.
335. Schorge S, vandeLeemput J, Singleton A, Houlden H, Hardy J. Human ataxias: a genetic dissection of inositol triphosphate receptor(ITPR1)-dependent signaling. *Trends Neurosci* 33: 211–219, 2010.
336. Sei Y, Gallagher KL, Daly JW. Multiple effects of caffeine on Ca^{2+} release and influx in human B lymphocytes. *Cell Calcium* 29: 149–160, 2001.
337. Sekulic A, Kim SY, Hostetter G, Savage S, Einspahr JG, Prasad A, Sagerman P, Curiel-Lewandrowski C, Krouse R, Bowden GT, Warneke J, Alberts DS, Pittelkow MR, DiCaudo D, Nickoloff BJ, Trent JM, Bittner M. Loss of inositol polyphosphate 5-phosphatase is an early event in development of cutaneous squamous cell carcinoma. *Cancer Prev Res* 3: 1277–1283, 2010.
338. Shadrina MI, Shulskaya MV, Klyushnikov SA, Nikopensius T, Nelis M, Kivistik PA, Komar AA, Limborska SA, Illarioshkin SN, Slominsky PA. *ITPR1* gene p.Val553Met mutation in Russian family with mild spinocerebellar ataxia. *Cerebellum Ataxias* 3: 2, 2016.
339. Shakhsalim N, Kazemi B, Basiri A, Houshmand M, Pakmanesh H, Golestan B, Eilanjeh AF, Kashi AH, Kilani M, Azadvari M. Association between calcium-sensing receptor gene polymorphisms and recurrent calcium kidney stone disease: a comprehensive gene analysis. *Scand J Urol Nephrol* 44: 406–412, 2010.
340. Sharma K, Deelman L, Mades M, Kurz B, Ciccone E, Siva S, Hu T, Zhu Y, Wang L, Henning R, Ma X, Hajnoczky G. Involvement of transforming growth factor- β in regulation of calcium transients in diabetic vascular smooth muscle cells. *Am J Physiol Renal Physiol* 285: F1258–F1270, 2003.
341. Shi JL, Fu L, Wang WD. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia. *Oncotarget* 6: 5299–5309, 2015.
342. Shibao Hirata K, Robert KME, Nathanson MH. Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis. *Gastroenterology* 125: 1175–1187, 2003.
343. Shibao K, Fiedler MJ, Nagata J, Minagawa N, Hirata K, Nakayama Y, Iwakiri Y, Nathanson MH, Yamaguchi K. The type III inositol 1,4,5-trisphosphate receptor is associated with aggressiveness of colorectal carcinoma. *Cell Calcium* 48: 315–323, 2010.
344. Shilling D, Müller M, Takano H, Mak DO, Abel T, Coulter DA, Foskett JK. Suppression of InsP_3 receptor-mediated Ca^{2+} signaling alleviates mutant presenilin-linked familial Alzheimer's disease pathogenesis. *J Neurosci* 34: 6910–6923, 2014.
345. Shinohara M, Takayanagi H. Novel osteoclast signaling mechanisms. *Curr Osteoporos Rep* 5: 67–72, 2007.
346. Shinozaki G, Potash JB. New developments in the genetics of bipolar disorder. *Curr Psychiatry Rep* 16: 493, 2014.
347. Singh N, Halliday AC, Thomas JM, Kuznetsova OV, Baldwin R, Woon ECY, Aley PV, Antoniadou I, Sharp T, Vasudevan SR, Churchill GC. A safe lithium mimetic for bipolar disorder. *Nature Commun* 4: 1332, 2013.
348. Singh N, Sharpley AL, Emir UE, Masaki C, Herzallah MM, Gluck MA, Sharp T, Harmer CJ, Vasudevan SR, Cowen PJ, Churchill GC. Effect of the putative lithium mimetic Ebselfen on brain myo-inositol, sleep, and emotional processing in humans. *Neuropharmacology* 41: 1768–1778, 2016.
349. Sklar P, Smoller JW, Fan J, Ferreira MA, Perlis RH, Chambert K, Nimgaonkar VL, McQueen MB, Farane SV, Kirby A, de Bakker PI, Ogdie MN, Thase ME, Sachs GS, Todd-Brown K, Gabriel SB, Sougnez C, Gates C, Blumenstiel B, Defelice M, Ardlie KG, Franklin J, Muir WJ, McGhee KA, MacIntyre DJ, McLean A, VanBeck M, McQuillin A, Bass NJ, Robinson M, Lawrence J, Anjorin A, Curtis D, Scolnick EM, Daly MJ, Blackwood DH, Gurling HM, Purcell SM. Whole-genome association study of bipolar disorder. *Mol Psychiatry* 13: 558–569, 2008.
350. Snyder MA, Gao WJ. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. *Front Cell Neurosci* 7: 31–42, 2013.
351. Spinelli AM, González-Cobos JC, Zhang X, Motiani RK, Rowan S, Zhang W, Garrett J, Vincent PA, Matrougui K, Singer HA, Trebak M. Airway smooth muscle STIM1 and Orai1 are upregulated in asthmatic mice and mediate PDGF-activated SOCE, CRAC currents, proliferation, and migration. *Pflügers Arch* 464: 481–492, 2012.
352. Srivastava M, Atwater I, Glasman M, Leighton X, Goping G, Caohuy H, Miller G, Pichel J, Westphal H, Mears D, Rojas E, Pollard HB. Defects in inositol 1,4,5-trisphosphate receptor expression, Ca^{2+} signaling, and insulin secretion in the *anx7(+/-)* knockout mouse. *Proc Natl Acad Sci USA* 96: 13783–13788, 1999.
353. Staats KA, Bogaert E, Hersmus N, Jaspers T, Luyten T, Bultynck G, Parys JB, Hisatsune C, Mikoshiba K, Van Damme P, Robberecht W, Van Den Bosch L. Neuronal overexpression of IP3 receptor 2 is detrimental in mutant SOD1 mice. *Biochem Biophys Res Commun* 429: 210–213, 2012.
354. Staats KA, Van Helleputte L, Jones AR, Bento-Abreu A, Van Hoecke A, Shatunov A, Simpson CL, Lemmens R, Jaspers T, Fukami K, Nakamura Y, Brown RH Jr, Van Damme P, Liston A, Robberecht W, Al-Chalabi A, Van Den Bosch L. Genetic ablation of phospholipase C delta 1 increases survival in SOD1(G93A) mice. *Neurobiol Dis* 60: 11–17, 2013.
355. Staley K. Molecular mechanisms of epilepsy. *Nat Neurosci* 18: 367–372, 2015.
356. Steinbeck JA, Henke N, Opitz J, Gruszczynska-Biegala J, Schneider L, Theiss S, Hamacher N, Steinfarz B, Golz S, Brüstle O, Kuznicki J, Methner A. Store-operated calcium entry modulates neuronal network activity in a model of chronic epilepsy. *Exp Neurol* 232: 185–194, 2011.
357. Storheim K, Zwart JA. Musculoskeletal disorders and the global burden of disease study. *Ann Rheumatic Dis* 73: 949–950, 2014.
358. Stutzmann GE, LaFerla FM, Parker I. Ca^{2+} signaling in mouse cortical neurons studied by two-photon imaging and photoreleased inositol triphosphate. *J Neurosci* 23: 758–765, 2003.
359. Stutzmann GE, Caccamo A, LaFerla FM, Parker I. Dysregulated IP_3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin 1 results in exaggerated Ca^{2+} signals and altered membrane excitability. *J Neurosci* 24: 508–513, 2004.
360. Stutzmann GE. Calcium dysregulation, IP_3 signaling, and Alzheimer's disease. *Neuroscientist* 11: 110–115, 2005.
361. Sugiyama K, Tomata Y, Kaiho Y, Honkura K, Sugawara Y, Tsuji I. Association between coffee consumption and incident risk of disabling dementia in elderly Japanese: The Ohsaki Cohort 2006 Study. *J Alzheimers Dis* 50: 491–500, 2015.
362. Swann K, Lai FA. PLC ζ and the initiation of Ca^{2+} oscillations in fertilizing mammalian eggs. *Cell Calcium* 53: 55–62, 2013.
363. Szalai G, Krishnamurthy R, Hajnoczky G. Apoptosis driven by IP_3 -linked mitochondrial calcium signals. *EMBO J* 18: 6349–6361, 1999.
364. Szatkowski C, Parys JB, Ouadid-Ahidouch H, Matifat F. Inositol 1,4,5-trisphosphate-induced Ca^{2+} signalling is involved in estradiol-induced breast cancer epithelial cell growth. *Mol Cancer* 9: 156, 2010.
365. Tada M, Nishizawa M, Onodera O. Roles of inositol 1,4,5-trisphosphate receptors in spinocerebellar ataxias. *Neurochem Int* 94: 1–8, 2016.
366. Tadic V, Prell T, Lautenschlaeger J, Grosskreutz J. The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. *Front Cell Neurosci* 8: 147–163, 2014.
367. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T. Induction and

- activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. *Dev Cell* 3: 889–901, 2002.
368. Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. *Neuron* 39: 227–239, 2003.
369. Tao HW, Li YT, Zhang LI. Formation of excitation-inhibition balance: inhibition listens and changes its tune. *Trends Neurosci* 37: 528–530, 2014.
370. Taylor CW, da Fonseca PCA, Morris EP. IP₃ receptors: the search for structure. *Trends Biochem Sci* 29: 210–219, 2004.
371. Taylor CW, Tovey SC, Rossi AM, Lopez Sanjurjo CI, Prole DL, Rahman T. Structural organization of signalling to and from IP₃ receptors. *Biochem Soc Trans* 42: 63–70, 2014.
372. Teos LY, Zhang Y, Cotrim AP, Swaim W, Won JH, Ambrus J, Shen L, Bebris L, Grisius M, Jang SI, Yule DI, Ambudkar IS, Alevizos I. IP₃R deficit underlies loss of salivary fluid secretion in Sjögren's Syndrome. *Sci Rep* 5: 13953, 2015.
373. Tesli M, Skutun KC, Ousdal OT, Brown AA, Thoresen C, Agartz I, Melle I, Djurovic S, Jensen J, Andreassen OA. CACNA1C risk variant and amygdala activity in bipolar disorder, schizophrenia and healthy controls. *PLoS One* 8: e56970, 2013.
374. Thompson SM, Kallarackal AJ, Kvarta MD, Van Dyke AM, LeGates TA, Cai X. An excitatory synapse hypothesis of depression. *Trends Neurosci* 38: 279–294, 2015.
375. Timms AE, Dorschner MO, Wechsler J, Choi KY, Kirkwood R, Girirajan S, Baker C, Eichler EE, Korvatska O, Roche KW, Horwitz MS, Tsuang DW. Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. *JAMA Psychiatry* 70: 582–590, 2013.
376. Tinelli H, Cancela JM, Mogami H, Gerasimenko JV, Gerasimenko OV, Tepikin AV, Petersen OH. Active mitochondria surrounding the pancreatic acinar granule region prevent spreading of inositol triphosphate-evoked local cytosolic Ca²⁺ signals. *EMBO J* 18: 4999–5008, 1999.
377. Tinker A, Finlay M, Nobles M, Opel A. The contribution of pathways initiated via the Gq/11 G-protein family to atrial fibrillation. *Pharmacol Res* 105: 54–61, 2016.
378. Tojima T, Hines JH, Henley JR, Kamiguchi H. Second messengers and membrane trafficking direct and organize growth cone steering. *Nat Rev Neurosci* 12: 191–203, 2011.
379. Tsuboi D, Kuroda K, Tanaka M, Namba T, Iizuka Y, Taya S, Shinoda T, Hikita T, Muraoka S, Iizuka M, Nimura A, Mizoguchi A, Shiina N, Sokabe M, Okano H, Mikoshiba K, Kaibuchi K. Disrupted-in-schizophrenia 1 regulates transport of ITPR1 mRNA for synaptic plasticity. *Nat Neurosci* 18: 698–707, 2015.
380. Uhlén P, Fritz N, Smedler E, Malmersjö S, Kanatani S. Calcium signaling in neocortical development. *Dev Neurobiol* 75: 360–368, 2015.
381. Um JW, Kaufman Kostylev AC, Heiss JK M, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. *Neuron* 79: 887–902, 2013.
382. Valdés JA, Gaggero E, Hidalgo J, Leal N, Jaimovich E, Carrasco MA. NFAT activation by membrane potential follows a calcium pathway distinct from other activity-related transcription factors in skeletal muscle cells. *Am J Physiol Cell Physiol* 294: C715–C725, 2008.
383. Vanderheyden V, Devogelaere B, Missiaen L, De Smedt H, Bultynck G, Parys JB. Regulation of inositol 1,4,5-triphosphate-induced Ca²⁺ release by reversible phosphorylation and dephosphorylation. *Biochim Biophys Acta* 1793: 959–970, 2009.
384. Van de Leemput J, Chandran J, Knight MA, Holtzman LA, Scholz S, Cookson MR, Houlden H, Gwinn-Hardy K, Fung HC, Lin X, Hernandez D, Simon-Sánchez J, Wood NW, Giunti P, Rafferty I, Hardy J, Storey E, Gardner RJ, Forrest SM, Fisher EM, Russell JT, Cai H, Singleton AB. Deletion at ITPR1 underlies ataxia in mice and spinocerebellar atrophy 15 in humans. *PLoS Genet* 3: e108, 2007.
385. Van Enkhuizen J, Janowsky DS, Olivier B, Minassian A, Perry W, Young JW, Geyer MA. The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. *Eur J Pharmacol* 753: 114–126, 2015.
386. Vaqué JP, Gómez-López G, Monsálvez V, Varela I, Martínez N, Pérez C, Domínguez O, Graña O, Rodríguez-Peralto JL, Rodríguez-Pinilla SM, González-Vela C, Rubio- Camarillo M, Martín-Sánchez E, Pisano DG, Papadavid E, Papadaki T, Requena L, García-Marco JA, Méndez M, Provencio M, Hospital M, Suárez-Massa D, Postigo C, San Segundo D, López-Hoyos M, Ortiz-Romero PL, Piris MA, Sánchez-Beato M. PLCG1 mutations in cutaneous T-cell lymphomas. *Blood* 123: 2034–2043, 2014.
387. Vervloesem T, Yule DI, Bultynck G, Parys JB. The type 2 inositol 1,4,5-triphosphate receptor, emerging functions for an intriguing Ca²⁺-release channel. *Biochim Biophys Acta* 1853: 1992–2005, 2015.
388. Viero C, Wegener S, Scholz A, Ruppenthal S, Tian Q, Tabellion W, Kreinest M, Laschke MW, Kaestner L, Lipp P. Endothelin-1-induced remodelling of murine adult ventricular myocytes. *Cell Calcium* 59: 41–53, 2016.
389. Vinogradova TM, Brochet DX, Sirenko S, Li Y, Spurgeon H, Lakatta EG. Sarcoplasmic reticulum Ca²⁺ pumping kinetics regulates timing of local Ca²⁺ releases and spontaneous beating rate of rabbit sinoatrial node pacemaker cells. *Circ Res* 107: 767–775, 2010.
390. Wakai T, Fissore RA. Ca²⁺ homeostasis and regulation of ER Ca²⁺ in mammalian oocytes/eggs. *Cell Calcium* 53: 63–67, 2013.
391. Wallace J. Calcium dysregulation, and lithium treatment to forestall Alzheimer's disease—a merging of hypotheses. *Cell Calcium* 55: 175–181, 2014.
392. Walliser C, Tron K, Clauss K, Gutman O, Kobitski AY, Retlich M, Schade A, Röcker C, Henis YI, Nienhaus GU, Gierschik P. Rac-mediated stimulation of phospholipase Cγ2 amplifies B cell receptor-induced calcium signaling. *J Biol Chem* 290: 17056–17072, 2015.
393. Wang SJ, Guo X, Zuo H, Zhang YG, Xu P, Ping ZG, Zhang Z, Geng D. Chondrocyte apoptosis and expression of Bcl-2, Bax, Fas, and iNOS in articular cartilage in patients with Kashin-Beck disease. *J Rheumatol* 33: 615–619, 2006.
394. Wang Y, Li G, Goode J, Paz JC, Ouyang K, Screamton R, Fischer WH, Chen J, Tabas I, Montminy M. Inositol-1,4,5-triphosphate receptor regulates hepatic gluconeogenesis in fasting and diabetes. *Nature* 485: 128–132, 2012.
395. Warsh JJ, Andreopoulos S, Li PP. Role of intracellular calcium signaling in the pathophysiology and pharmacotherapy of bipolar disorder: current status. *Clin Neurosci Res* 4: 201–213, 2004.
396. Waugh MG. Chromosomal instability and phosphoinositide pathway gene signatures in glioblastoma multiforme. *Mol Neurobiol* 53: 621–630, 2016.
397. Weerachayaphorn J, Amaya MJ, Spirli C, Chansela P, Mitchell-Richards KA, Ananthanarayanan M, Nathanson MH. Nuclear Factor, Erythroid 2-Like 2 regulates expression of type 3 Inositol 1,4,5-triphosphate receptor and calcium signaling in cholangiocytes. *Gastroenterology* 149: e222–e210, 2015.
398. Weissman TA, Riquelme PA, Ivic L, Flint AC, Kriegstein AR. Calcium waves propagate through radial glial cells and modulate proliferation in the developing neocortex. *Neuron* 43: 647–661, 2004.
399. Weston-Green K, Huang XF, Deng C. Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor. *CNS Drugs* 27: 1069–1080, 2013.
400. Wilson C, Saunter CD, Girkin JM, McCarron JG. Pressure-dependent regulation of Ca²⁺ signalling in the vascular endothelium. *J Physiol* 593: 5231–5253, 2015.
401. Wiltgen SM, Dickinson GD, Swaminathan D, Parker I. Termination of calcium puffs and coupled closings of inositol triphosphate receptor channels. *Cell Calcium* 56: 157–168, 2014.
402. Witt JA, Helmstaedter C. Cognition in the early stages of adult epilepsy. *Seizure* 26: 65–68, 2015.
403. Woods NM, Cuthbertson KSR, Cobbold PH. Repetitive transient rises in cytoplasmic free calcium in hormone-stimulated hepatocytes. *Nature* 319: 600–602, 1986.
404. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapata M, Ruppert AS, Xue L, Li DH, Steggerda SM, Verstege M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *N Engl J Med* 370: 2286–2294, 2014.
405. Wright FA, Lu JP, Sliter DA, Dupré N, Rouleau GA, Wojcikiewicz RJ. A point mutation in the ubiquitin ligase RNF170 that causes autosomal dominant sensory ataxia destabilizes the protein and impairs inositol 1,4,5-triphosphate receptor-mediated Ca²⁺ signaling. *J Biol Chem* 290: 13948–13957, 2015.

406. Wu X, Zhang T, Bossuyt J, Li X, McKinsey TA, Dedman JR, Olson EN, Chen J, Brown JH, Bers DM. Local InsP₃-dependent perinuclear Ca²⁺ signaling in cardiac myocyte excitation-transcription coupling. *J Clin Invest* 116: 675–682, 2006.
407. Wu J, Ryskamp DA, Liang X, Egorova P, Zakhارова О, Hung G, Bezprozvanny I. Enhanced store-operated calcium entry leads to striatal synaptic loss in a Huntington's disease mouse model. *J Neurosci* 36: 125–141, 2016.
408. Xia L, Zhang D, Wang C, Wei F, Hu Y. PC-PLC is involved in osteoclastogenesis induced by TNF- α through upregulating IP₃RI expression. *FEBS Lett* 586: 3341–3348, 2012.
409. Xiao J, Liang D, Zhao H, Liu Y, Zhang H, Lu X, Liu Y, Li J, Peng L, Chen YH. 2-Aminooethoxydiphenyl borate, a inositol 1,4,5-triphosphate receptor inhibitor, prevents atrial fibrillation. *Exp Biol Med* 235: 862–868, 2010.
410. Yamamura A. Pathological function of Ca²⁺-sensing receptor in pulmonary arterial hypertension. *J Smooth Muscle Res* 50: 8–17, 2014.
411. Yamazaki Y, Sugihara T, Goto J, Chida K, Fujiwara H, Kaneko K, Fujii S, Mikoshiba K. Role of inositol 1, 4, 5-trisphosphate receptors in the postsynaptic expression of guinea pig hippocampal mossy fiber depotentiation. *Brain Res* 1387: 19–28, 2011.
412. Yamada J, Ohkusa T, Nao T, Ueyama T, Yano M, Kobayashi S, Hamano K, Esato K, Matsuzaki M. Up-regulation of inositol 1,4,5 trisphosphate receptor expression in atrial tissue in patients with chronic atrial fibrillation. *J Am Coll Cardiol* 37: 1111–1119, 2001.
413. Yang YC, Chang TY, Chen TC, Chang SC, Chen WF, Chan HW, Lin WS, Wu FT, Lee YJ. Genetic polymorphisms in the ITPKC gene and cervical squamous cell carcinoma risk. *Cancer Immunol Immunother* 61: 2153–2159, 2012.
414. Yang AW, Sachs AJ, Nyström AM. Deletion of Inpp5a causes ataxia and cerebellar degeneration in mice. *Neurogenetics* 16: 277–285, 2015.
415. Ye R, Ni M, Wang M, Luo S, Zhu G, Chow RH, Lee AS. Inositol 1,4,5-trisphosphate receptor I mutation perturbs glucose homeostasis and enhances susceptibility to diet-induced diabetes. *J Endocrinol* 210: 209–217, 2011.
416. Yeter D, Deth R. ITPKC susceptibility in Kawasaki syndrome as a sensitizing factor for autoimmunity and coronary arterial wall relaxation induced by thimerosal's effects on calcium signaling via IP₃. *Autoimmun Rev* 11: 903–908, 2012.
417. Young JW, Dulcis D. Investigating the mechanism(s) underlying switching between states in bipolar disorder. *Eur J Pharmacol* 759: 151–162, 2015.
418. Yule DI, Straub SV, Bruce JI. Modulation of Ca²⁺ oscillations by phosphorylation of Ins(1,4,5)P₃ receptors. *Biochem Soc Trans* 31: 954–957, 2003.
419. Zeng G, Cui X, Liu Z, Zhao H, Zheng X, Zhang B, Xia C. Disruption of phosphoinositide-specific phospholipases C γ contributes to extracellular matrix synthesis of human osteoarthritis chondrocytes. *Int J Mol Sci* 15: 13236–13246, 2014.
420. Zhang L, McKenna MA, Said-Al-Naief N, Wu X, Feng X, McDonald JM. Osteoclastogenesis: the role of calcium and calmodulin. *Crit Rev Eukaryot Gene Expr* 15: 1–13, 2005.
421. Zhang S, Fritz N, Ibarra C, Uhlen P. Inositol 1,4,5-trisphosphate receptor subtype-specific regulation of calcium oscillations. *Neurochem Res* 36: 1175–1185, 2011.
422. Zhang Z, Tian J, Liao Q, Wang Y. The analysis of expression of CCK and IP₃ receptors in gallstones patients with type 2 diabetes mellitus. *Hepatogastroenterology* 61: 2173–2176, 2014.
423. Zhang F, Wen Y, Guo X, Zhang Y, Wang X, Yang T, Shen H, Chen X, Tian Q, Deng HW. Genome-wide association study identifies ITPR2 as a susceptibility gene for Kashin-Beck disease in Han Chinese. *Arthritis Rheumatol* 67: 176–181, 2015.
424. Zhu Y, Usui HK, Sharma K. Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. *Semin Nephrol* 27: 153–160, 2007.
425. Zhuang GZ, Keeler B, Grant J, Bianchi L, Fu ES, Zhang YP, Erasso DM, Cui JG, Wilshire T, Li Q, Hao S, Sarantopoulos KD, Candiotti K, Wishnek SM, Smith SB, Maixner W, Diatchenko L, Martin ER, Levitt RC. Carbonic anhydrase-8 regulates inflammatory pain by inhibiting the ITPR1-cytosolic free calcium pathway. *PLoS One* 10: e0118273, 2015.
426. Zima AV, Blatter LA. Inositol-1,4,5-trisphosphate-dependent Ca²⁺ signalling in cat atrial excitation-contraction coupling and arrhythmias. *J Physiol* 555: 607–615, 2004.
427. Zima AV, Bare DJ, Mignery GA, Blatter LA. IP₃-dependent nuclear Ca²⁺ signalling in the mammalian heart. *J Physiol* 584: 601–611, 2007.
428. Zou JJ, Gao YD, Geng S, Yang J. Role of STIM1/Orai1-mediated store-operated Ca²⁺ entry in airway smooth muscle cell proliferation. *J Appl Physiol* 110: 1256–1263, 2011.